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Reported Tuberculosis in the United States, 
2013 presents summary data for tuberculosis 
(TB) cases verified and counted in 2013.  Re-
port of Verified Case of Tuberculosis (RVCT) 
forms are submitted to the Division of Tubercu-
losis Elimination (DTBE), Centers for Disease 
Control and Prevention (CDC), by 60 reporting 
areas (the 50 states, the District of Columbia, 
New York City, Puerto Rico, and seven other 
jurisdictions in the Pacific and Caribbean). First 
released in 1993, the RVCT was expanded in 
2009 to collect additional information for each 
reported TB case in order to better monitor 
trends in TB and TB control.  
Reported Tuberculosis in the United States, 
2013 is similar to previous publications (see 
page xi, #19) and contains an Executive Com-
mentary, Technical Notes, seven major data 
sections, and appendices. The Executive Com-
mentary includes highlights of the 2013 data, 
and the Technical Notes section provides infor-
mation about how the data were collected and 
reported; these sections are included to help the 
reader interpret the data. 
Morbidity Trend Tables present trends in the 
overall TB case counts and case rates for the 
United States and the United States Affili-
ated Pacific Islands by selected demographic, 
clinical, and genotypic characteristics. Morbid-
ity Tables, 2013 present overall case counts 
and case rates for the United States and other 
jurisdictions by selected demographic and 
genotypic characteristics for the most recent 
year for which data are available.  Morbidity 
Tables, 2011 present overall case counts for 
the United States by selected demographic and 
clinical characteristics for the most recent year 
for which data are available on certain follow-
up variables that require a longer data collec-
tion period. Morbidity Tables, Reporting Areas, 
2013 present TB case counts and case rates by 
state and by other jurisdictions with tables of 
selected demographic and clinical characteris-
tics.  Morbidity Tables, Reporting Areas, 2011 
present data for the most recent year for which 
data are available on certain follow-up variables 
that require a longer data collection period. Mor-
bidity Tables, Cities and Metropolitan Statistical 
Areas, 2013 provide TB case counts and case rates 
by metropolitan statistical areas (MSAs: see Tech-
nical Notes, page 9, for further details) with tables 
of selected demographic and clinical characteris-
tics. Surveillance Slide Set, 2013 presents figures 
from the annual surveillance slide set, which 
emphasize key recent trends in TB epidemiology 
in the United States. The slides with accompany-
ing text can also be viewed and downloaded from 
the DTBE website accessible at http://www.cdc.
gov/tb/.  
The current Tuberculosis Case Definition for 
Public Health Surveillance and Recommendations 
for Reporting and Counting Tuberculosis Cases 
are provided in Appendices A and B, respectively 
(pages 171 and 172).  National Surveillance for 
Severe Adverse Events Associated with Treatment 
for Latent Tuberculosis Infection - Reporting In-
formation is provided in Appendix C (page 181). 
Genotyping Background Information and Glos-
sary is provided in Appendix D (page 182).
x
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Highlights of 2013 Report
Since 1953, in cooperation with state and local health departments, the United States national tuberculosis program 
has collected information on each newly reported case of tuberculosis (TB) disease in the United States.  Currently, 
each individual TB case report (Report of Verified Case of Tuberculosis or RVCT) is submitted electronically. Fol-
lowing are the highlights of the 2013 report.
1. Updated case counts for each year from 1993 through 2012.
2. Case counts: 9,582 TB cases were reported to CDC from the 50 states and the District of Columbia (DC) 
for 2013, representing a 3.6% decrease from 2012 (Table 1).
• Eighteen states reported increased case counts from 2012 (Table 30).
• California, Texas, New York, and Florida accounted for 51% of the national case total (Table 31). 
• Asians exceeded all other racial or ethnic groups with the largest percentage of total cases (31%) (Table 
2).
• Hispanics comprise the second largest racial or ethnic group (28%) (Table 2).
• Blacks or African Americans born in the United States represented 37% of TB cases in U.S.-born per-
sons (Table 18) and accounted for 13% of the national case total.
• Asians born outside the United States represented 46% of TB cases in foreign-born persons (Table19) 
and accounted for 30% of the national case total.
3. Case rates: In 2013, the TB case rate declined from 3.2 to 3.0 per 100,000 persons, representing a 4.3% 
decrease from 2012 (Table 1). 
• Fourteen states and DC reported rates above the national average (Table 30).
• The TB case rate was 1.2 per 100,000 for U.S.-born persons and 15.6 for foreign-born persons (Table 5). 
• Asians continued to have the highest case rate (18.7 per 100,000 persons) among all racial or ethnic 
groups (Table 2).
4. Burden among the foreign-born:  In 2013, the percentage of cases occurring in foreign-born persons in-
creased to 65% of the national case total (Table 5). This percentage has risen steadily since 1993.
• Foreign-born Hispanics and Asians together represented 79% of TB cases in foreign-born persons, and 
accounted for 51% of the national case total (Table 19).
• In 34 states, ≥ 50% of TB cases occurred among foreign-born persons (Table 34).
• The top five countries of origin of foreign-born persons with TB were Mexico, the Philippines, India, 
Vietnam, and China (Table 6).
5. Drug resistance:  1.0% of reported cases had primary multidrug resistance, which is defined as no previ-
ous history of TB disease and resistance to at least isoniazid and rifampin (Table 9). This percentage has remained 
stable, fluctuating from 0.9% to 1.3%, over the past decade.
6. HIV status: In 2013, 88% of persons with TB reported HIV test results.
• The percentage of persons with HIV test results reported remained relatively stable between 2012 and 
2013 at 86–88% among persons of all ages and 93–94% among persons 25–44 years of age (Table 11).
7. Genotype surveillance coverage: In 2013, genotype surveillance coverage was 94.6%.   
• Genotype surveillance coverage has increased steadily since 2004.  Thirty-nine states met or exceeded 
the national target of 94% genotype surveillance coverage in 2013 (Table 53). Among genotyped cases 
during 2011–2013, 21% were clustered, suggesting recent transmission (Table 23). 
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Tuberculosis in the United States
In 2013, the reported number of TB cases (9,582) and 
case rate (3.0 cases per 100,000) both decreased; these 
represented declines of 3.6% and 4.3%, respectively, 
compared to 2012.  Since the 1992 TB resurgence peak 
in the United States, the number of TB cases reported 
annually has decreased by 64% (Table 1).
TB case rates vary by well-known factors such as age, 
race and ethnicity, and country of origin. The propor-
tion of total cases occurring in foreign-born persons 
has been increasing since 1993.  In 2013, 65% of TB 
cases occurred in foreign-born persons, an all-time high. 
Foreign-born persons have accounted for the majority 
of TB cases in the United States every year since 2001.  
Moreover, the case rate among foreign-born persons in 
2013 was approximately 13 times higher than among 
U.S.-born persons (Table 5).
Tuberculosis deaths compiled from National Vital 
Statistics reports decreased by 5.8%, from 569 deaths in 
2010 to 536 deaths in 2011.   The number of TB deaths 
reported annually has decreased by 69% since 1992 
(Table 1).
Age
Since 1993, TB case rates have declined annually for 
almost all age groups. In 2013, TB case rates continued 
the trend with declines in all age groups except among 
children aged ≤ 14, which remained the same as the 
previous year at 0.8/100,000.  The highest burden of 
disease continues to be among older adults.  In 2013, 
adults aged 65 years and older had a case rate of 4.9 
cases per 100,000, while children aged ≤ 14 years had 
the lowest rate at 0.8 cases per 100,000 (Table 4).  
Race and Ethnicity
In 2003, the race and ethnicity category “non-Hispanic, 
Asian or Pacific Islander” was split into “non-Hispanic 
Asian” and “non-Hispanic Native Hawaiian or Other 
Pacific Islander.”  In 2013, Asians had the highest TB 
case rate at 18.7 cases per 100,000, which was a slight 
decrease from 19.0 in 2012.  Native Hawaiians or Other 
Pacific Islanders had the second-highest TB case rate at 
11.3 cases per 100,000, which is a decrease compared to 
12.1 cases per 100,000 reported in 2012.  Owing to low 
case numbers among Native Hawaiians or other Pacific 
Islanders, case rates fluctuate and must be interpreted 
with caution (Table 2).
Since 1993, TB case rates have declined in almost all 
racial and ethnic groups:  among Hispanic or Lati-
nos, the decline has been from 19.9 to 5.0 cases per 
100,000 (-75%); among non-Hispanic blacks or African 
Americans, from 28.5 to 5.4 cases per 100,000 (-81%); 
among American Indian or Alaska Natives, from 14.0 
to 5.4 cases per 100, 000 (-61%);  among non-Hispanic 
whites, from 3.6 to 0.7 cases per 100,000 (-81%); and 
among Asians, from 41.2 to 18.7 cases per 100,000 
(-55%).  In 2013, the TB case rate for Asians remained 
over three times higher than that for Hispanics or blacks 
or African Americans (Table 2).
Origin of Birth
Since 1993, the TB case rate among U.S.-born persons 
has declined annually.  In 2013, the TB case rate for 
U.S.-born persons was 1.2 cases per 100,000, represent-
ing a 84% decrease from 7.4 cases per 100,000 in 1993. 
The TB case rate among foreign-born persons also 
declined during the same interval, though the decline 
was less substantial.  In 2013, the TB case rate among 
foreign-born persons was 15.6 cases per 100,000, repre-
senting a 54% decrease from 34.0 cases per 100,000 in 
1993 (Table 5). 
The proportion of TB cases among persons born in the 
United States has also declined annually since 1993.  In 
2013, 35% of TB cases were among U.S-born persons 
compared to 69% in 1993 (Table 5).  In 34 states, ≥ 
50% of TB cases occurred among foreign-born persons.  
In 17 states (Arizona, California, Colorado, Connecti-
cut, Hawaii, Maryland, Massachusetts, Minnesota, New 
Hampshire, New Jersey, New York, Oregon, Rhode 
Island, Utah, Vermont, Virginia, Washington), ≥ 70% of 
TB cases occurred among foreign-born persons (Table 
34).
Country of Origin and World Region
From 2009 through 2013, the top five countries of 
origin of foreign-born persons with TB were Mexico, 
the Philippines, India, Vietnam and China (Table 6).  
The distribution of TB cases by world region of origin 
reflects immigration patterns among persons settling 
in the United States.  Of the 6,193 TB cases reported 
among foreign-born persons in 2013, 37% occurred 
among persons born in the Americas region, and 32% 
occurred among persons born in the Western Pacific 
region (Table 20).  From 1993 through 2013, the pro-
portion of cases increased among persons born in the 
Eastern Mediterranean region (3% in 1993 to 5% in 
2013), the Southeast Asia region (6% in 1993 to 15% 
in 2013), and the Africa region (2% in 1993 to 8% in 
2013) (Table 20).
Multidrug-resistant Tuberculosis
Since 1993 the proportion of patients with primary 
multidrug-resistant (MDR) TB, which is defined as no 
previous history of TB disease and resistance to at least 
isoniazid and rifampin, decreased from 3% to 1% by 
1998.  During 2009 through 2013, the percentage of 
5
primary MDR TB cases has remained stable at approxi-
mately 1%.  Since 1997, the percentage of U.S.-born 
patients with primary MDR TB has remained below 
1%.  However, of the total number of reported primary 
MDR TB cases, the proportion occurring in foreign-
born persons increased from 25% (103 of 407) in 1993 
to 92% (75 of 82) in 2013 (Table 9).
Extensively Drug-resistant Tuberculosis
CDC has included an updated case count of extensively 
drug-resistant (XDR) TB cases from 1993 to 2013 in 
the slide set that accompanies this report.  XDR TB is 
defined as resistance to isoniazid and rifampin, plus 
resistance to any fluoroquinolone and at least one of 
three injectable second-line anti-TB drugs (i.e., amika-
cin, kanamycin, or capreomycin).1,2  Four cases were 
reported as XDR TB in 2013, compared to two cases in 
2012, five cases in 2011, one case in 2010, and 0 cases 
in 2009. Of the 12 XDR TB cases reported since 2009, 
9 were among foreign-born persons.
Tuberculosis Therapy
The proportion of TB patients prescribed an initial treat-
ment regimen including isoniazid, rifampin, pyrazin-
amide, and ethambutol increased from 40.3% in 1993 to 
84.1% in 2013.  The proportion of patients who com-
pleted therapy within 1 year increased from 63.4% in 
1993 to 89.0% in 2011 (the latest year for which com-
plete outcome data are available).  The proportion of 
persons receiving directly observed therapy for at least 
a portion of the treatment duration also increased from 
36% in 1993 to 88% in 2011, the latest year for which 
complete outcome data are available (Table 10).
HIV Status
Between 2012 and 2013, the proportion of persons with 
TB who reported HIV test results has remained high 
at 86–88% for all ages and 93–94% for persons aged 
25–44 (Table 11). The percentage of persons with TB 
who reported HIV test results and who were HIV-
positive was 7% in 2013, which has remained the same 
since 2011 (Table 11). Among persons 25–44 years 
of age, 9% of persons with TB who reported HIV test 
results were HIV-positive in 2013, decreasing from 11% 
in 2012 (Table 11). The percentages have declined since 
1993, when 48% of persons with TB of all ages with 
HIV test results reported HIV-positive results; among 
persons between 25−44 years of age, the percentage 
1 Centers for Disease Control and Prevention. Revised 
Definition of Extensively Drug-Resistant Tuberculosis. 
MMWR Morb Mortal Wkly Rep 2006;55:1176.
2 Extensively drug-resistant tuberculosis (XDR-TB): rec-
ommendations for prevention and control. Wkly Epidemiol 
Rec 2006;81:430-2.
was 63% in 1993 (Table 11). The American Thoracic 
Society and the Infectious Diseases Society of America 
recommend that all TB patients be counseled and tested 
for HIV.3 
Genotyping
TB genotyping is a laboratory-based analysis of the 
genetic material of the bacteria that cause TB disease.  
In the United States, routine genotyping of isolates 
from culture-positive TB cases started in 2004 CDC’s 
National Tuberculosis Genotyping Service (NTGS).  
TB genotyping surveillance coverage, defined as the 
proportion of culture-positive TB cases with a genotype 
result, has increased from 53% in 2004 to 95% in 2013 
(Table 13).  TB genotype clusters are defined as two or 
more cases with matching genotypes in the same county 
during a 3-year time period. Cases that are clustered 
suggest recent transmission, while unique cases are 
more likely attributable to reactivation of disease that 
was acquired in the past.  Among genotyped cases dur-
ing 2011–2013, 21% were clustered (Table 23).  During 
this period, the percentage of clustered cases among 
U.S.-born persons with TB was 35%, compared to 
14% among foreign-born persons with TB (Table 22). 
Among 4,625 cases in clusters during 2011–2013, 976 
cases were in 101 high-alert clusters, 997 cases were 
in 338 medium-alert clusters, and 2652 cases were in 
1093 non-alerted clusters (Table 22). In 2013, among all 
genotyped cases, 1.6% had a genotype that was consis-
tent with Mycobacterium bovis; the majority of these 
(67.3%) were among foreign-born cases (Table 15).  
United States Affiliated Pacific Islands (USAPI) 
The USAPI consist of six jurisdictions in the Pacific 
Ocean: American Samoa, the Commonwealth of the 
Northern Mariana Islands, Guam, Federated States 
of Micronesia, Republic of the Marshall Islands, and 
Republic of Palau. As a result of their affiliations with 
the United States, the USAPI are among the recipients 
of U.S. federal government funding, including CDC 
cooperative agreement funding for domestic TB control 
program activities. In 2013, the USAPI had 357 report-
ed cases of TB. Among these, 186 (52%) were male, 66 
(19%) were aged less than 15 years and 107 (30%) were 
aged 25-44 years. In addition, 28 (8%) were not born 
in the USAPI jurisdictions or the United States, and 
of those, 22 (79%) emigrated from the Republic of the 
Philippines. Some other data highlights of the 357 re-
ported USAPI cases are that 306 (86%) were diagnosed 
with pulmonary disease only, 171 (48%) were posi-
tive culture for Mycobacterium tuberculosis; less than 
3 CDC. Treatment of tuberculosis. American Thoracic 
Society, CDC, and Infectious Diseases Society of America. 
MMWR 2003;52(No. RR-11).
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1% had MDR TB, and 148 (42%) were unemployed. 
Genotype surveillance coverage for USAPI was 82% in 
2013.
Puerto Rico
In 2013, the Commonwealth of Puerto Rico reported 
50 TB cases to CDC, a case rate of 1.4 per 100,000 
persons.  Among those cases, 37 (74%) were male, 
four (8%) were aged less than 25 years, and 35 (70%) 
were aged 45 years and older. Of the 50 reported cases, 
13 were born outside of Puerto Rico, and of those, 9 
(70%) emigrated from the Dominican Republic. The 
majority of reported cases (92%) were diagnosed with 
pulmonary disease only, 90% were positive culture for 
Mycobacterium tuberculosis, 2.3% had MDR TB, and 
42% were unemployed. Genotype surveillance coverage 
for Puerto Rico was 91% in 2013.
Summary 
Both the absolute number of TB cases and the TB case 
rate in the United States have declined each year since 
1993. The total case count of 9,582 and case rate of 3.0 
per 100,000 persons represent steady progress toward 
the goal of TB elimination in the United States (< 1 case 
per 1,000,000 population)4. However, despite consistent 
declines in TB cases and case rates over the past 60 
years, vulnerable populations remain at higher risk for 
TB in the United States.
Although progress has been made in closing the gap 
among disparate groups, racial and ethnic minorities 
and the foreign-born continue to be disproportionately 
affected by TB. In 2013, 85% of all TB cases occurred 
among persons who were Asian, black or African Amer-
ican, Hispanic, American Indian or Alaskan Native, or 
Native Hawaiian. Asians accounted for 31% of all TB 
cases reported in 2013, the highest percentage of any 
racial or ethnic group; 95% of TB patients in that group 
were foreign-born.  Hispanics comprise the second 
largest racial or ethnic group at 28%. African Americans 
represent 37% of TB cases among U.S.-born persons, 
the highest racial or ethnic group percentage among the 
U.S.-born. In 2013, the percentage of cases reported in 
foreign-born persons increased to 65% of the national 
case total.  To achieve TB elimination, intensified ef-
forts are needed to address the persistent disparities that 
exist between U.S. –born and foreign-born persons, and 
between whites and minorities in the United States. 
4 Ending Neglect: The Elimination of Tuberculosis in the 
United States. Washington, DC: National Academy Press; 
2000.
There are a number of tables contained in this report 
that highlight the disproportionate incidence of TB 
among racial/ethnic and foreign-born minorities. Tables 
2, 3, 5, 6, and 21 contain national-level race/ethnicity 
and country of origin data while Tables 33-37, 59, 65, 
and 66 contain similar data stratified by state and Met-
ropolitan Statistical Area. 
To address cases and case rates among TB disparity 
groups, CDC and the Division of Tuberculosis are col-
laborating with national and local  organizations to ad-
dress social determinates of health (SDH), which are the 
economic and social conditions that influence the health 
of people and communities as a whole. CDC collects 10 
SDH variables: ethnicity (Table 33), occupation (Table 
48), incarceration status (Table 42), immigration status 
and date of arrival in the United States (Tables 36 and 
37), country of birth (Table 35), homelessness (Tables 
43 and 67), and resident of long-term care facility at 
time of treatment (Table 44), HIV status (Table 51), and 
receipt of treatment (Tables 58 and 59). CDC continues 
to strengthen collaborations with local partners collect-
ing and evaluating progress reports on SHD measures.  
Progress toward TB elimination in the United States 
will require ongoing surveillance and improved TB 
control and prevention activities to address persistent 
disparities between U.S.-born and foreign-born persons, 
and between whites and racial/ethnic minorities. Along 
with sustained focus on domestic TB control activities, 
continued support of global TB control initiatives, and 
focused initiatives are needed to address conditions that 
might contribute to increased exposure to TB5.  Dispari-
ties and inequalities among racial/ethnic minorities are 
affected by many unmeasured factors. CDC recom-
mends improving awareness, testing, and treatment 
of latent infection and TB disease in minorities and 
foreign-born populations to reduce TB5.
5 CDC; Tuberculosis—United States, 1993-2010. CDC 
Health Disparities and Inequalities Report---United States, 







National Tuberculosis Surveillance System
Reporting areas (i.e., the 50 states, the District of 
Columbia, New York City, Puerto Rico, and other 
U.S. jurisdictions in the Pacific and Caribbean1) report 
tuberculosis (TB) cases to CDC’s National TB Surveil-
lance System (NTSS) using a standard case report form, 
Report of Verified Case of Tuberculosis (RVCT). TB 
cases are verified according to the Tuberculosis Case 
Definition for Public Health Surveillance in Appendix A. 
TB cases are reported and counted according to the Rec-
ommendations for Reporting and Counting Tuberculosis 
Cases in Appendix B.  
TB Case Definition
In 2009, the case definition was modified. TB cases are 
verified according to the following specified laboratory 
and clinical criteria (see Appendix A, page 171).
Laboratory criteria for diagnosis
A case may be verified by the laboratory case definition 
with at least one of the following criteria: 1) isolation 
of M. tuberculosis complex from a clinical specimen, 
OR 2) demonstration of M. tuberculosis complex from 
a clinical specimen by nucleic acid amplification test 
(NAAT), OR 3) demonstration of acid-fast bacilli (AFB) 
in a clinical specimen when a culture has not been or 
cannot be obtained or is falsely negative or contami-
nated.
Clinical case criteria
A case may be verified by the clinical case definition in 
the presence of ALL of the following clinical criteria: 
1) a positive tuberculin skin test (TST) result or positive 
interferon gamma release assay (IGRA) result for M. 
tuberculosis, AND 2) other signs and symptoms compat-
ible with TB  (e.g., abnormal chest radiograph, abnormal 
chest computerized tomography scan or other chest im-
aging study, or clinical evidence of current disease, AND 
3) treatment with two or more anti-TB drugs, AND 4) a 
completed diagnostic evaluation. 
Provider Diagnosis
Provider diagnosis is not a component of the case defini-
tion for TB as described in Appendix A. However, when 
cases of TB are diagnosed but do not meet either the 
clinical or laboratory case definition, reporting areas 
have the option of verifying TB cases based on provider 
diagnosis as described in Appendix B. Through 2008, 
1Other U.S. jurisdictions include American Samoa, the Com-
monwealth of the Northern Mariana Islands, the Federated States 
of Micronesia, Guam, the Republic of the Marshall Islands, the 
Republic of Palau, and U.S. Virgin Islands
the RVCT did not collect information on IGRA results. 
If an IGRA was performed in lieu of the TST, then the 
RVCT would have indicated that the TST was not per-
formed. Thus, culture- and smear-negative cases without 
a TST that are diagnosed by a positive IGRA result prior 
to 2008 were considered to have been confirmed by 
provider diagnosis. However, starting in 2009, positive 
results for an IGRA are included as part of the clinical 
case definition for TB confirmation. A case of an anergic 
patient with a clinical presentation consistent with TB 
but without laboratory evidence of M. tuberculosis com-
plex would also be an example of provider diagnosis.
TB Case Verification Criteria Calculation
The software for TB surveillance developed by CDC 
includes a calculated variable for TB case verification 
called “Vercrit,” which was modified in 2009.  The new 
variables, Nucleic Acid Amplification Test Result, 
Interferon Gamma Release Assay (IGRA) for Myco-
bacterium tuberculosis at Diagnosis, and Initial Chest 
CT Scan or Other Chest Imaging Study were added 
in the Vercrit calculation.
“Vercrit” is calculated by using the following criteria in 
hierarchical order:
1. Positive culture
2. Positive nucleic acid amplification test
3. Positive acid-fast bacilli test
4. Clinical case confirmation
5. Provider diagnosis
Changes in Reporting and Counting TB Cases
In 2009, the Recommendations for Reporting and 
Counting Tuberculosis Cases in Appendix B were modi-
fied. TB cases that are verified but not countable for 
morbidity statistics can now be reported to CDC as a 
measure of programmatic and case management burden. 
However, data on noncountable TB cases are incom-
plete and not included in this report. 
The recommendations for counting TB cases among 
immigrants, refugees, and foreign visitors were revised 
based on the recommendations in the 2007 Technical 
Instructions for Tuberculosis Screening and Treatment 
for Panel Physicians.2 Regardless of Panel Physician 
classification or citizenship status, immigrants and refu-
gees examined after arriving in the United States and 
diagnosed with clinically active TB requiring anti-TB 
medications should be reported and counted by the lo-
2CDC. Immigration Requirements: Technical Instructions for 
Tuberculosis Screening and Treatment, 2007.  Atlanta: CDC, 
Division of Global Migration and Quarantine, revised September 
2007; http://www.cdc.gov/ncidod/dq/pdf/ti_tb_8_9_2007.pdf.
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cality of their current residence at the time of diagnosis. 
Foreign visitors diagnosed with TB, receiving anti-TB 
therapy, and planning to remain in the United States for 
90 days or more should be reported and counted by the 
locality of current residence.
New and Expanded RVCT Variables
Data on demographic, clinical, laboratory, initial treat-
ment, and treatment outcomes are collected through the 
RVCT’s three data collection reports:
1. Report of Verified Case of Tuberculosis: for all 
patients with a verified case of TB.
2. Initial Drug Susceptibility Report (Follow-Up 
Report 1): for all patients who had a culture 
that was positive for M. tuberculosis complex. 
3. Case Completion Report (Follow-Up Report 
2): for all patients who were alive when TB 
was diagnosed. 
In 2009, the RVCT was modified and expanded to 
include 11 additional variables. Modifications to the 
RVCT accommodate the changing epidemiology of 
TB in terms of risk factors, new drug treatments, and 
enhanced laboratory capacity for diagnostic tests.  The 
2013 Report contains many tables reflecting the addi-
tion of these variables
The instructions for completing the RVCT forms 
and the definitions for all data items are available at: 
CDC. Report of Verified Case of Tuberculosis (RVCT) 
Instruction Manual.  Atlanta, GA: U.S. Department of 
Health and Human Services, CDC, 2009.  http://www.
cdc.gov/tb/programs/rvct/InstructionManual.pdf. 
Tabulation and Presentation of TB Data  
This report presents summary data for TB cases report-
ed to CDC in 2013. TB cases are tabulated by year in 
which the reporting area verified that the patient had TB 
and included the patient in its official annual TB case 
count. Since 2004, the published report has reflected 
updated information on the numbers of cases of con-
firmed TB for each year from 1993 onward. Totals for 
the United States include data from the 50 states, the 
District of Columbia (DC), and New York City.  
Trend data are presented in Tables 1 through 15.  Age 
group tabulations are based on the patient’s age in the 
month and year the patient was reported to the health 
department as a suspected TB case.  State or metro-
politan area data tabulations are based on the patient’s 
residence at diagnosis of TB.
Rates
Rates are expressed as the number of cases reported 
each calendar year per 100,000 persons. Population 
denominators used in calculating TB rates were based 
on official census and midyear postcensal estimates 
from the U.S. Census Bureau.  In Tables 1, 30, and 31, 
the U.S. total populations for 2000–2010 were taken 
from the U.S. Census Annual Estimates of the Resident 
Population for the United States, Regions, States, and 
Puerto Rico (April 1, 2000 to July 1, 2010); populations 
for 2011–2013 were taken from the U.S. Census Annual 
Estimates of the Resident Population for the United 
States, Regions, States, and Puerto Rico (April 1, 2010 
to July 1, 2013).
In 2003, two modifications were made to the RVCT 
form: 1) entries for multiple race (two or more races 
reported for a person) were allowed, and 2) the previous 
category of “Asian/Pacific Islander” was divided into 
“Asian” and “Native Hawaiian or Other Pacific Is-
lander.” To calculate rates in Table 2, denominators for 
2000–2013 were obtained from the National Population 
Estimates for the 2000s: Monthly Postcensal Resident 
Population, by single year of age, sex, race, and His-
panic origin and National Population Estimates for the 
2010s: Monthly Postcensal Resident Population, by 
single year of age, sex, race, and Hispanic origin. The 
population source for nativity is the Current Population 
Survey and is used to calculate case rates for U.S. and 
foreign-born TB.  This population source includes pop-
ulations for the 50 states and D.C., those born abroad of 
U.S. parents, and those born in U.S. outlying areas (the 
U.S.-affiliated areas) as the U.S-born population.  
To calculate rates for Table 4, denominators were 
obtained from the Annual Estimates of the Resident 
Population by Sex and Five-Year Age Groups for the 
United States (April 1, 2000 to July 1, 2009) and An-
nual Estimates of the Resident Population for Selected 
Age Groups by Sex for the United States, States, Coun-
ties, and Puerto Rico Commonwealth and Municipios 
(April 1, 2010 to July 1, 2013).  Denominators for 
computing 2013 rates in Table 17 were obtained from 
U.S. Census Monthly Postcensal Resident Population, 
by single year of age, sex, race, and Hispanic origin. In 
2004, the method for calculating the annual percentage 
change in the TB case rate was modified. Unrounded 
figures are applied to calculate the percentage change in 
the case rate.
In Table 5, the populations for U.S.-born and foreign-
born persons for 1993 and 1994 were obtained from 
Quarterly Estimates of the United States Foreign-born 
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and Native Resident Populations: April 1, 1990–July 
1, 1999.  Denominators for computing the 1995–2013 
rates were based on extrapolations from the U.S. Cen-
sus Current Population Survey (July Supplement).
Mortality Data
Official TB mortality statistics for the United States are 
compiled by the National Center for Health Statistics 
(NCHS), CDC. The annual mortality rate is calculated 
as the number of deaths due to TB in that year, divided 
by the estimated population for the year, multiplied by 
100,000 (Table 1). The preliminary number of deaths 
for 2011 was obtained from the NCHS, National Vital 
Statistics Report, Vol. 61, No. 6, October 10, 2012. 
Finalized numbers of deaths for 2011 or preliminary 
numbers for later years were not available at the time of 
this publication.
Drug Resistance
Drug-resistance patterns are displayed in separate tables 
with drug-resistance trend data by previous TB status 
and origin of birth. Isoniazid (INH) resistance and 
multidrug resistance (MDR) are shown in Tables 8 and 
9, respectively.
Completion of Tuberculosis Therapy
Tables 10, 59, 60, and 61 present rates of completion 
of TB therapy (COT).  Data collected by RVCT Fol-
low Up Report-2 on date and reason therapy stopped 
(e.g., patient completed therapy) were used to calculate 
rates of COT.  Cases were stratified by the indicated 
length of therapy, based on American Thoracic Society/
CDC/Infectious Diseases Society of America treatment 
guidelines3 in effect during the period covered, and the 
patient’s initial drug-susceptibility test results, age, and 
site of disease. 
In Table 60, the first column shows the total number of 
cases reported during 2011.  The remaining columns 
are grouped under three headings: therapy of 1 year or 
less indicated therapy, greater than 1 year indicated, and 
overall. Patients eligible to complete therapy within 1 
year had to have been alive at diagnosis, and initiated 
therapy with at least one drug. Eligible patients did not 
have rifampin resistance, did not die within 1 year of 
initiating therapy, did not move out of country within 1 
year of initiating therapy, and did not have meningeal 
TB, bone and joint TB or TB of the central nervous 
system, regardless of age.  In addition, TB patients un-
der the age of 15 were not eligible to complete therapy 
within 1 year if they had disseminated disease (defined 
3CDC. Treatment of Tuberculosis, American Thoracic Society, 
CDC, and the Infectious Diseases Society of America. MMWR 
2003;52(No.RR-11):1-77.
as miliary tuberculosis and/or a positive tuberculosis 
blood culture). Patients with culture-negative disease, 
those with an unknown culture status, and those with 
culture-positive disease but unknown initial drug-sus-
ceptibility test results were included under the category 
of 1 year or less of therapy indicated.    
In Table 60, each group under an indicated length of 
therapy has an initial column showing the number 
of cases in persons who were alive at diagnosis and 
prescribed an initial regimen of one or more drugs, and 
who did not die during therapy. This number was used 
as the denominator in COT rate calculations.
COT rates, shown as percentages, were only calculated 
for areas reporting reason therapy stopped for at least 
90% of cases shown in the overall column. For the 
group with an indicated length of therapy of 1 year or 
less, rates are shown for both COT in 1 year or less 
(COT ≤1 year) and for COT, regardless of duration 
(i.e., duration of therapy ≤1 year, >1 year, or unknown).  
For COT ≤1 year, the numerator included only those 
patients completing therapy in ≤366 days (based on the 
dates therapy started and stopped).  Patients with miss-
ing dates were classified as “treatment not completed” 
for this calculation.
Rates of COT, regardless of duration, were calculated 
by dividing the number of patients reported as having 
completed therapy by the number of total eligible pa-
tients.  Patients with an outcome other than completed 
therapy (i.e., moved, lost, refused treatment, or other) 
were classified as “treatment not completed.”  Patients 
with an unknown outcome were also classified as “treat-
ment not completed.”  For the remaining two groups 
of indicated therapy length (greater than 1 year and 
overall), only rates of COT, regardless of duration, are 
presented.  Table 10 provides rates for COT ≤1 year and 
for COT, regardless of duration, only for the group with 
an indicated therapy of 1 year or less.  Table 59 presents 
rates of COT by ethnicity and non-Hispanic race and 
by state for those in whom therapy less than 1 year was 
indicated.
Because streptomycin is no longer being used as part of 
the standard treatment for TB disease, streptomycin has 
been removed from the calculated variable for initial 
drug regimen. Consequently, a separate column for the 
treatment regimen of isoniazid, rifampin, pyrazinamide 
(IRZ), ethambutol, streptomycin (E/S) is no longer 
reported in Tables 10 and 49.
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Site of TB Disease
Miliary disease is classified as both an extrapulmonary 
and a pulmonary form of TB (Tables 7, 38, and 39).  In 
publications prior to 1997, miliary disease was classi-
fied as extrapulmonary TB unless pulmonary disease 
was reported as the major site of TB disease.  Begin-
ning in 2009, miliary disease could not be classified as 
a site of TB disease because it is a clinical or radiologic 
finding and should be recorded under Initial Chest 
Radiograph, Initial Chest CT Scan, or Other Chest 
Imaging Study.
Reporting of HIV Status 
Information on HIV status for persons with TB is 
shown in Tables 11 and 51 among those persons not 
dead at diagnosis; Table 11 additionally shows trend 
data for persons aged 25–44 years. The completeness 
of reporting on HIV status among persons with TB 
has significantly improved to 94% of TB cases tested 
among persons aged 25–44 years in 2013; however, this 
variable is still underreported among jurisdictions. Data 
on the HIV-infection status of persons with reported TB 
cases should be interpreted with caution.  These data are 
not representative of all TB patients with HIV infection. 
HIV testing is performed after a patient receives coun-
seling and gives informed consent.  TB patients who are 
tested anonymously may choose not to share the results 
of HIV testing with their health care provider.  TB 
patients managed in the private sector may receive con-
fidential HIV testing, but results may not be reported to 
the TB program in the health department.  In addition, 
many factors may influence HIV testing of TB patients, 
including the extent to which testing is targeted or 
routinely offered to specific groups (e.g., 25- to 44-year-
old males, injecting drug users, homeless persons), and 
the availability of and access to HIV testing services.  
These data may overrepresent or underrepresent the 
proportion of TB patients known to be HIV infected in a 
reporting area.
Primary Occupation for the Past Year
Table 48 now reflects the new 2009 RVCT variable, 
Primary Occupation Within the Past Year, which 
replaces the Occupation Within Past 24 months of 
TB Diagnosis in previous reports. Following the 2009 
RVCT revision, “Multiple Occupation” was removed 
and the “Retired” and “Not Seeking Employment” 
categories were added.
Reason Therapy Stopped
Tables 12 and 57 now include a patient’s adverse reac-
tion to anti-TB drug therapy as an option for the reason 
therapy stopped. The 2009 RVCT revision removed 
the option of “Moved” as a valid response to the vari-
able Reason Therapy Stopped and this option is not 
reported after 2009.
Metropolitan Statistical Areas
Tables 63 through 67 present data by metropolitan sta-
tistical areas (MSAs) with an estimated 2013 population 
of 500,000 or more. MSAs are defined by the federal 
Office of Management and Budget, and the definitions 
were based on the application of the 2010 OMB stan-
dards to 2010 Census and 2006-2010 American Com-
munity Survey data announced as of February 2013 
(http://www.whitehouse.gov/sites/default/files/omb/
bulletins/b-13-01.pdf). 
The MSA definitions apply to all areas except the six 
New England states; for these states, the New England 
County Metropolitan Areas (NECMAs) are used. MSAs 
are named for a central city in the MSA or NECMA, 
may include several cities and counties, and may cross 
state boundaries. For example, the TB cases and case 
rates presented for the District of Columbia in Table 
30 include only persons residing within the geographic 
boundaries of the District. However, the TB cases and 
case rates for the Washington, D.C., MSA (Table 63) 
include persons residing within the several counties in 
the metropolitan area, including counties in Maryland, 
Virginia, and West Virginia.   
A city/MSA with incomplete or unavailable data was 
not included in the tables and some cities’ or MSAs’ 
total numbers may be underreported owing to missing 
information
National Tuberculosis Genotyping Service (NTGS)
NTGS laboratories primarily use two genotyping meth-
ods: spoligotyping and MIRU–VNTR. Both methods 
require only a small amount of culture material, provide 
digital results, and are relatively quick. IS6110-restric-
tion fragment length polymorphism (IS6110-RFLP) and 
retrospective 24-locus MIRU-VNTR for older isolates 
can be performed, if requested, and may help in further 
differentiating genotype clusters. All isolates are pre-
pared for long-term storage at genotyping laboratories 
or CDC. 
Tuberculosis Genotyping Information Management 
System (TB GIMS)
In March 2010, TB GIMS was launched by CDC as 
a secure Web-based system to support ongoing use of 
TB genotyping data in TB control activities.  TB GIMS 
facilitates systematic data collection of TB genotyping 
results and integrates genotyping results with epide-
miologic data collected by the National TB Surveil-
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lance System (NTSS) to form a national and central-
ized database. Primary users of TB GIMS include TB 
laboratories that submit isolates for genotyping, national 
CDC-contracted genotyping laboratories, state and local 
TB control programs, and CDC that apply this informa-
tion for TB control activities. 
Genotyping results from the national genotyping labo-
ratories or CDC are uploaded into TB GIMS as they be-
come available.  Line-listed data from the National TB 
Surveillance System are also uploaded into TB GIMS 
weekly.  Once genotyping results have been linked to 
individual patient surveillance data in TB GIMS, the 
record is considered complete.  Complete records are 
essential for most of the applications of TB genotyp-
ing, including all reports and maps as well as using the 
outbreak detection system to identify potential chains of 
transmission and outbreaks. 
There have been 16 system updates adding new reports, 
data management functions, and other tools since TB 
GIMS was released in March 2010. As of June 2014, 
there were 463 local, state, and federal users of the 
system.
Genotype Clustering
A genotype cluster consists of two or more cases in 
a jurisdiction during a specified time period with M. 
tuberculosis isolates that share matching genotypes. 
The jurisdiction and time period used vary based on 
the specific application.  Cases that are part of the same 
genotype cluster are likely to be related by TB trans-
mission in some way; however, the cases may not be 
directly related (i.e., one case did not necessarily give 
TB to another case in the cluster) or recently related 
(i.e., both cases may have gotten TB from the same 
person, but the exposure may have happened years 
ago). Therefore, while we use genotype clustering to 
identify likely TB transmission, transmission must be 
confirmed using field data from contact investigations 
or other sources. In TB GIMS, clustering is defined as 
2 or more cases with matching genotypes (spoligotype 
and 24-locus MIRU-VNTR) in a single county within a 
3-year time period.
Mycobacterium bovis
Mycobacterium bovis can be defined on the basis of 
spoligotyping results; spoligotyping is a tool for dif-
ferentiating M. bovis from M. tuberculosis. The spoligo-
typing-based definition requires either (1) the absence 
of spacers 3, 9, 16, and 39–43; the presence of at least 
1 of the spacers 29–32; and the presence of at least 1 of 
the spacers 33–36; or (2) the absence of spacers 3, 9, 







1953 84,304 52.6 -- -- 19,707 12.4 -- --
1954 79,775 48.9 -5.4 -7.0 16,527 10.2 -16.1 -17.7
1955 77,368 46.6 -3.0 -4.7 15,016 9.1 -9.1 -10.8
1956 69,895 41.4 -9.7 -11.1 14,137 8.4 -5.9 -7.7
1957 67,149 39.0 -3.9 -5.8 13,390 7.8 -5.3 -7.1
1958 63,534 36.3 -5.4 -6.9 12,417 7.1 -7.3 -9.0
1959 57,535 32.4 -9.4 -10.7 11,474 6.5 -7.6 -8.5
1960 55,494 30.7 -3.5 -5.2 10,866 6.0 -5.3 -7.7
1961 53,726 29.2 -3.2 -4.9 9,938 5.4 -8.5 -10.0
1962 53,315 28.6 -0.8 -2.1 9,506 5.1 -4.3 -5.6
1963 54,042 28.6 1.4 0.0 9,311 4.9 -2.1 -3.9
1964 50,874 26.5 -5.9 -7.3 8,303 4.3 -10.8 -12.2
1965 49,016 25.2 -3.7 -4.9 7,934 4.1 -4.4 -4.7
1966 47,767 24.3 -2.5 -3.6 7,625 3.9 -3.9 -4.9
1967 45,647 23.0 -4.4 -5.3 6,901 3.5 -9.5 -10.3
1968 42,623 21.2 -6.6 -7.8 6,292 3.1 -8.8 -11.4
1969 39,120 19.3 -8.2 -9.0 5,567 2.8 -11.5 -9.7
1970 37,137 18.1 -5.1 -6.2 5,217 2.6 -6.3 -7.1
1971 35,217 17.0 -5.2 -6.1 4,501 2.2 -13.7 -15.4
1972 32,882 15.7 -6.6 -7.6 4,376 2.1 -2.8 -4.5
1973 30,998 14.6 -5.7 -7.0 3,875 1.8 -11.4 -14.5
 19742 30,122 14.1 -2.8 -3.4 3,513 1.7 -9.3 -5.6
1975 33,989 15.7 -- -- 3,333 1.6 -5.1 -5.9
1976 32,105 14.7 -5.5 -6.4 3,130 1.5 -6.1 -6.3
1977 30,145 13.7 -6.1 -6.8 2,968 1.4 -5.2 -6.7
1978 28,521 12.8 -5.4 -6.6 2,914 1.3 -1.8 -7.1
 19793 27,669 12.3 -3.0 -3.9 2,007 0.9 -31.1 -30.8
1980 27,749 12.2 0.3 -0.7 1,978 0.9 -1.4 0.0
1981 27,373 11.9 -1.4 -2.3 1,937 0.8 -2.1 -11.1
1982 25,520 11.0 -6.8 -7.7 1,807 0.8 -6.7 0.0
1983 23,846 10.2 -6.6 -7.4 1,779 0.8 -1.5 0.0
1984 22,255 9.4 -6.7 -7.5 1,729 0.7 -2.8 -12.5
1985 22,201 9.3 -0.2 -1.1 1,752 0.7 1.3 0.0
1986 22,768 9.5 2.6 1.6 1,782 0.7 1.7 0.0
1987 22,517 9.3 -1.1 -2.0 1,755 0.7 -1.5 0.0
1988 22,436 9.2 -0.4 -1.3 1,921 0.8 9.5 14.3
1989 23,495 9.5 4.7 3.7 1,970 0.8 2.6 0.0
1990 25,701 10.3 9.4 8.2 1,810 0.7 -8.1 -12.5
1991 26,283 10.4 2.3 0.9 1,713 0.7 -5.4 0.0
1992 26,673 10.4 1.5 0.1 1,705 0.7 -0.5 0.0
1993 25,102 9.7 -5.9 -7.1 1,631 0.6 -4.3 -14.3
1994 24,206 9.2 -3.6 -4.7 1,478 0.6 -9.4 0.0
1995 22,726 8.5 -6.1 -7.2 1,336 0.5 -9.6 -16.7
1996 21,210 7.9 -6.7 -7.8 1,202 0.5 -10.0 0.0
1997 19,751 7.2 -6.9 -8.0 1,166 0.4 -3.0 -20.0
1998 18,286 6.6 -7.4 -8.5 1,112 0.4 -4.6 0.0
1999 17,499 6.3 -4.3 -5.4 930 0.3 -16.4 -25.0
2000 16,308 5.8 -6.8 -7.8 776 0.3 -16.6 0.0
2001 15,945 5.6 -2.2 -3.2 764 0.3 -1.6 0.0
2002 15,055 5.2 -5.6 -6.5 784 0.3 2.6 0.0
2003 14,835 5.1 -1.5 -2.3 711 0.2 -10.2 -33.3
2004 14,499 4.9 -2.3 -3.2 662 0.2 -6.9 0.0
2005 14,061 4.8 -3.0 -3.9 648 0.2 -2.1 0.0
2006 13,727 4.6 -2.4 -3.3 644 0.2 -0.6 0.0
2007 13,282 4.4 -3.2 -4.2 554 0.2 -14.0 0.0
2008 12,893 4.2 -2.9 -3.8 590 0.2 6.5 0.0
2009 11,519 3.8 -10.7 -11.4 529 0.2 -10.3 0.0
2010 11,164 3.6 -3.1 -3.8 569 0.2 7.6 0.0
2011 10,509 3.4 -5.9 -6.5 536 0.2 -5.8 0.0
2012 9,940 3.2 -5.4 -6.1 … … … …
2013 9,582 3.0 -3.6 -4.3 … … … …
Table 1. Tuberculosis Cases, Case Rates per 100,000 Population, Deaths, and Death Rates 
per 100,000 Population, and Percent Change:  United States, 1953–2013
Tuberculosis Cases Tuberculosis Deaths
Percent ChangePercent Change
Number Rate Number RateNumber Number1Rate Rate1Year
1 Official tuberculosis mortality statistics were compiled by the National Center for Health Statistics, CDC, National Vital Statistics Reports. 
2 Case data after 1974 are not comparable to prior years due to changes in the surveillance case definition that became effective in 1975. 
3 The large decrease in death rate in 1979 occurred because late effects of tuberculosis (e.g., bronchiectasis or fibrosis) and pleurisy with effusion (without mention of cause) are 
no longer included in tuberculosis deaths.
Percent change in tuberculosis death rates is calculated with rounded figures. See Technical Notes. 
Note: 1993 to 2013 tuberculosis case counts and rates updated as of June 11, 2014, using Bridged-Race 1990–1999 Intercensal Population Estimates for 1990–1999 (ftp://ftp.
cdc.gov/pub/health_statistics/nchs/datasets/nvss/bridgepop/documentationbridgedintercena1.doc) (accessed July 15, 2014) and Intercensal Estimates of the Resident Popula-
tion for the United States, Regions, States, and Puerto Rico: April 1, 2000 to July 1, 2010 (http://www.census.gov/popest/data/intercensal/state/state2010.html) (accessed July 
15, 2014) and Annual Estimates of the Resident Population for the United States, Regions, States, and Puerto Rico: April 1, 2010 to July 1, 2013 (http://www.census.gov/popest/
data/national/totals/2013/index.html) (accessed July 15, 2014). 





































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Total Cases 6193 (100) 6274 (100) 6522 (100) 6773 (100) 6956 (100)
Mexico 1,244 (20) 1,312 (21) 1,444 (22) 1,542 (23) 1,593 (23)
Philippines 783 (13) 772 (12) 756 (12) 757 (11) 806 (12)
India 495 (8) 531 (8) 511 (8) 585 (9) 540 (8)
Viet Nam 456 (7) 454 (7) 550 (8) 542 (8) 529 (8)
China 377 (6) 353 (6) 378 (6) 370 (5) 344 (5)
Guatemala 213 (3) 194 (3) 172 (3) 198 (3) 214 (3)
Haiti 172 (3) 197 (3) 189 (3) 195 (3) 207 (3)
Ethiopia 157 (3) 162 (3) 154 (2) 162 (2) 171 (2)
Honduras 122 (2) 125 (2) 129 (2) 143 (2) 150 (2)
Myanmar 102 (2) 116 (2) 92 (1) 116 (2) 104 (2)
Korea, Republic of 101 (2) 109 (2) 131 (2) 120 (2) 155 (2)
El Salvador 97 (3) 116 (2) 103 (2) 116 (2) 118 (2)
Somalia 85 (1) 100 (2) 116 (2) 124 (2) 113 (2)
Peru 90 (1) 79 (1) 93 (1) 111 (2) 94 (1)
Cambodia 72 (1) 78 (1) 91 (1) 70 (1) 99 (1)
Ecuador 79 (1) 65 (1) 79 (1) 84 (1) 99 (1)
Pakistan 78 (1) 68 (1) 87 (1) 74 (1) 84 (1)
Nepal 73 (1) 81 (1) 77 (1) 64 (1) 74 (1)
Dominican Republic 62 (1) 74 (1) 75 (1) 85 (1) 71 (1)
Laos 88 (1) 64 (1) 62 (1) 70 (1) 60 (1)
Kenya 48 (1) 58 (1) 75 (1) 63 (1) 73 (1)
Bangladesh 71 (1) 54 (1) 66 (1) 58 (1) 44 (1)
Nigeria 69 (1) 58 (1) 52 (1) 43 (1) 46 (1)
Bhutan 56 (1) 58 (1) 39 (1) 37 (1) 33 (0)
Thailand 38 (1) 33 (1) 37 (1) 47 (1) 57 (1)
Indonesia 35 (1) 41 (1) 32 (0) 58 (1) 34 (0)
Colombia 37 (1) 25 (0) 32 (0) 43 (1) 40 (1)
Korea, Dem. Peoples Republic 37 (1) 47 (1) 38 (1) 35 (1) 16 (0)
Cuba 25 (0) 30 (0) 40 (1) 33 (0) 36 (1)
Liberia 29 (0) 33 (1) 28 (0) 36 (1) 33 (0)
All Others3 802 (12) 787 (13) 794 (12) 792 (12) 919 (13)
 Table 6. Tuberculosis Cases and Percentages Among Foreign-born Persons1 by the Top 30 
Countries2 of Birth: United States, 2009–2013
Country of Origin
2013 2012 2011 2010 2009
Year
No. No. No. No. No.(%) (%) (%) (%) (%)
1Includes persons born outside the United States, American Samoa, the Federated States of Micronesia, Guam, the Republic of the 
Marshall Islands, Midway Island, the Commonwealth of the Northern Mariana Islands, Puerto Rico, the Republic of Palau, the U.S. Virgin 
Islands, and U.S. minor and outlying Pacific islands.
2The top 30 countries were selected based on their ranked 5-year average number of TB cases.
3 Includes Not Specified for Country of Origin. 
Note: Zero (0) denotes <0.5%.






































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































1993 (13.0) (31.2) (40.3) (21.7) (14.4) (63.4) (86.0)
1994 (7.0) (23.3) (55.7) (28.1) (20.5) (68.6) (86.8)
1995 (5.2) (20.3) (62.7) (37.3) (21.5) (74.1) (89.2)
1996 (4.2) (17.5) (67.3) (42.5) (22.4) (76.8) (90.2)
1997 (3.2) (15.1) (71.9) (47.0) (23.8) (78.7) (91.0)
1998 (2.6) (12.9) (74.3) (47.7) (26.6) (81.2) (92.2)
1999 (2.2) (11.2) (76.9) (49.4) (27.6) (81.4) (92.2)
2000 (2.0) (10.4) (78.5) (52.5) (25.8) (82.2) (92.5)
2001 (1.7) (9.6) (79.8) (53.6) (27.5) (82.5) (92.7)
2002 (1.8) (8.9) (80.3) (55.4) (27.8) (83.0) (92.5)
2003 (1.4) (8.1) (81.3) (56.5) (28.5) (83.6) (92.8)
2004 (1.5) (6.4) (82.4) (58.9) (27.7) (84.3) (92.6)
2005 (1.3) (5.5) (83.7) (57.9) (29.6) (84.0) (92.5)
2006 (1.2) (4.8) (83.3) (57.5) (30.4) (84.8) (93.2)
2007 (1.1) (4.6) (83.6) (56.3) (32.9) (85.6) (93.9)
2008 (1.0) (3.5) (84.3) (56.3) (33.5) (86.0) (93.3)
2009 (0.9) (3.1) (84.6) (59.5) (30.3) (88.7) (95.5)
2010 (0.8) (2.8) (84.8) (59.0) (31.2) (89.6) (96.0)
20115 (0.7) (2.6) (85.4) (62.0) (29.3) (89.0) (95.7)
2012 (0.6) (2.1) (85.2) (61.6) (29.4) (86.6) (92.0)
2013 (0.5) (2.4) (84.1) (64.1) (27.4) (55.2) (56.2)
 Table 10.  Percentages of Tuberculosis Cases by Initial Drug Regimen, Use of Directly  




Therapy <1 Year Indicated4
IRZ DOT Only
Both DOT and Self-
Administered COT <1 Year COTIR
 1 Includes persons alive at diagnosis.
2 I=isoniazid; R=rifampin; Z=pyrazinamide; E=ethambutol.  Excludes cases with no information on initial drug regimen; In 2013, 0.57% re-
ceived no initial drug therapy, 0.02% were started on one drug, and 12.36% had an initial multidrug regimen other than IR, IRZ, or IRZE.
3 Includes persons alive at diagnosis with initial drug regimen of one or more drugs prescribed.
4 Includes persons alive at diagnosis, with initial drug regimen of one or more drugs prescribed, who did not die during therapy.  Excludes 
persons with initial isolate rifampin resistant, or patient with meningeal disease, or pediatric patient (aged <15) with miliary disease or 
positive blood culture. 
5 Begining in 2011, those who moved out of country during treatment are excluded from the denominator of those eligible for COT.
Note: Data for all years updated through June 11, 2014.
See Technical Notes for description of COT calculation.









































































































































































































































































































































































































































































































































































































































































































































































































































































































1993 23740 18043 (76.0) 0 (0.0) 1120 (4.7) 1086 (4.6) 223 (0.9) 3053 (12.9) 215 (0.9)
1994 23052 17764 (77.1) 0 (0.0) 1194 (5.2) 740 (3.2) 183 (0.8) 2743 (11.9) 428 (1.9)
1995 21705 17306 (79.7) 0 (0.0) 969 (4.5) 570 (2.6) 155 (0.7) 2396 (11.0) 309 (1.4)
1996 20298 16528 (81.4) 0 (0.0) 783 (3.9) 525 (2.6) 156 (0.8) 1998 (9.8) 308 (1.5)
1997 18930 15673 (82.8) 0 (0.0) 667 (3.5) 444 (2.3) 119 (0.6) 1755 (9.3) 272 (1.4)
1998 17583 14766 (84.0) 0 (0.0) 533 (3.0) 411 (2.3) 104 (0.6) 1579 (9.0) 190 (1.1)
1999 16861 14234 (84.4) 0 (0.0) 456 (2.7) 359 (2.1) 104 (0.6) 1437 (8.5) 271 (1.6)
2000 15784 13407 (84.9) 0 (0.0) 406 (2.6) 397 (2.5) 112 (0.7) 1294 (8.2) 168 (1.1)
2001 15409 13242 (85.9) 0 (0.0) 378 (2.5) 402 (2.6) 99 (0.6) 1121 (7.3) 167 (1.1)
2002 14564 12482 (85.7) 0 (0.0) 336 (2.3) 412 (2.8) 87 (0.6) 1080 (7.4) 167 (1.1)
2003 14379 12418 (86.4) 0 (0.0) 313 (2.2) 389 (2.7) 84 (0.6) 994 (6.9) 181 (1.3)
2004 14080 12118 (86.1) 0 (0.0) 337 (2.4) 370 (2.6) 82 (0.6) 975 (6.9) 198 (1.4)
2005 13674 11728 (85.8) 1 (0.0) 323 (2.4) 338 (2.5) 90 (0.7) 985 (7.2) 209 (1.5)
2006 13316 11540 (86.7) 0 (0.0) 292 (2.2) 358 (2.7) 79 (0.6) 939 (7.1) 108 (0.8)
2007 12907 11348 (87.9) 0 (0.0) 241 (1.9) 327 (2.5) 73 (0.6) 819 (6.3) 99 (0.8)
2008 12550 10886 (86.7) 7 (0.1) 257 (2.0) 329 (2.6) 78 (0.6) 843 (6.7) 150 (1.2)
2009 11182 9830 (87.9) 22 (0.2) 96 (0.9) 166 (1.5) 82 (0.7) 681 (6.1) 305 (2.7)
2010 10833 9534 (88.0) 29 (0.3) … (0.0) 155 (1.4) 64 (0.6) 653 (6.0) 396 (3.7)
2011 10203 8912 (87.3) 28 (0.3) … (0.0) 124 (1.2) 68 (0.7) 684 (6.7) 385 (3.8)







Moved2 Lost Refused Died3 Unknown4
1 Includes all cases in persons reported as alive at diagnosis and taking one or more TB drugs.
2 In 2009 the moved variable was removed from the RVCT; see Technical Notes for details.
3 Died = died of any cause (not only TB).
4 Includes cases in persons reporting reason therapy stopped = Other, Missing, or Unknown. 
Note: Data for all years are updated through June 11, 2014.
Data complete through 2011 only.  See Technical Notes for details.




2004 14,499 11,327 5,955 52.6
2005 14,061 10,955 7,500 68.5
2006 13,727 10,744 7,527 70.1
2007 13,282 10,426 8,431 80.9
2008 12,893 10,022 8,179 81.6
2009 11,519 8,882 7,712 86.8
2010 11,164 8,460 7,745 91.5
2011 10,509 8,086 7,610 94.1
2012 9,940 7,615 7,210 94.7
2013 9,582 7,358 6,957 94.6




1 Genotype surveillance coverage is defined as the percentage of all culture positive tuberculosis (TB) cases for which there was a 
genotyped isolate.
NOTE: This table reflects genotyping surveillance coverage for the 50 states and the District of Columbia; for genotyping surveillance 
coverage of the United States Affiliated Pacific Islands, please see Table 14.











2004 288 213 19 8.9
2005 388 237 95 40.1
2006 344 211 84 39.8
2007 526 180 84 46.7
2008 553 240 72 30.0
2009 533 237 207 87.3
2010 617 308 270 87.7
2011 462 229 187 81.7
2012 488 247 221 89.5
2013 407 216 176 81.5




1 Genotype surveillance coverage is defined as the percentage of all culture positive tuberculosis (TB) cases for which there was a 
genotyped isolate 
2 The United States affiliates include:  American Samoa, Northern Mariana Islands, Federated States of Micronesia, Guam, Marshall 











2004 5,955 87 1.5 28 32.2 59 67.8
2005 7,500 100 1.3 33 33.0 67 67.0
2006 7,527 129 1.7 33 25.6 95 73.6
2007 8,431 129 1.5 27 20.9 101 78.3
2008 8,179 147 1.8 39 26.5 108 73.5
2009 7,712 131 1.7 39 29.8 92 70.2
2010 7,745 121 1.6 30 24.8 91 75.2
2011 7,610 134 1.8 43 32.1 91 67.9
2012 7,210 125 1.7 31 24.8 94 75.2
2013 6,957 113 1.6 37 32.7 76 67.3
Table 15.  Genotyped Tuberculosis Cases with Mycobacterium bovis1 by Origin of Birth: 
United States, 2004–2013
1 Defined by Spoligotype motifs ending in “600”. 
2 This column reports all genotyped M. bovis cases, including those where origin of birth is unknown.







(%) No. (%)3 No. (%)3
32






Total 6193 949 (15) 994 (16) 3688 (60) 562 (9)
Mexico 1244 98 (8) 99 (8) 918 (74) 129 (10)
Philippines 783 83 (11) 99 (13) 529 (68) 72 (9)
India 495 101 (20) 106 (21) 243 (49) 45 (9)
Vietnam 456 44 (10) 63 (14) 285 (63) 64 (14)
China 377 58 (15) 44 (12) 244 (65) 31 (8)
Guatemala 213 39 (18) 42 (20) 120 (56) 12 (6)
Haiti 172 36 (21) 54 (31) 75 (44) 7 (4)
Ethiopia 157 43 (27) 56 (36) 55 (35) 3 (2)
Honduras 122 33 (27) 17 (14) 64 (52) 8 (7)
Myanmar 102 32 (31) 40 (39) 22 (22) 8 (8)
Korea, Republic of 101 8 (8) 3 (3) 80 (79) 10 (10)
El Salvador 97 11 (11) 13 (13) 66 (68) 7 (7)
Peru 90 13 (14) 15 (17) 57 (63) 5 (6)
Laos 88 2 (2) 3 (3) 71 (81) 12 (14)
Somalia 85 27 (32) 18 (21) 37 (44) 3 (4)
Ecuador 79 6 (8) 10 (13) 57 (72) 6 (8)
Pakistan 78 17 (22) 14 (18) 38 (49) 9 (12)
Nepal 73 21 (29) 29 (40) 21 (29) 2 (3)
Cambodia 72 4 (6) 6 (8) 54 (75) 8 (11)
Bangladesh 71 18 (25) 23 (32) 23 (32) 7 (10)
Nigeria 69 21 (30) 25 (36) 22 (32) 1 (1)
Dominican Republic 62 12 (19) 12 (19) 36 (58) 2 (3)
Bhutan 56 35 (63) 18 (32) 1 (2) 2 (4)
Kenya 48 12 (25) 13 (27) 21 (44) 2 (4)
Thailand 38 8 (21) 8 (21) 18 (47) 4 (11)
Colombia 37 5 (14) 3 (8) 29 (78) 0 (0)
Korea Dem People S. Republic 37 3 (8) 0 (0) 22 (59) 12 (32)
Indonesia 35 2 (6) 13 (37) 15 (43) 5 (14)
Congo 32 13 (41) 7 (22) 10 (31) 2 (6)
Liberia 29 9 (31) 3 (10) 13 (45) 4 (14)
All Others4 795 135 (17) 138 (17) 442 (56) 80 (10)
 Table 16. Tuberculosis Cases and Percentages Among Foreign-born Persons1 by the Top 30 
Countries of Birth and Years in the United States Before TB Diagnosis: United States, 2013
Country of Origin2
Total Cases < 1 Year 1 - 4 Years ≥ 5 Years Unknown
No.Years in U.S.3
No. No. No. No. No.(%) (%) (%) (%)
1 Includes persons born outside the United States, American Samoa, the Federated States of Micronesia, Guam, the Republic of the 
Marshall Islands, Midway Island, the Commonwealth of the Northern Mariana Islands, Puerto Rico, the Republic of Palau, the U.S. Virgin 
Islands, and U.S. minor and outlying Pacific islands.
2 Ranked by total case count.
3 Among foreign-born persons, the number of years since arrival in the United States before diagnosis with tuberculosis.
4 Includes Not Specified for Country of Origin. 












































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Total Cases 3,375 262 123 324 693 1,233 739 1
Male 2,183 135 64 169 415 906 494 0
Female 1,188 127 59 155 276 325 245 1
Unknown 4 0 0 0 2 2 0 0
Hispanic or Latino1 658 109 53 129 157 131 79 0
Male 397 55 27 67 108 99 41 0
Female 261 54 26 62 49 32 38 0
Unknown 0 0 0 0 0 0 0 0
American Indian or Alaska Native 124 6 6 15 25 49 23 0
Male 83 4 5 13 15 34 12 0
Female 38 2 1 2 8 14 11 0
Unknown 3 0 0 0 2 1 0 0
Asian 152 50 13 40 25 10 13 1
Male 81 26 6 19 13 6 11 0
Female 71 24 7 21 12 4 2 1
Unknown 0 0 0 0 0 0 0 0
Black or African American 1,257 63 29 100 292 533 240 0
Male 804 32 17 50 170 368 167 0
Female 453 31 12 50 122 165 73 0
Unknown 0 0 0 0 0 0 0 0
Native	Hawaiian	or	Other	Pacific	Islander 44 5 4 9 14 11 1 0
Male 19 3 1 5 4 5 1 0
Female 25 2 3 4 10 6 0 0
Unknown 0 0 0 0 0 0 0 0
White 1,099 23 16 25 173 484 378 0
Male 774 13 7 12 101 382 259 0
Female 325 10 9 13 72 102 119 0
Unknown 0 0 0 0 0 0 0 0
Multiple Race2 34 5 2 6 5 13 3 0
Male 22 2 1 3 3 11 2 0
Female 12 3 1 3 2 2 1 0
Unknown 0 0 0 0 0 0 0 0
Unknown 7 1 0 0 2 2 2 0
Male 3 0 0 0 1 1 1 0
Female 3 1 0 0 1 0 1 0
Unknown 1 0 0 0 0 1 0 0
Age Group
Race/Ethnicity and Sex All Ages Under 5 5–14 15–24 25–44 45–64 >65 Unknown
Table 18.  Tuberculosis Cases in U.S.-born Persons by Hispanic Ethnicity and Non-Hispanic 
Race, Sex, and Age Group: United States, 2013
1 Persons of Hispanic or Latino origin may be of any race or multiple race.             
2 Indicates two or more races reported for a person.         
Note: Case counts for race categories (American Indian or Alaska Native, Asian, Black or African American, Native Hawaiian or Other 
Pacific Islander, and White) are mutually exclusive and do not include persons of Hispanic ethnicity or multiple race. Multiple race does 
not include persons of Hispanic ethnicity.
See Technical Notes.
See Surveillance Slide #15.
39
Age Group
Total Cases 6,193 33 65 654 2,264 1,728 1,447 2
Male 3,623 19 33 371 1,270 1,068 861 1
Female 2,568 14 32 283 994 659 586 0
Unknown 2 0 0 0 0 1 0 1
Hispanic or Latino2 2,036 5 14 219 830 565 403 0
Male 1,320 4 6 154 540 391 225 0
Female 715 1 8 65 290 173 178 0
Unknown 1 0 0 0 0 1 0 0
American Indian or Alaska Native 2 0 0 0 0 1 1 0
Male 2 0 0 0 0 1 1 0
Female 0 0 0 0 0 0 0 0
Unknown 0 0 0 0 0 0 0 0
Asian 2,851 15 22 289 868 833 822 2
Male 1,605 8 12 144 412 492 536 1
Female 1,245 7 10 145 456 341 286 0
Unknown 1 0 0 0 0 0 0 1
Black or African American 837 9 25 112 423 204 64 0
Male 449 3 14 55 244 105 28 0
Female 388 6 11 57 179 99 36 0
Unknown 0 0 0 0 0 0 0 0
Native	Hawaiian	or	Other	Pacific	Islander 16 1 0 1 5 7 2 0
Male 8 1 0 0 2 4 1 0
Female 8 0 0 1 3 3 1 0
Unknown 0 0 0 0 0 0 0 0
White 328 3 3 25 92 87 118 0
Male 172 3 1 15 53 52 48 0
Female 156 0 2 10 39 35 70 0
Unknown 0 0 0 0 0 0 0 0
Multiple Race3 113 0 1 8 43 28 33 0
Male 61 0 0 3 18 20 20 0
Female 52 0 1 5 25 8 13 0
Unknown 0 0 0 0 0 0 0 0
Unknown 10 0 0 0 3 3 4 0
Male 6 0 0 0 1 3 2 0
Female 4 0 0 0 2 0 2 0
Unknown 0 0 0 0 0 0 0 0
Table 19.  Tuberculosis Cases in Foreign-born Persons1 by Hispanic Ethnicity and 
Non-Hispanic Race, Sex, and Age Group: United States, 2013
1 Includes persons born outside the United States, American Samoa, the Federated States of Micronesia, Guam, the Republic of the 
Marshall Islands, Midway Island, the Commonwealth of the Northern Mariana Islands, Puerto Rico, the Republic of Palau, the U.S. Virgin 
Islands, and U.S. minor and outlying Pacific islands.                 
2 Persons of Hispanic or Latino ethnicity may be of any race or multiple race.            
3 Indicates two or more races reported for a person.         
Note: Case counts for race categories (American Indian or Alaska Native, Asian, Black or African American, Native Hawaiian or Other 
Pacific Islander, and White) are mutually exclusive and do not include persons of Hispanic ethnicity or multiple race. Multiple race does 
not include persons of Hispanic ethnicity.
See Technical Notes.
See Surveillance Slide #15.
Race/Ethnicity and Sex All Ages Under 5 5–14 15–24 25–44 45–64 >65 Unknown
40
Algeria 1 Ethiopia 157 Niger 1
Angola 6 Gabon 0 Nigeria 69
Benin 0 Gambia 6 Rwanda 6
Botswana 1 Ghana 21 Sao Tome and Principe 0
Burkina Faso 1 Guinea 9 Senegal 5
Burundi 1 Guinea-Bissau 2 Seychelles 0
Cameroon 27 Kenya 48 Sierra Leone 22
Cape Verde 6 Lesotho 0 South Africa 10
Central African Republic 2 Liberia 29 Swaziland 1
Chad 2 Madagascar 0 Tanzania, UR 0
Comoros 0 Malawi 1 Togo 1
Congo, Republic of 32 Mali 3 Uganda 6
Côte d’Ivoire 7 Mauritania 1 Zambia 7
DR Congo 2 Mauritius 0 Zimbabwe 3
Equatorial Guinea 0 Mozambique 3   
Eritrea 24 Namibia 1
Anguilla 0 Costa Rica 4 Netherland Antilles 0
Antigua and Barbuda 2 Cuba 25 Nicaragua 15
Argentina 6 Dominica 0 Panama 5
Bahamas 0 Dominican Republic 62 Paraguay 2
Barbados 1 Ecuador 79 Peru 90
Belize 1 El Salvador 97 St. Kitts and Nevis 0
Bermuda 0 Grenada 0 St. Lucia 0
Bolivia 9 Guatemala 213 St. Vincent & Grenadines 0
Brazil 21 Guyana 14 Suriname 0
British Virgin Islands 0 Haiti 172 Trinidad and Tobago 9
Canada 6 Honduras 122 Turks and Caicos Islands 1
Cayman Islands 0 Jamaica 17 Uruguay 4
Chile 2 Mexico 1244 Venezuela 15
Colombia 37 Montserrat 0
  
 
Afghanistan 18 Lebanon 1 Sudan 17
Bahrain 0 Libyan Arab Jamahiriya 0 Syrian Arab Republic 0
Djibouti 1 Morocco 11 Tunisia 1
Egypt 5 Oman 0 United Arab Emirates 2
Iran, Islamic Republic of 24 Pakistan 78 West Bank and Gaza 0
Iraq 19 Qatar 1 Yemen 10
Jordan 0 Saudi Arabia 10
Kuwait 3 Somalia 85
Eastern Mediterranean Region
Total Cases = 286
Table 20. Tuberculosis Cases Among Foreign-born Persons1 by Country of Birth2: 
United States, 2013
African Region
Total Cases = 524
Americas Region
Total Cases = 2,275
41
Albania 7 Greece 8 Poland 11
Andorra 0 Hungary 1 Portugal 4
Armenia 4 Iceland 0 Romania 11
Austria 1 Ireland 4 Russian Federation 22
Azerbaijan 3 Israel 4 San Marino 0
Belarus 1 Italy 5 Serbia 5
Belgium 0 Kazakhstan 0 Slovakia 0
Bosnia and Herzegovina 15 Kyrgyzstan 3 Slovenia 1
Bulgaria 2 Latvia 1 Spain 6
Croatia 2 Lithuania 0 Sweden 1
Cyprus 0 Luxembourg 0 Switzerland 0
Czech Republic 1 Macedonia, TFYR 1 Tajikistan 3
Denmark 1 Malta 0 Turkey 5
Estonia 1 Moldova, Republic of 2 Turkmenistan 0
Finland 0 Monaco 0 Ukraine 23
France 2 Montenegro 1 United Kingdom 6
Georgia 2 Netherlands 0 Uzbekistan 4
Germany 12 Norway 2
Bangladesh 71 Korea, DPR 37 Sri Lanka 10
Bhutan 56 Maldives 0 Thailand 38
India 495 Myanmar 102 Timor-Leste 0
Indonesia 35 Nepal 73
Australia 0 Kiribati 0 Philippines 783
Brunei Darussalam 0 Korea, Rep. 101 Samoa 0
Cambodia 72 Lao, PDR 88 Singapore 2
China 377 Malaysia 16 Solomon Islands 0
China, Hong Kong SAR 24 Mongolia 10 Tokelau 0
China, Macao SAR 0 Nauru 0 Tonga 3
Cook Islands 3 New Caledonia 0 Tuvalu 0
Fiji 2 New Zealand 0 Vanuatu 0
French Polynesia 0 Niue 0 Vietnam 456
Japan 14 Papua New Guinea 3 Wallis and Futuna 0
1 Includes persons born outside the United States, American Samoa, the Federated States of Micronesia, Guam, the Republic of the 
Marshall Islands, Midway Island, the Commonwealth of the Northern Mariana Islands, Puerto Rico, the Republic of Palau, the U.S. Virgin 
Islands, and U.S. minor and outlying Pacific islands
2 Country as reported by patient.
3 Includes country codes currently reported via the National Tuberculosis Surveillance System that are not represented by WHO member 
states.
Note:  Regional composition of countries based on WHO Report Global Tuberculosis Report 2013, World Health Organization  
(http://www.who.int/tb/publications/global_report/en).
Table 20.  (Cont’d) Tuberculosis Cases Among Foreign-born Persons1 by Country of Birth2: 
United States, 2013
European Region
Total Cases = 188
Other3
Total Cases = 32
Unknown
Total Cases = 17
Southeast Asia Region
Total Cases = 917
Western	Pacific	Region















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Table 23.  Tuberculosis Cases by Cluster Status1: United States, 2011–2013
1 Cluster status indicates whether a case is unique or clustered within a county for cases with a valid GENType. 
2 A unique case is a case with a GENType (spoligotype and 24 locus mycobacterial interspersed repetitive unit-variable number tandem 
repeat type) that does not match any other case in that county during the specified three-year time period.
3 Clustered cases are defined as two or more cases with same GENType within a county during the specified 3-year time period.






Total 1,532 (100.0) 4,625 (100.0)
2 case cluster 1,015 66.3 2030 43.9
3 case cluster 250 16.3 750 16.2
4 case cluster 111 7.3 444 9.6
5 case cluster 59 3.8 295 6.4
6 case cluster 23 1.5 138 3.0
7 case cluster 17 1.1 119 2.6
8 case cluster 12 0.8 96 2.1
9 case cluster 7 0.5 63 1.4
≥10 case cluster 38 2.5 690 14.9
Table 24.  Tuberculosis Cases and Clusters by Cluster Size1: United States, 2011–2013
1 Clusters have two or more cases with matching spoligotype and 24-locus mycobacterial interspersed repetitive unit-variable number 
tandem repeat type (GENType) within a county during the specified 3-year time period .
2 Cases with matching spoligotype and 24-locus mycobacterial interspersed repetitive unit-variable number tandem repeat type (GEN-
Type) are members of a cluster within a county during the specified 3-year time period.
3 Denominator is total number of clusters
4 Denominator is total number of cases 







G00010 PCR00002 000000000003771 223325173533 444534423428 181 (0.8) 23
G00012 PCR00002 000000000003771 223325173533 445644423328 140 (0.6) 28
G05056 PCR00041 677777477413771 254326223432 14a943263217 109 (0.5) 19
G10345 PCR00160 777776777760601 224325143323 244234423337 97 (0.4) 6
G00016 PCR00041 677777477413771 254326223432 14a843263217 96 (0.4) 24
G00011 PCR00015 777776777760601 224325153323 444234423337 92 (0.4) 29
G00013 PCR00016 700036777760731 222325143223 434534412334 73 (0.3) 20
G00014 PCR00051 776037777760771 223125163324 242434223525 71 (0.3) 17
G01521 PCR01201 000000000003771 223325173534 244544423239 63 (0.3) 11
G00017 PCR00803 000000000003771 222325173533 445644423328 62 (0.3) 13
 Table 25. Ten Most Frequently Reported GENTypes1 Among Genotyped Tuberculosis Cases: 
United States, 2011–2013
PCRType2 Spoligotype 24-locus MIRU-VNTR





1 GENType is defined as a unique combination of spoligotype and 24-locus mycobacterial interspersed repetitive unit-variable number 
tandem repeat (MIRU-VNTR) type.
2 PCRType is defined as a unique combination of spoligotype and 12-locus MIRU-VNTR; every GENType has a corresponding 
PCRType.
3 Among 21,702 cases with GENTypes during 2011–2013.
4 This table reflects common GENTypes for the 50 states and the District of Columbia; for common GENTypes in the United States Affili-
ated Pacific Islands, please see Table 26.
GENType
49
G00017 PCR00803 `000000000003771 222325173533  445644423328 124 (20.9) 2
G01967 PCR03284 000000007720771 225413153223 133532423434 19 (3.2) 1
G01284 PCR00002 `000000000003771 223325173533  44474442334A 18 (3.0) 3
G04701 PCR00117 677777477413771 254326223422 147843263217 14 (2.4) 2
G13204 PCR01535 777777770020771 122325143323 233334213326 13 (2.2) 1
 Table 26. Five Most Frequently Reported GENTypes2 Among Genotyped Tuberculosis Cases: 
United	States	Affiliates1, 2011–2013
PCRType3 Spoligotype 24-locus MIRU-VNTR






1 The United States affiliates include:  American Samoa, Northern Mariana Islands, Federated States of Micronesia, Guam, Marshall 
Islands, Palau, Puerto Rico, and United States Virgin Islands.
2 GENType is defined as a unique combination of spoligotype and 24-locus mycobacterial interspersed repetitive unit-variable number 
tandem repeat (MIRU-VNTR) type.
3 PCRType is defined as a unique combination of spoligotype and 12-locus MIRU-VNTR; every GENType has a corresponding 
PCRType.
4 Among culture-positive genotyped TB cases during 2011–2013 (n=584).
GENType
50






Moved in state2 336 258 (76.8) 2 (0.6) 7 (2.1) 5 (1.5) 24 (7.1) 34 (10.1) 6 (1.8)
Moved out of 
state3 284 213 (75.0) 0 (0.0) 17 (6.0) 2 (0.7) 6 (2.1) 38 (13.4) 8 (2.8)
Moved out of 
country4 397 165 (41.6) 0 (0.0) 22 (5.5) 0 (0.0) 7 (1.8) 193 (48.6) 10 (2.5)
Did not move5 9134 8211 (89.9) 26 (0.3) 72 (0.8) 61 (0.7) 645 (7.1) 28 (0.3) 91 (1.0)
Table 27.  Tuberculosis Cases and Percentages by Reason Tuberculosis Therapy Stopped 






Lost Refused Died Other1 Unknown
1 Therapy was discontinued for a known reason other than those listed (e.g. patient moved outside the U.S., or patient moved from state 
A to state B, and though state A notified state B, state B never followed up).
2 Includes patients who were alive at diagnosis, started on treatment, and moved in state.
3 Includes patients who were alive at diagnosis, started on treatment, and moved out of state.
4  Includes patients who were alive at diagnosis, started on treatment, and moved out of the country; transnational referrals were provided 
for 264 (66.7%) TB patients who moved out of the country.
5 Includes patients who were alive at diagnosis, started on treatment, and did not indicate having moved.
Note: There may be differences in the way jurisdictions determine treatment completion for patients who moved out of the country; some 
reporting jurisdictions may be classifying all patients who moved out of the country as ‘other’ for reason therapy stopped.

















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































United States 9,582 9,940 3.0 3.2 -- -- 316,128,839
Alabama 108 134 2.2 2.8 21 18 4,833,722
Alaska 71 66 9.7 9.0 1 1 735,132
Arizona 184 211 2.8 3.2 15 12 6,626,624
Arkansas 72 70 2.4 2.4 18 24 2,959,373
California 2,171 2,189 5.7 5.8 3 3 38,332,521
Colorado 74 64 1.4 1.2 36 43 5,268,367
Connecticut 62 74 1.7 2.1 29 29 3,596,080
Delaware 19 28 2.1 3.1 26 14 925,749
District of Columbia1 38 37 5.9 5.8 -- -- 646,449
Florida 652 678 3.3 3.5 8 9 19,552,860
Georgia 340 357 3.4 3.6 7 8 9,992,167
Hawaii 115 117 8.2 8.4 2 2 1,404,054
Idaho 11 15 0.7 0.9 48 45 1,612,136
Illinois 327 347 2.5 2.7 17 20 12,882,135
Indiana 94 102 1.4 1.6 34 34 6,570,902
Iowa 47 46 1.5 1.5 33 36 3,090,416
Kansas 36 42 1.2 1.5 39 38 2,893,957
Kentucky 59 78 1.3 1.8 37 32 4,395,295
Louisiana 139 148 3.0 3.2 11 13 4,625,470
Maine 15 17 1.1 1.3 42 41 1,328,302
Maryland 176 224 3.0 3.8 13 6 5,928,814
Massachusetts 201 216 3.0 3.3 12 11 6,692,824
Michigan 141 149 1.4 1.5 35 35 9,895,622
Minnesota 151 162 2.8 3.0 14 16 5,420,380
Mississippi 65 81 2.2 2.7 25 19 2,991,207
Missouri 104 89 1.7 1.5 30 37 6,044,171
Montana 6 5 0.6 0.5 49 49 1,015,165
Nebraska 21 22 1.1 1.2 43 44 1,868,516
Nevada 92 84 3.3 3.0 9 15 2,790,136
New Hampshire 15 9 1.1 0.7 41 46 1,323,459
New Jersey 319 302 3.6 3.4 6 10 8,899,339
New Mexico 50 40 2.4 1.9 19 30 2,085,287
New York 872 864 4.4 4.4 5 5 19,651,127
North Carolina 216 211 2.2 2.2 22 28 9,848,060
North Dakota 12 26 1.7 3.7 32 7 723,393
Ohio 148 149 1.3 1.3 38 40 11,570,808
Oklahoma 69 88 1.8 2.3 28 25 3,850,568
Oregon 73 61 1.9 1.6 27 33 3,930,065
Pennsylvania 214 234 1.7 1.8 31 31 12,773,801
Rhode Island 27 23 2.6 2.2 16 27 1,051,511
South Carolina 112 122 2.3 2.6 20 22 4,774,839
South Dakota 9 19 1.1 2.3 44 26 844,877
Tennessee 142 163 2.2 2.5 23 23 6,495,978
Texas 1,222 1,234 4.6 4.7 4 4 26,448,193
Utah 33 37 1.1 1.3 40 39 2,900,872
Vermont 5 4 0.8 0.6 46 47 626,630
Virginia 180 235 2.2 2.9 24 17 8,260,405
Washington 210 185 3.0 2.7 10 21 6,971,406
West Virginia 13 8 0.7 0.4 47 50 1,854,304
Wisconsin 50 71 0.9 1.2 45 42 5,742,713
Wyoming 0 3 ... 0.5 50 48 582,658
American Samoa1,2 2 1 3.7 1.8 -- -- 54,719
Fed. States of Micronesia1,2 130 173 122.5 162.5 -- -- 106,104
Guam1,2 48 68 29.9 42.5 -- -- 160,378
Marshall Islands1,2 153 147 219.4 214.7 -- -- 69,747
N. Mariana Islands1,2 16 21 31.3 40.9 -- -- 51,170
Puerto Rico1,2 50 71 1.4 1.9 -- -- 3,645,648
Republic of Palau1,2 6 4 28.4 19.0 -- -- 21,108
U.S. Virgin Islands1,2 2 3 1.9 2.8 -- -- 104,737
Table 30. Tuberculosis Cases and Case Rates per 100,000 Population: 
Reporting Areas, 2013 and 2012
1 Not ranked with the states. See Table 31 for District of Columbia ranking among states.
2 Not included in U.S. totals. 
Note: Denominators for computing 2012 and 2013 rates for states, the District of Columbia, and Puerto Rico were obtained from Annual 
Estimates of the Resident Population for the United States, Regions, States, and Puerto Rico: April 1, 2010 to July 1, 2013  (http://www.
census.gov/popest/data/national/totals/2013/index.html) (accessed July 15, 2014); for all other areas, from IDB Summary Demographic 
Data (http://www.census.gov/population/international/data/idb/informationGateway.php) (accessed July 15, 2014).
Ellipses indicate data not available.
See Technical Notes.
See Surveillance Slide #4.
Reporting Area
Cases Case Rates Rank According to Rate Population Estimates
July 1, 20132013 2012 2013 2012 2013 2012
60
Total 9,582 3.0 9,940 3.2 -3.6 -4.3 …
>= 500 cases in 2013
California 2,171 5.7 2,189 5.8 -0.8 -1.7 3
Texas 1,222 4.6 1,234 4.7 -1.0 -2.4 4
New York1 872 4.4 864 4.4 0.9 0.5 5
Florida 652 3.3 678 3.5 -3.8 -5.0 8
100 - 499 cases in 2013
Georgia 340 3.4 357 3.6 -4.8 -5.5 7
Illinois 327 2.5 347 2.7 -5.8 -5.9 17
New Jersey 319 3.6 302 3.4 5.6 5.3 6
North Carolina 216 2.2 211 2.2 2.4 1.3 22
Pennsylvania 214 1.7 234 1.8 -8.5 -8.6 31
Washington 210 3.0 185 2.7 13.5 12.3 10
Massachusetts 201 3.0 216 3.3 -6.9 -7.6 12
Arizona 184 2.8 211 3.2 -12.8 -13.8 15
Virginia 180 2.2 235 2.9 -23.4 -24.1 24
Maryland 176 3.0 224 3.8 -21.4 -22.0 13
Minnesota 151 2.8 162 3.0 -6.8 -7.5 14
Ohio 148 1.3 149 1.3 -0.7 -0.9 38
Tennessee 142 2.2 163 2.5 -12.9 -13.4 23
Michigan 141 1.4 149 1.5 -5.4 -5.5 35
Louisiana 139 3.0 148 3.2 -6.1 -6.6 11
Hawaii 115 8.2 117 8.4 -1.7 -2.7 2
South Carolina 112 2.3 122 2.6 -8.2 -9.2 20
Alabama 108 2.2 134 2.8 -19.4 -19.7 21
Missouri 104 1.7 89 1.5 16.9 16.5 30
< 100 cases in 2013
Indiana 94 1.4 102 1.6 -7.8 -8.3 34
Nevada 92 3.3 84 3.1 9.5 8.1 9
Colorado 74 1.4 64 1.2 15.6 13.9 36
Oregon 73 1.9 61 1.6 19.7 18.7 27
Arkansas 72 2.4 70 2.4 2.9 2.5 18
Alaska 71 9.7 66 9.0 7.6 6.9 1
Oklahoma 69 1.8 88 2.3 -21.6 -22.3 28
Mississippi 65 2.2 81 2.7 -19.8 -19.9 25
Connecticut 62 1.7 74 2.1 -16.2 -16.3 29
Kentucky 59 1.3 78 1.8 -24.4 -24.6 37
New Mexico 50 2.4 40 1.9 25.0 24.9 19
Wisconsin 50 0.9 71 1.2 -29.6 -29.8 45
Iowa 47 1.5 46 1.5 2.2 1.7 33
District of Columbia 38 5.9 37 5.8 2.7 0.6 --
Kansas 36 1.2 42 1.5 -14.3 -14.6 39
Utah 33 1.1 37 1.3 -10.8 -12.2 40
Rhode Island 27 2.6 23 2.2 17.4 17.3 16
Nebraska 21 1.1 22 1.2 -4.5 -5.2 43
Delaware 19 2.1 28 3.1 -32.1 -32.8 26
Maine 15 1.1 17 1.3 -11.8 -11.8 42
New Hampshire 15 1.1 9 0.7 66.7 66.4 41
West Virginia 13 0.7 8 0.4 62.5 62.6 47
North Dakota 12 1.7 26 3.7 -53.8 -55.2 32
Idaho 11 0.7 15 0.9 -26.7 -27.4 48
South Dakota 9 1.1 19 2.3 -52.6 -53.2 44
Montana 6 0.6 5 0.5 20.0 18.9 49
Vermont 5 0.8 4 0.6 25.0 24.9 46
Wyoming 0 0.0 3 0.5 -100.0 -100.0 50
Table 31.  Tuberculosis Cases and Case Rates per 100,000 Population, Ranked and Grouped 
by Number of Cases: United States and the District of Columbia, 2013 and 2012
Reporting Area
2013 2012 2012–2013 % Change




1 Includes New York City.
Note: Denominators for computing 2012 and 2013 rates for states, the District of Columbia, and Puerto Rico were obtained from Annual 
Estimates of the Resident Population for the United States, Regions, States, and Puerto Rico: April 1, 2010 to July 1, 2013  (http://www.
census.gov/popest/data/national/totals/2013/index.html) (accessed July 15, 2014).
See Table 30 for ranking of states without the District of Columbia.
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United States 9,582 3,375 (35.2) 6,193 (64.6) 14 (0.1)
Alabama 108 87 (80.6) 21 (19.4) 0 (0.0)
Alaska 71 56 (78.9) 15 (21.1) 0 (0.0)
Arizona 184 48 (26.1) 136 (73.9) 0 (0.0)
Arkansas 72 54 (75.0) 18 (25.0) 0 (0.0)
California 2,171 473 (21.8) 1,691 (77.9) 7 (0.3)
Colorado 74 16 (21.6) 58 (78.4) 0 (0.0)
Connecticut 62 15 (24.2) 47 (75.8) 0 (0.0)
Delaware 19 9 (47.4) 10 (52.6) 0 (0.0)
District of Columbia 38 12 (31.6) 26 (68.4) 0 (0.0)
Florida 652 288 (44.2) 364 (55.8) 0 (0.0)
Georgia 340 168 (49.4) 172 (50.6) 0 (0.0)
Hawaii 115 32 (27.8) 83 (72.2) 0 (0.0)
Idaho 11 4 (36.4) 7 (63.6) 0 (0.0)
Illinois 327 113 (34.6) 214 (65.4) 0 (0.0)
Indiana 94 43 (45.7) 51 (54.3) 0 (0.0)
Iowa 47 15 (31.9) 32 (68.1) 0 (0.0)
Kansas 36 12 (33.3) 24 (66.7) 0 (0.0)
Kentucky 59 31 (52.5) 28 (47.5) 0 (0.0)
Louisiana 139 108 (77.7) 31 (22.3) 0 (0.0)
Maine 15 8 (53.3) 7 (46.7) 0 (0.0)
Maryland 176 46 (26.1) 130 (73.9) 0 (0.0)
Massachusetts 201 43 (21.4) 158 (78.6) 0 (0.0)
Michigan 141 56 (39.7) 83 (58.9) 2 (1.4)
Minnesota 151 29 (19.2) 122 (80.8) 0 (0.0)
Mississippi 65 49 (75.4) 16 (24.6) 0 (0.0)
Missouri 104 58 (55.8) 46 (44.2) 0 (0.0)
Montana 6 6 (100.0) 0 (0.0) 0 (0.0)
Nebraska 21 6 (28.6) 13 (61.9) 2 (9.5)
Nevada 92 33 (35.9) 59 (64.1) 0 (0.0)
New Hampshire 15 1 (6.7) 14 (93.3) 0 (0.0)
New Jersey 319 74 (23.2) 245 (76.8) 0 (0.0)
New Mexico 50 18 (36.0) 32 (64.0) 0 (0.0)
New York 872 152 (17.4) 719 (82.5) 1 (0.1)
North Carolina 216 114 (52.8) 102 (47.2) 0 (0.0)
North Dakota 12 8 (66.7) 4 (33.3) 0 (0.0)
Ohio 148 68 (45.9) 80 (54.1) 0 (0.0)
Oklahoma 69 48 (69.6) 19 (27.5) 2 (2.9)
Oregon 73 21 (28.8) 52 (71.2) 0 (0.0)
Pennsylvania 214 74 (34.6) 140 (65.4) 0 (0.0)
Rhode Island 27 5 (18.5) 22 (81.5) 0 (0.0)
South Carolina 112 93 (83.0) 19 (17.0) 0 (0.0)
South Dakota 9 6 (66.7) 3 (33.3) 0 (0.0)
Tennessee 142 101 (71.1) 41 (28.9) 0 (0.0)
Texas 1,222 549 (44.9) 673 (55.1) 0 (0.0)
Utah 33 7 (21.2) 26 (78.8) 0 (0.0)
Vermont 5 1 (20.0) 4 (80.0) 0 (0.0)
Virginia 180 33 (18.3) 147 (81.7) 0 (0.0)
Washington 210 53 (25.2) 157 (74.8) 0 (0.0)
West Virginia 13 10 (76.9) 3 (23.1) 0 (0.0)
Wisconsin 50 21 (42.0) 29 (58.0) 0 (0.0)
Wyoming 0 0 … 0 … 0 …
1Includes persons born outside the United States, American Samoa, the Federated States of Micronesia, Guam, the Republic of the 
Marshall Islands, Midway Island, the Commonwealth of the Northern Mariana Islands, Puerto Rico, the Republic of Palau, the U.S. Virgin 
Islands, and U.S. minor and outlying Pacific islands.
Note: See Surveillance Slide #16.




Cases No. No. No.(%) (%) (%)
U.S.-born Persons Foreign-born Persons1 Unknown Origin
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United States 6,193 949 (15.3) 994 (16.1) 865 (14.0) 1,235 (19.9) 1,588 (25.6) 562 (9.1)
Alabama 21 2 (9.5) 1 (4.8) 10 (47.6) 6 (28.6) 1 (4.8) 1 (4.8)
Alaska 15 1 (6.7) 3 (20.0) 4 (26.7) 2 (13.3) 3 (20.0) 2 (13.3)
Arizona 136 50 (36.8) 16 (11.8) 9 (6.6) 26 (19.1) 30 (22.1) 5 (3.7)
Arkansas 18 5 (27.8) 5 (27.8) 1 (5.6) 5 (27.8) 2 (11.1) 0 (0.0)
California 1,691 151 (8.9) 178 (10.5) 169 (10.0) 337 (19.9) 599 (35.4) 257 (15.2)
Colorado 58 13 (22.4) 9 (15.5) 10 (17.2) 7 (12.1) 11 (19.0) 8 (13.8)
Connecticut 47 7 (14.9) 7 (14.9) 11 (23.4) 10 (21.3) 12 (25.5) 0 (0.0)
Delaware 10 2 (20.0) 3 (30.0) 1 (10.0) 2 (20.0) 2 (20.0) 0 (0.0)
District of Columbia 26 5 (19.2) 10 (38.5) 5 (19.2) 2 (7.7) 4 (15.4) 0 (0.0)
Florida 364 73 (20.1) 54 (14.8) 55 (15.1) 76 (20.9) 92 (25.3) 14 (3.8)
Georgia 172 36 (20.9) 30 (17.4) 27 (15.7) 42 (24.4) 35 (20.3) 2 (1.2)
Hawaii 83 11 (13.3) 9 (10.8) 11 (13.3) 13 (15.7) 25 (30.1) 14 (16.9)
Idaho 7 1 (14.3) 4 (57.1) 0 (0.0) 0 (0.0) 2 (28.6) 0 (0.0)
Illinois 214 35 (16.4) 20 (9.3) 32 (15.0) 46 (21.5) 79 (36.9) 2 (0.9)
Indiana 51 9 (17.6) 9 (17.6) 3 (5.9) 2 (3.9) 3 (5.9) 25 (49.0)
Iowa 32 3 (9.4) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 29 (90.6)
Kansas 24 2 (8.3) 7 (29.2) 5 (20.8) 7 (29.2) 3 (12.5) 0 (0.0)
Kentucky 28 11 (39.3) 2 (7.1) 7 (25.0) 6 (21.4) 2 (7.1) 0 (0.0)
Louisiana 31 6 (19.4) 5 (16.1) 3 (9.7) 8 (25.8) 9 (29.0) 0 (0.0)
Maine 7 4 (57.1) 0 (0.0) 1 (14.3) 1 (14.3) 1 (14.3) 0 (0.0)
Maryland 130 25 (19.2) 40 (30.8) 25 (19.2) 23 (17.7) 17 (13.1) 0 (0.0)
Massachusetts 158 34 (21.5) 41 (25.9) 27 (17.1) 31 (19.6) 22 (13.9) 3 (1.9)
Michigan 83 13 (15.7) 5 (6.0) 9 (10.8) 14 (16.9) 16 (19.3) 26 (31.3)
Minnesota 122 20 (16.4) 29 (23.8) 27 (22.1) 20 (16.4) 26 (21.3) 0 (0.0)
Mississippi 16 3 (18.8) 3 (18.8) 1 (6.3) 6 (37.5) 3 (18.8) 0 (0.0)
Missouri 46 11 (23.9) 8 (17.4) 4 (8.7) 10 (21.7) 13 (28.3) 0 (0.0)
Montana 0 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Nebraska 13 2 (15.4) 0 (0.0) 4 (30.8) 3 (23.1) 2 (15.4) 2 (15.4)
Nevada 59 12 (20.3) 6 (10.2) 10 (16.9) 6 (10.2) 23 (39.0) 2 (3.4)
New Hampshire 14 1 (7.1) 2 (14.3) 4 (28.6) 5 (35.7) 2 (14.3) 0 (0.0)
New Jersey 245 25 (10.2) 40 (16.3) 38 (15.5) 57 (23.3) 49 (20.0) 36 (14.7)
New Mexico 32 8 (25.0) 2 (6.3) 4 (12.5) 6 (18.8) 9 (28.1) 3 (9.4)
New York 719 112 (15.6) 134 (18.6) 115 (16.0) 156 (21.7) 153 (21.3) 49 (6.8)
North Carolina 102 15 (14.7) 19 (18.6) 13 (12.7) 8 (7.8) 6 (5.9) 41 (40.2)
North Dakota 4 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 4 (100.0)
Ohio 80 20 (25.0) 23 (28.8) 8 (10.0) 15 (18.8) 13 (16.3) 1 (1.3)
Oklahoma 19 1 (5.3) 3 (15.8) 2 (10.5) 3 (15.8) 1 (5.3) 9 (47.4)
Oregon 52 3 (5.8) 8 (15.4) 6 (11.5) 5 (9.6) 10 (19.2) 20 (38.5)
Pennsylvania 140 25 (17.9) 42 (30.0) 22 (15.7) 32 (22.9) 17 (12.1) 2 (1.4)
Rhode Island 22 4 (18.2) 7 (31.8) 2 (9.1) 3 (13.6) 6 (27.3) 0 (0.0)
South Carolina 19 4 (21.1) 2 (10.5) 7 (36.8) 4 (21.1) 1 (5.3) 1 (5.3)
South Dakota 3 0 (0.0) 0 (0.0) 0 (0.0) 3 (100.0) 0 (0.0) 0 (0.0)
Tennessee 41 9 (22.0) 6 (14.6) 14 (34.1) 8 (19.5) 4 (9.8) 0 (0.0)
Texas 673 121 (18.0) 116 (17.2) 91 (13.5) 144 (21.4) 201 (29.9) 0 (0.0)
Utah 26 7 (26.9) 7 (26.9) 3 (11.5) 4 (15.4) 5 (19.2) 0 (0.0)
Vermont 4 2 (50.0) 0 (0.0) 1 (25.0) 1 (25.0) 0 (0.0) 0 (0.0)
Virginia 147 28 (19.0) 38 (25.9) 26 (17.7) 25 (17.0) 30 (20.4) 0 (0.0)
Washington 157 13 (8.3) 33 (21.0) 30 (19.1) 40 (25.5) 37 (23.6) 4 (2.5)
West Virginia 3 1 (33.3) 1 (33.3) 1 (33.3) 0 (0.0) 0 (0.0) 0 (0.0)
Wisconsin 29 3 (10.3) 7 (24.1) 7 (24.1) 5 (17.2) 7 (24.1) 0 (0.0)
Wyoming 0 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Table 37. Tuberculosis Cases and Percentages in Foreign-born Persons1 by Number of Years 




1 Includes persons born outside the United States, American Samoa, the Federated States of Micronesia, Guam, the Republic of the 
Marshall Islands, Midway Island, the Commonwealth of the Northern Mariana Islands, Puerto Rico, the Republic of Palau, the U.S. Virgin 
Islands, and U.S. minor and outlying Pacific islands.
                 
<1 Year 1–4 5–9 10–19 >20 Unknown or 
Missing
No. No. No. No. No. No.(%) (%) (%) (%) (%) (%)
73
United States 9,582 6,683 (69.7) 1,994 (20.8) 895 (9.3) 353
Alabama 108 92 (85.2) 10 (9.3) 6 (5.6) 0
Alaska 71 63 (88.7) 5 (7.0) 3 (4.2) 1
Arizona 184 148 (80.4) 16 (8.7) 20 (10.9) 9
Arkansas 72 54 (75.0) 14 (19.4) 4 (5.6) 5
California 2,171 1,505 (69.3) 446 (20.5) 220 (10.1) 67
Colorado 74 49 (66.2) 18 (24.3) 7 (9.5) 8
Connecticut 62 36 (58.1) 15 (24.2) 11 (17.7) 3
Delaware 19 15 (78.9) 3 (15.8) 1 (5.3) 2
District of Columbia 38 25 (65.8) 10 (26.3) 3 (7.9) 0
Florida 652 506 (77.6) 107 (16.4) 39 (6.0) 31
Georgia 340 255 (75.0) 67 (19.7) 17 (5.0) 11
Hawaii 115 89 (77.4) 12 (10.4) 14 (12.2) 2
Idaho 11 6 (54.5) 4 (36.4) 1 (9.1) 0
Illinois 327 215 (65.7) 83 (25.4) 29 (8.9) 13
Indiana 94 69 (73.4) 17 (18.1) 8 (8.5) 4
Iowa 47 29 (61.7) 11 (23.4) 3 (6.4) 2
Kansas 36 28 (77.8) 7 (19.4) 1 (2.8) 0
Kentucky 59 45 (76.3) 12 (20.3) 2 (3.4) 0
Louisiana 139 117 (84.2) 16 (11.5) 6 (4.3) 5
Maine 15 9 (60.0) 5 (33.3) 1 (6.7) 1
Maryland 176 103 (58.5) 61 (34.7) 12 (6.8) 6
Massachusetts 201 126 (62.7) 57 (28.4) 18 (9.0) 9
Michigan 141 84 (59.6) 55 (39.0) 2 (1.4) 9
Minnesota 151 87 (57.6) 52 (34.4) 12 (7.9) 7
Mississippi 65 53 (81.5) 9 (13.8) 3 (4.6) 1
Missouri 104 75 (72.1) 21 (20.2) 8 (7.7) 3
Montana 6 3 (50.0) 2 (33.3) 1 (16.7) 1
Nebraska 21 17 (81.0) 3 (14.3) 1 (4.8) 1
Nevada 92 76 (82.6) 14 (15.2) 2 (2.2) 4
New Hampshire 15 6 (40.0) 8 (53.3) 1 (6.7) 2
New Jersey 319 200 (62.7) 72 (22.6) 47 (14.7) 17
New Mexico 50 35 (70.0) 15 (30.0) 0 (0.0) 0
New York 872 531 (60.9) 215 (24.7) 125 (14.3) 22
North Carolina 216 142 (65.7) 48 (22.2) 26 (12.0) 13
North Dakota 12 6 (50.0) 3 (25.0) 0 (0.0) 1
Ohio 148 93 (62.8) 36 (24.3) 19 (12.8) 7
Oklahoma 69 57 (82.6) 9 (13.0) 2 (2.9) 0
Oregon 73 46 (63.0) 18 (24.7) 9 (12.3) 2
Pennsylvania 214 147 (68.7) 54 (25.2) 13 (6.1) 12
Rhode Island 27 19 (70.4) 7 (25.9) 1 (3.7) 0
South Carolina 112 63 (56.3) 30 (26.8) 19 (17.0) 7
South Dakota 9 6 (66.7) 3 (33.3) 0 (0.0) 0
Tennessee 142 98 (69.0) 27 (19.0) 17 (12.0) 6
Texas 1,222 929 (76.0) 182 (14.9) 111 (9.1) 35
Utah 33 15 (45.5) 11 (33.3) 7 (21.2) 2
Vermont 5 3 (60.0) 2 (40.0) 0 (0.0) 0
Virginia 180 122 (67.8) 47 (26.1) 11 (6.1) 12
Washington 210 140 (66.7) 41 (19.5) 29 (13.8) 4
West Virginia 13 8 (61.5) 4 (30.8) 1 (7.7) 1
Wisconsin 50 38 (76.0) 10 (20.0) 2 (4.0) 5
Wyoming 0 0 ... 0 ... 0 ... 0
American Samoa4 2 2 (100.0) 0 (0.0) 0 (0.0) 2
Fed. States of Micronesia4 130 115 (88.5) 10 (7.7) 4 (3.1) 12
Guam4 48 40 (83.3) 4 (8.3) 4 (8.3) 7
Marshall Islands4 153 125 (81.7) 26 (17.0) 2 (1.3) 3
N. Mariana Islands4 16 16 (100.0) 0 (0.0) 0 (0.0) 0
Puerto Rico4 50 46 (92.0) 4 (8.0) 0 (0.0) 0
Republic of Palau4 6 6 (100.0) 0 (0.0) 0 (0.0) 0
U.S. Virgin Islands4 2 2 (100.0) 0 (0.0) 0 (0.0) 0









No. No. No. No.(%) (%) (%)
1 Includes cases with pulmonary listed as the only site of disease.
2 Includes cases with pleural, lymphatic, bone and/or joint, meningeal, peritoneal, genitourinary, or other site, excluding pulmonary, listed 
as site of disease.
3 Includes cases with evidence of miliary disease.
4 Not included in U.S. totals.







































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































United States 9094 9053 (99.5) 359 (4.0)
Alabama 101 101 (100.0) 1 (1.0)
Alaska 61 59 (96.7) 1 (1.7)
Arizona 177 177 (100.0) 45 (25.4)
Arkansas 71 71 (100.0) 3 (4.2)
California 2079 2074 (99.8) 72 (3.5)
Colorado 72 72 (100.0) 2 (2.8)
Connecticut 61 61 (100.0) 0 (0.0)
Delaware 16 16 (100.0) 0 (0.0)
District of Columbia 34 34 (100.0) 0 (0.0)
Florida 625 625 (100.0) 28 (4.5)
Georgia 312 312 (100.0) 9 (2.9)
Hawaii 111 111 (100.0) 1 (0.9)
Idaho 10 10 (100.0) 0 (0.0)
Illinois 311 310 (99.7) 4 (1.3)
Indiana 90 90 (100.0) 0 (0.0)
Iowa 46 46 (100.0) 0 (0.0)
Kansas 30 30 (100.0) 1 (3.3)
Kentucky 57 57 (100.0) 2 (3.5)
Louisiana 124 123 (99.2) 5 (4.1)
Maine 13 12 (92.3) 0 (0.0)
Maryland 167 167 (100.0) 0 (0.0)
Massachusetts 198 198 (100.0) 3 (1.5)
Michigan 139 133 (95.7) 3 (2.3)
Minnesota 144 144 (100.0) 0 (0.0)
Mississippi 62 62 (100.0) 3 (4.8)
Missouri 97 97 (100.0) 2 (2.1)
Montana 6 6 (100.0) 0 (0.0)
Nebraska 21 21 (100.0) 0 (0.0)
Nevada 76 75 (98.7) 2 (2.7)
New Hampshire 15 15 (100.0) 1 (6.7)
New Jersey 306 306 (100.0) 5 (1.6)
New Mexico 50 50 (100.0) 5 (10.0)
New York State5 209 208 (99.5) 3 (1.4)
New York City 641 631 (98.4) 9 (1.4)
North Carolina 201 201 (100.0) 6 (3.0)
North Dakota 9 7 (77.8) 0 (0.0)
Ohio 141 141 (100.0) 0 (0.0)
Oklahoma 65 55 (84.6) 3 (5.5)
Oregon 68 67 (98.5) 2 (3.0)
Pennsylvania 207 207 (100.0) 6 (2.9)
Rhode Island 25 25 (100.0) 0 (0.0)
South Carolina 99 99 (100.0) 4 (4.0)
South Dakota 9 9 (100.0) 0 (0.0)
Tennessee 127 127 (100.0) 7 (5.5)
Texas 1145 1145 (100.0) 116 (10.1)
Utah 30 30 (100.0) 0 (0.0)
Vermont 4 4 (100.0) 0 (0.0)
Virginia 171 171 (100.0) 0 (0.0)
Washington 202 202 (100.0) 4 (2.0)
West Virginia 13 13 (100.0) 0 (0.0)
Wisconsin 46 46 (100.0) 1 (2.2)
Wyoming 0 0 … 0 …
American Samoa6 2 2 (100.0) 0 (0.0)
Fed. States of Micronesia6 104 103 (99.0) 0 (0.0)
Guam6 37 37 (100.0) 0 (0.0)
Marshall Islands6 124 124 (100.0) 0 (0.0)
N. Mariana Islands6 15 15 (100.0) 0 (0.0)
Puerto Rico6 50 50 (100.0) 0 (0.0)
Republic of Palau6 6 6 (100.0) 0 (0.0)
U.S. Virgin Islands6 1 0 (0.0) 0 …
Table 42. Tuberculosis Cases and Percentages by Residence in and Type of 




Cases with Information on Residence
 in Correctional Facilities
Cases Reported As Residents
 of Correctional Facilities2
No. No.(%) (%)
81
51 (14.2) 47 (13.1) 179 (49.9) 6 (1.7) 69 (19.2) 7 (1.9) 352 (98.1) 131 (37.2)
0 (0.0) 0 (0.0) 1 (100.0) 0 (0.0) 0 (0.0) 0 (0.0) 1 (100.0) 0 (0.0)
0 (0.0) 1 (100.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 1 (100.0) 0 (0.0)
1 (2.2) 1 (2.2) 30 (66.7) 3 (6.7) 10 (22.2) 0 (0.0) 45 (100.0) 34 (75.6)
0 (0.0) 0 (0.0) 2 (66.7) 0 (0.0) 1 (33.3) 0 (0.0) 3 (100.0) 0 (0.0)
16 (22.2) 5 (6.9) 42 (58.3) 2 (2.8) 7 (9.7) 0 (0.0) 72 (100.0) 19 (26.4)
0 (0.0) 0 (0.0) 2 (100.0) 0 (0.0) 0 (0.0) 0 (0.0) 2 (100.0) 1 (50.0)
0 … 0 ... 0 ... 0 ... 0 ... 0 ... 0 ... 0 ...
0 … 0 ... 0 ... 0 ... 0 ... 0 ... 0 ... 0 ...
0 … 0 ... 0 ... 0 ... 0 ... 0 ... 0 ... 0 ...
1 (3.6) 7 (25.0) 12 (42.9) 0 (0.0) 8 (28.6) 0 (0.0) 28 (100.0) 10 (35.7)
0 (0.0) 4 (44.4) 4 (44.4) 0 (0.0) 1 (11.1) 0 (0.0) 9 (100.0) 2 (22.2)
0 (0.0) 1 (100.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 1 ... 0 ...
0 … 0 ... 0 ... 0 ... 0 ... 0 ... 0 ... 0 ...
0 (0.0) 1 (25.0) 3 (75.0) 0 (0.0) 0 (0.0) 0 (0.0) 4 (100.0) 0 (0.0)
0 … 0 ... 0 ... 0 ... 0 ... 0 ... 0 ... 0 ...
0 … 0 ... 0 ... 0 ... 0 ... 0 ... 0 ... 0 ...
0 (0.0) 0 (0.0) 1 (100.0) 0 (0.0) 0 (0.0) 0 (0.0) 1 (100.0) 1 (100.0)
1 (50.0) 1 (50.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 1 (50.0) 0 (0.0)
1 (20.0) 2 (40.0) 1 (20.0) 0 (0.0) 1 (20.0) 0 (0.0) 5 (100.0) 2 (40.0)
0 … 0 ... 0 ... 0 ... 0 ... 0 ... 0 ... 0 ...
0 … 0 ... 0 ... 0 ... 0 ... 0 ... 0 ... 0 ...
0 (0.0) 0 (0.0) 1 (33.3) 0 (0.0) 2 (66.7) 0 (0.0) 3 (100.0) 1 (33.3)
0 (0.0) 0 (0.0) 2 (66.7) 0 (0.0) 0 (0.0) 1 (33.3) 2 (66.7) 0 (0.0)
0 … 0 ... 0 ... 0 ... 0 ... 0 ... 0 ... 0 ...
2 (66.7) 1 (33.3) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 3 (100.0) 1 (33.3)
0 (0.0) 1 (50.0) 1 (50.0) 0 (0.0) 0 (0.0) 0 (0.0) 2 (100.0) 0 (0.0)
0 … 0 ... 0 ... 0 ... 0 ... 0 ... 0 ... 0 ...
0 … 0 ... 0 ... 0 ... 0 ... 0 ... 0 ... 0 ...
1 (50.0) 0 (0.0) 1 (50.0) 0 (0.0) 0 (0.0) 0 (0.0) 2 (100.0) 0 (0.0)
1 (100.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 1 (100.0) 0 (0.0)
2 (40.0) 2 (40.0) 0 (0.0) 0 (0.0) 1 (20.0) 0 (0.0) 5 (100.0) 3 (60.0)
0 (0.0) 2 (40.0) 2 (40.0) 0 (0.0) 1 (20.0) 0 (0.0) 5 (100.0) 4 (80.0)
0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 3 (100.0) 3 (100.0) 0 (0.0)
2 (22.2) 0 (0.0) 5 (55.6) 0 (0.0) 0 (0.0) 2 (22.2) 5 (55.6) 1 (20.0)
1 (16.7) 4 (66.7) 1 (16.7) 0 (0.0) 0 (0.0) 0 (0.0) 6 (100.0) 0 (0.0)
0 … 0 ... 0 ... 0 ... 0 ... 0 ... 0 ... 0 ...
0 … 0 ... 0 ... 0 ... 0 ... 0 ... 0 ... 0 ...
2 (66.7) 1 (33.3) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 3 (100.0) 1 (33.3)
2 (100.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 2 (100.0) 0 (0.0)
1 (16.7) 0 (0.0) 5 (83.3) 0 (0.0) 0 (0.0) 0 (0.0) 6 (100.0) 2 (33.3)
0 … 0 ... 0 ... 0 ... 0 ... 0 ... 0 ... 0 ...
2 (50.0) 0 (0.0) 2 (50.0) 0 (0.0) 0 (0.0) 0 (0.0) 4 (100.0) 0 (0.0)
0 … 0 ... 0 ... 0 ... 0 ... 0 ... 0 ... 0 ...
0 (0.0) 0 (0.0) 6 (85.7) 1 (14.3) 0 (0.0) 0 (0.0) 7 (100.0) 0 (0.0)
14 (12.1) 12 (10.3) 53 (45.7) 0 (0.0) 37 (31.9) 0 (0.0) 116 (100.0) 48 (41.4)
0 … 0 ... 0 ... 0 ... 0 ... 0 ... 0 ... 0 ...
0 … 0 ... 0 ... 0 ... 0 ... 0 ... 0 ... 0 ...
0 … 0 ... 0 ... 0 ... 0 ... 0 ... 0 ... 0 ...
1 (25.0) 1 (25.0) 1 (25.0) 0 (0.0) 0 (0.0) 1 (25.0) 3 (75.0) 1 (33.3)
0 … 0 ... 0 ... 0 ... 0 ... 0 ... 0 ... 0 ...
0 (0.0) 0 (0.0) 1 (100.0) 0 (0.0) 0 (0.0) 0 (0.0) 1 (100.0) 0 (0.0)
0 … 0 ... 0 ... 0 ... 0 ... 0 ... 0 ... 0 ...
0 … 0 ... 0 ... 0 ... 0 ... 0 ... 0 ... 0 ...
0 … 0 ... 0 ... 0 ... 0 ... 0 ... 0 ... 0 ...
0 … 0 ... 0 ... 0 ... 0 ... 0 ... 0 ... 0 ...
0 … 0 ... 0 ... 0 ... 0 ... 0 ... 0 ... 0 ...
0 … 0 ... 0 ... 0 ... 0 ... 0 ... 0 ... 0 ...
0 … 0 ... 0 ... 0 ... 0 ... 0 ... 0 ... 0 ...
0 … 0 ... 0 ... 0 ... 0 ... 0 ... 0 ... 0 ...
0 … 0 ... 0 ... 0 ... 0 ... 0 ... 0 ... 0 ...
Table 42. (Con’t) Tuberculosis Cases and Percentages by Residence in and Type of 




1 Resident of correctional facility at time of TB diagnosis. Percentage based on 52 reporting areas (50 states, New York City, and the District of Columbia). 
Counts and percentages shown only for reporting areas with information reported for >75% of cases.
2 Percent of those with known status.
3 Excludes youth who are under 15 years of age.
4 Immigration and Customs Enforcement (ICE) detainment among cases who were residents in correctional facilities.
5 Excludes New York City.
6 Not included in U.S. totals.
Note: Ellipses indicate data not available.
























United States 9,094 9,019 (99.2) 514 (5.7)
Alabama 101 100 (99.0) 6 (6.0)
Alaska 61 58 (95.1) 9 (15.5)
Arizona 177 164 (92.7) 17 (10.4)
Arkansas 71 71 (100.0) 11 (15.5)
California 2,079 2,070 (99.6) 129 (6.2)
Colorado 72 71 (98.6) 6 (8.5)
Connecticut 61 61 (100.0) 3 (4.9)
Delaware 16 16 (100.0) 0 (0.0)
District of Columbia 34 34 (100.0) 1 (2.9)
Florida 625 620 (99.2) 55 (8.9)
Georgia 312 312 (100.0) 26 (8.3)
Hawaii 111 110 (99.1) 6 (5.5)
Idaho 10 10 (100.0) 1 (10.0)
Illinois 311 310 (99.7) 14 (4.5)
Indiana 90 90 (100.0) 10 (11.1)
Iowa 46 46 (100.0) 3 (6.5)
Kansas 30 30 (100.0) 1 (3.3)
Kentucky 57 57 (100.0) 3 (5.3)
Louisiana 124 124 (100.0) 11 (8.9)
Maine 13 13 (100.0) 1 (7.7)
Maryland 167 166 (99.4) 5 (3.0)
Massachusetts 198 198 (100.0) 4 (2.0)
Michigan 139 136 (97.8) 8 (5.9)
Minnesota 144 144 (100.0) 4 (2.8)
Mississippi 62 62 (100.0) 3 (4.8)
Missouri 97 97 (100.0) 1 (1.0)
Montana 6 6 (100.0) 0 (0.0)
Nebraska 21 21 (100.0) 0 (0.0)
Nevada 76 74 (97.4) 5 (6.8)
New Hampshire 15 15 (100.0) 1 (6.7)
New Jersey 306 306 (100.0) 4 (1.3)
New Mexico 50 50 (100.0) 3 (6.0)
New York State3 209 202 (96.7) 6 (3.0)
New York City 641 633 (98.8) 15 (2.4)
North Carolina 201 200 (99.5) 12 (6.0)
North Dakota 9 7 (77.8) 1 (14.3)
Ohio 141 141 (100.0) 5 (3.5)
Oklahoma 65 52 (80.0) 3 (5.8)
Oregon 68 66 (97.1) 2 (3.0)
Pennsylvania 207 207 (100.0) 4 (1.9)
Rhode Island 25 25 (100.0) 0 (0.0)
South Carolina 99 99 (100.0) 8 (8.1)
South Dakota 9 9 (100.0) 0 (0.0)
Tennessee 127 127 (100.0) 9 (7.1)
Texas 1,145 1,145 (100.0) 75 (6.6)
Utah 30 30 (100.0) 1 (3.3)
Vermont 4 4 (100.0) 0 (0.0)
Virginia 171 171 (100.0) 8 (4.7)
Washington 202 200 (99.0) 12 (6.0)
West Virginia 13 13 (100.0) 0 (0.0)
Wisconsin 46 46 (100.0) 2 (4.3)
Wyoming 0 0 -- 0 --
American Samoa4 2 2 (100.0) 0 (0.0)
Fed. States of Micronesia4 104 103 (99.0) 3 (2.9)
Guam4 37 37 (100.0) 0 (0.0)
Marshall Islands4 124 124 (100.0) 1 (0.8)
N. Mariana Islands4 15 15 (100.0) 1 (6.7)
Puerto Rico4 50 50 (100.0) 3 (6.0)
Republic of Palau4 6 6 (100.0) 0 (0.0)









Table 43. Tuberculosis Cases and Percentages by Homeless Status,1 Age >15: 
Reporting Areas, 2013
1 Homeless within past 12 months of TB diagnosis. Percentage based on 52 reporting areas (50 states, New York City, and the District of 
Columbia). Counts and percentages shown only for reporting areas with information reported for >75% of cases.
2 Percent of those with known status. 
3 Excludes New York City.
4 Not included in U.S. totals. 
Note: Ellipses indicate data not available.
See Surveillance Slide #29
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United States 9,094 9,047 (99.5) 191 (2.1)
Alabama 101 101 (100.0) 2 (2.0)
Alaska 61 58 (95.1) 2 (3.4)
Arizona 177 177 (100.0) 4 (2.3)
Arkansas 71 71 (100.0) 0 (0.0)
California 2,079 2,076 (99.9) 51 (2.5)
Colorado 72 72 (100.0) 1 (1.4)
Connecticut 61 61 (100.0) 4 (6.6)
Delaware 16 16 (100.0) 1 (6.3)
District of Columbia 34 34 (100.0) 1 (2.9)
Florida 625 625 (100.0) 6 (1.0)
Georgia 312 311 (99.7) 2 (0.6)
Hawaii 111 111 (100.0) 3 (2.7)
Idaho 10 10 (100.0) 0 (0.0)
Illinois 311 309 (99.4) 8 (2.6)
Indiana 90 90 (100.0) 3 (3.3)
Iowa 46 45 (97.8) 0 (0.0)
Kansas 30 30 (100.0) 0 (0.0)
Kentucky 57 57 (100.0) 3 (5.3)
Louisiana 124 124 (100.0) 3 (2.4)
Maine 13 12 (92.3) 3 (25.0)
Maryland 167 167 (100.0) 2 (1.2)
Massachusetts 198 198 (100.0) 2 (1.0)
Michigan 139 132 (95.0) 4 (3.0)
Minnesota 144 144 (100.0) 2 (1.4)
Mississippi 62 62 (100.0) 4 (6.5)
Missouri 97 97 (100.0) 1 (1.0)
Montana 6 6 (100.0) 0 (0.0)
Nebraska 21 21 (100.0) 0 (0.0)
Nevada 76 75 (98.7) 0 (0.0)
New Hampshire 15 15 (100.0) 0 (0.0)
New Jersey 306 306 (100.0) 8 (2.6)
New Mexico 50 50 (100.0) 1 (2.0)
New York State3 209 207 (99.0) 4 (1.9)
New York City 641 630 (98.3) 8 (1.3)
North Carolina 201 201 (100.0) 3 (1.5)
North Dakota 9 7 (77.8) 0 (0.0)
Ohio 141 141 (100.0) 4 (2.8)
Oklahoma 65 55 (84.6) 1 (1.8)
Oregon 68 67 (98.5) 2 (3.0)
Pennsylvania 207 205 (99.0) 7 (3.4)
Rhode Island 25 25 (100.0) 0 (0.0)
South Carolina 99 99 (100.0) 3 (3.0)
South Dakota 9 9 (100.0) 0 (0.0)
Tennessee 127 127 (100.0) 9 (7.1)
Texas 1,145 1,145 (100.0) 20 (1.7)
Utah 30 30 (100.0) 0 (0.0)
Vermont 4 4 (100.0) 0 (0.0)
Virginia 171 171 (100.0) 4 (2.3)
Washington 202 202 (100.0) 3 (1.5)
West Virginia 13 13 (100.0) 1 (7.7)
Wisconsin 46 46 (100.0) 1 (2.2)
Wyoming 0 0 -- 0 --
American Samoa4 2 2 (100.0) 0 (0.0)
Fed. States of Micronesia4 104 102 (98.1) 0 (0.0)
Guam4 37 37 (100.0) 0 (0.0)
Marshall Islands4 124 123 (99.2) 0 (0.0)
N. Mariana Islands4 15 14 (93.3) 0 (0.0)
Puerto Rico4 50 50 (100.0) 2 (4.0)
Republic of Palau4 6 6 (100.0) 0 (0.0)




Cases with Information on
Residence in Long-term Care Facilities
Cases Reported As Residents of
Long-term Care Facilities2
No. No.(%) (%)
Table 44. Tuberculosis Cases and Percentages by Residence in Long-term Care Facilities,1 
Age >15: Reporting Areas, 2013
1 Resident of long-term care facility at time of TB diagnosis. Percentage based on 52 reporting areas (50 states, New York City, and the 
District of Columbia). Counts and percentages shown only for reporting areas with information reported for >75% of cases.
2 Percent of those with known status.
3 Excludes New York City.
4 Not included in U.S. totals. 
Note: Ellipses indicate data not available.
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United States 9,094 8,966 (98.6) 142 (1.6)
Alabama 101 99 (98.0) 1 (1.0)
Alaska 61 57 (93.4) 0 (0.0)
Arizona 177 165 (93.2) 14 (8.5)
Arkansas 71 71 (100.0) 1 (1.4)
California 2,079 2,055 (98.8) 32 (1.6)
Colorado 72 71 (98.6) 1 (1.4)
Connecticut 61 60 (98.4) 1 (1.7)
Delaware 16 16 (100.0) 0 (0.0)
District of Columbia 34 34 (100.0) 0 (0.0)
Florida 625 619 (99.0) 9 (1.5)
Georgia 312 308 (98.7) 4 (1.3)
Hawaii 111 103 (92.8) 0 (0.0)
Idaho 10 10 (100.0) 0 (0.0)
Illinois 311 300 (96.5) 4 (1.3)
Indiana 90 90 (100.0) 1 (1.1)
Iowa 46 46 (100.0) 0 (0.0)
Kansas 30 30 (100.0) 0 (0.0)
Kentucky 57 57 (100.0) 0 (0.0)
Louisiana 124 123 (99.2) 5 (4.1)
Maine 13 13 (100.0) 0 (0.0)
Maryland 167 167 (100.0) 1 (0.6)
Massachusetts 198 198 (100.0) 3 (1.5)
Michigan 139 135 (97.1) 1 (0.7)
Minnesota 144 144 (100.0) 1 (0.7)
Mississippi 62 62 (100.0) 0 (0.0)
Missouri 97 97 (100.0) 0 (0.0)
Montana 6 6 (100.0) 0 (0.0)
Nebraska 21 19 (90.5) 0 (0.0)
Nevada 76 75 (98.7) 1 (1.3)
New Hampshire 15 15 (100.0) 0 (0.0)
New Jersey 306 306 (100.0) 3 (1.0)
New Mexico 50 48 (96.0) 1 (2.1)
New York State2 209 199 (95.2) 2 (1.0)
New York City 641 632 (98.6) 6 (0.9)
North Carolina 201 201 (100.0) 1 (0.5)
North Dakota 9 6 (66.7) -- --
Ohio 141 141 (100.0) 5 (3.5)
Oklahoma 65 59 (90.8) 1 (1.7)
Oregon 68 65 (95.6) 1 (1.5)
Pennsylvania 207 204 (98.6) 1 (0.5)
Rhode Island 25 25 (100.0) 0 (0.0)
South Carolina 99 96 (97.0) 1 (1.0)
South Dakota 9 9 (100.0) 0 (0.0)
Tennessee 127 127 (100.0) 0 (0.0)
Texas 1,145 1,145 (100.0) 35 (3.1)
Utah 30 30 (100.0) 0 (0.0)
Vermont 4 4 (100.0) 0 (0.0)
Virginia 171 169 (98.8) 2 (1.2)
Washington 202 196 (97.0) 3 (1.5)
West Virginia 13 13 (100.0) 0 (0.0)
Wisconsin 46 46 (100.0) 0 (0.0)
Wyoming 0 0 -- 0 --
Amercian Samoa3 2 2 (100.0) 0 (0.0)
Fed. States of Micronesia3 104 103 (99.0) 0 (0.0)
Guam3 37 37 (100.0) 0 (0.0)
Marshall Islands3 124 124 (100.0) 1 (0.8)
N. Mariana Islands3 15 15 (100.0) 0 (0.0)
Puerto Rico3 50 50 (100.0) 10 (20.0)
Republic of Palau3 6 6 (100.0) 0 (0.0)




Cases with Information on
Injecting Drug Use
Cases Reporting Injecting Drug Use
No. No.(%) (%)
Table 45. Tuberculosis Cases and Percentages by Injecting Drug Use,1 Age >15: 
Reporting Areas, 2013
1 Injecting drug use within past 12 months of TB diagnosis. Percentage based on 52 reporting areas (50 states, New York City, and the 
District of Columbia). Counts and percentages shown only for reporting areas with information reported for >75% of cases.
2 Excludes New York City.
3 Not included in U.S. totals. 
Note: Ellipses indicate data not available.
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United States 9,094 8,956 (98.5) 633 (7.1)
Alabama 101 99 (98.0) 12 (12.1)
Alaska 61 56 (91.8) 7 (12.5)
Arizona 177 163 (92.1) 29 (17.8)
Arkansas 71 71 (100.0) 5 (7.0)
California 2,079 2,051 (98.7) 141 (6.9)
Colorado 72 71 (98.6) 3 (4.2)
Connecticut 61 60 (98.4) 1 (1.7)
Delaware 16 16 (100.0) 1 (6.3)
District of Columbia 34 34 (100.0) 0 (0.0)
Florida 625 619 (99.0) 55 (8.9)
Georgia 312 308 (98.7) 25 (8.1)
Hawaii 111 103 (92.8) 0 (0.0)
Idaho 10 10 (100.0) 0 (0.0)
Illinois 311 299 (96.1) 23 (7.7)
Indiana 90 90 (100.0) 9 (10.0)
Iowa 46 46 (100.0) 1 (2.2)
Kansas 30 30 (100.0) 1 (3.3)
Kentucky 57 57 (100.0) 5 (8.8)
Louisiana 124 123 (99.2) 16 (13.0)
Maine 13 13 (100.0) 2 (15.4)
Maryland 167 167 (100.0) 4 (2.4)
Massachusetts 198 198 (100.0) 10 (5.1)
Michigan 139 133 (95.7) 6 (4.5)
Minnesota 144 144 (100.0) 3 (2.1)
Mississippi 62 62 (100.0) 1 (1.6)
Missouri 97 97 (100.0) 6 (6.2)
Montana 6 6 (100.0) 0 (0.0)
Nebraska 21 20 (95.2) 1 (5.0)
Nevada 76 75 (98.7) 4 (5.3)
New Hampshire 15 15 (100.0) 0 (0.0)
New Jersey 306 306 (100.0) 15 (4.9)
New Mexico 50 48 (96.0) 3 (6.3)
New York State2 209 200 (95.7) 6 (3.0)
New York City 641 632 (98.6) 27 (4.3)
North Carolina 201 201 (100.0) 23 (11.4)
North Dakota 9 6 (66.7) -- --
Ohio 141 141 (100.0) 11 (7.8)
Oklahoma 65 59 (90.8) 6 (10.2)
Oregon 68 65 (95.6) 5 (7.7)
Pennsylvania 207 204 (98.6) 3 (1.5)
Rhode Island 25 25 (100.0) 1 (4.0)
South Carolina 99 96 (97.0) 10 (10.4)
South Dakota 9 9 (100.0) 0 (0.0)
Tennessee 127 127 (100.0) 16 (12.6)
Texas 1,145 1,145 (100.0) 122 (10.7)
Utah 30 30 (100.0) 0 (0.0)
Vermont 4 4 (100.0) 0 (0.0)
Virginia 171 169 (98.8) 6 (3.6)
Washington 202 195 (96.5) 6 (3.1)
West Virginia 13 12 (92.3) 1 (8.3)
Wisconsin 46 46 (100.0) 0 (0.0)
Wyoming 0 0 -- 0 --
American Samoa3 2 2 (100.0) 0 (0.0)
Fed. States of Micronesia3 104 103 (99.0) 28 (27.2)
Guam3 37 37 (100.0) 0 (0.0)
Marshall Islands3 124 124 (100.0) 1 (0.8)
N. Mariana Islands3 15 15 (100.0) 0 (0.0)
Puerto Rico3 50 50 (100.0) 7 (14.0)
Republic of Palau3 6 6 (100.0) 0 (0.0)




Cases with Information on
Noninjecting Drug Use
Cases Reporting Noninjecting Drug Use
No. No.(%) (%)
Table 46. Tuberculosis Cases and Percentages by Noninjecting Drug Use,1 Age >15: 
Reporting Areas, 2013
1 Noninjecting drug use within past 12 months of TB diagnosis. Percentage based on 52 reporting areas (50 states, New York City, and 
the District of Columbia). Counts and percentages shown only for reporting areas with information reported for >75% of cases.
2 Excludes New York City.
3 Not included in U.S. totals. 
Note: Ellipses indicate data not available.
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United States 9,094 8,930 (98.2) 982 (11.0)
Alabama 101 100 (99.0) 23 (23.0)
Alaska 61 55 (90.2) 19 (34.5)
Arizona 177 161 (91.0) 21 (13.0)
Arkansas 71 71 (100.0) 10 (14.1)
California 2,079 2,054 (98.8) 172 (8.4)
Colorado 72 71 (98.6) 7 (9.9)
Connecticut 61 60 (98.4) 5 (8.3)
Delaware 16 16 (100.0) 0 (0.0)
District of Columbia 34 34 (100.0) 1 (2.9)
Florida 625 620 (99.2) 96 (15.5)
Georgia 312 308 (98.7) 35 (11.4)
Hawaii 111 103 (92.8) 9 (8.7)
Idaho 10 10 (100.0) 1 (10.0)
Illinois 311 300 (96.5) 32 (10.7)
Indiana 90 90 (100.0) 13 (14.4)
Iowa 46 46 (100.0) 6 (13.0)
Kansas 30 30 (100.0) 0 (0.0)
Kentucky 57 57 (100.0) 9 (15.8)
Louisiana 124 122 (98.4) 28 (23.0)
Maine 13 13 (100.0) 2 (15.4)
Maryland 167 167 (100.0) 9 (5.4)
Massachusetts 198 198 (100.0) 13 (6.6)
Michigan 139 134 (96.4) 12 (9.0)
Minnesota 144 144 (100.0) 8 (5.6)
Mississippi 62 62 (100.0) 9 (14.5)
Missouri 97 97 (100.0) 15 (15.5)
Montana 6 6 (100.0) 3 (50.0)
Nebraska 21 18 (85.7) 3 (16.7)
Nevada 76 75 (98.7) 8 (10.7)
New Hampshire 15 15 (100.0) 1 (6.7)
New Jersey 306 306 (100.0) 18 (5.9)
New Mexico 50 48 (96.0) 7 (14.6)
New York State2 209 196 (93.8) 21 (10.7)
New York City 641 618 (96.4) 10 (1.6)
North Carolina 201 201 (100.0) 22 (10.9)
North Dakota 9 5 (55.6) -- --
Ohio 141 141 (100.0) 19 (13.5)
Oklahoma 65 47 (72.3) -- --
Oregon 68 66 (97.1) 3 (4.5)
Pennsylvania 207 204 (98.6) 12 (5.9)
Rhode Island 25 25 (100.0) 1 (4.0)
South Carolina 99 97 (98.0) 22 (22.7)
South Dakota 9 9 (100.0) 3 (33.3)
Tennessee 127 127 (100.0) 23 (18.1)
Texas 1,145 1,145 (100.0) 205 (17.9)
Utah 30 30 (100.0) 1 (3.3)
Vermont 4 4 (100.0) 0 (0.0)
Virginia 171 169 (98.8) 13 (7.7)
Washington 202 197 (97.5) 12 (6.1)
West Virginia 13 12 (92.3) 2 (16.7)
Wisconsin 46 46 (100.0) 4 (8.7)
Wyoming 0 0 -- 0 --
American Samoa3 2 2 (100.0) 0 (0.0)
Fed. States of Micronesia3 104 103 (99.0) 5 (4.9)
Guam3 37 37 (100.0) 2 (5.4)
Marshall Islands3 124 123 (99.2) 14 (11.4)
N. Mariana Islands3 15 15 (100.0) 0 (0.0)
Puerto Rico3 50 50 (100.0) 5 (10.0)
Republic of Palau3 6 6 (100.0) 1 (16.7)









Table 47. Tuberculosis Cases and Percentages by Excess Alcohol Use,1 Age >15: 
Reporting Areas, 2013
1 Excess alcohol use within past 12 months of TB diagnosis. Percentage based on 52 reporting areas (50 states, New York City, and the 
District of Columbia). Counts and percentages shown only for reporting areas with information reported for >75% of cases.
2 Excludes New York City.
3 Not included in U.S. totals. 
Note: Ellipses indicate data not available.
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United States 9,094 8,922 (98.1) (27.4) (4.0) (0.1) (1.5) (16.4) (16.0) (34.5)
Alabama 101 100 (99.0) (13.0) (3.0) (0.0) (2.0) (24.0) (32.0) (26.0)
Alaska 61 57 (93.4) (38.6) (0.0) (0.0) (7.0) (10.5) (22.8) (21.1)
Arizona 177 159 (89.8) (21.4) (3.1) (0.0) (4.4) (23.3) (13.8) (34.0)
Arkansas 71 71 (100.0) (18.3) (5.6) (1.4) (0.0) (33.8) (8.5) (32.4)
California 2,079 2,060 (99.1) (21.7) (4.0) (0.1) (2.7) (24.5) (15.0) (31.9)
Colorado 72 72 (100.0) (9.7) (2.8) (0.0) (1.4) (16.7) (34.7) (34.7)
Connecticut 61 61 (100.0) (8.2) (6.6) (0.0) (0.0) (19.7) (11.5) (54.1)
Delaware 16 16 (100.0) (31.3) (0.0) (0.0) (6.3) (18.8) (12.5) (31.3)
District of Columbia 34 34 (100.0) (64.7) (5.9) (0.0) (0.0) (11.8) (0.0) (17.6)
Florida 625 602 (96.3) (68.9) (1.7) (0.0) (1.5) (3.7) (2.3) (21.9)
Georgia 312 310 (99.4) (37.1) (1.9) (0.6) (1.0) (9.7) (11.9) (37.7)
Hawaii 111 107 (96.4) (14.0) (4.7) (0.0) (1.9) (26.2) (14.0) (39.3)
Idaho 10 10 (100.0) (0.0) (0.0) (0.0) (0.0) (30.0) (10.0) (60.0)
Illinois 311 292 (93.9) (24.0) (4.1) (0.0) (1.0) (19.9) (14.4) (36.6)
Indiana 90 90 (100.0) (15.6) (4.4) (0.0) (0.0) (16.7) (28.9) (34.4)
Iowa 46 46 (100.0) (6.5) (0.0) (0.0) (0.0) (15.2) (23.9) (54.3)
Kansas 30 30 (100.0) (16.7) (0.0) (0.0) (0.0) (20.0) (30.0) (33.3)
Kentucky 57 57 (100.0) (14.0) (7.0) (0.0) (0.0) (12.3) (31.6) (35.1)
Louisiana 124 118 (95.2) (28.0) (1.7) (0.0) (1.7) (12.7) (12.7) (43.2)
Maine 13 12 (92.3) (8.3) (0.0) (0.0) (0.0) (50.0) (8.3) (33.3)
Maryland 167 167 (100.0) (15.6) (3.6) (0.0) (0.0) (10.2) (22.2) (48.5)
Massachusetts 198 198 (100.0) (26.3) (4.0) (0.0) (0.0) (17.7) (14.6) (37.4)
Michigan 139 124 (89.2) (77.4) (0.8) (0.0) (1.6) (0.0) (0.0) (20.2)
Minnesota 144 144 (100.0) (9.0) (10.4) (0.0) (0.0) (10.4) (36.1) (34.0)
Mississippi 62 62 (100.0) (35.5) (1.6) (0.0) (0.0) (21.0) (11.3) (30.6)
Missouri 97 97 (100.0) (27.8) (2.1) (0.0) (0.0) (28.9) (15.5) (25.8)
Montana 6 6 (100.0) (0.0) (0.0) (0.0) (0.0) (33.3) (50.0) (16.7)
Nebraska 21 19 (90.5) (5.3) (0.0) (0.0) (5.3) (5.3) (15.8) (68.4)
Nevada 76 76 (100.0) (9.2) (6.6) (0.0) (0.0) (18.4) (15.8) (50.0)
New Hampshire 15 15 (100.0) (26.7) (20.0) (0.0) (0.0) (6.7) (6.7) (40.0)
New Jersey 306 306 (100.0) (22.9) (5.9) (0.0) (1.3) (15.7) (20.6) (33.7)
New Mexico 50 50 (100.0) (16.0) (0.0) (0.0) (2.0) (22.0) (40.0) (20.0)
New York State2 209 191 (91.4) (25.7) (7.3) (0.0) (1.0) (18.8) (10.5) (36.6)
New York City 641 635 (99.1) (39.8) (5.2) (0.0) (0.9) (13.2) (3.1) (37.6)
North Carolina 201 201 (100.0) (30.8) (2.0) (1.0) (1.5) (17.9) (7.5) (39.3)
North Dakota 9 0 (0.0) -- -- -- -- -- -- --
Ohio 141 141 (100.0) (22.7) (5.7) (0.0) (1.4) (18.4) (18.4) (33.3)
Oklahoma 65 50 (76.9) (32.0) (4.0) (0.0) (0.0) (14.0) (8.0) (42.0)
Oregon 68 68 (100.0) (20.6) (5.9) (0.0) (2.9) (22.1) (13.2) (35.3)
Pennsylvania 207 200 (96.6) (22.5) (5.0) (0.0) (0.0) (20.0) (21.5) (31.0)
Rhode Island 25 24 (96.0) (8.3) (8.3) (0.0) (0.0) (29.2) (33.3) (20.8)
South Carolina 99 98 (99.0) (27.6) (5.1) (0.0) (1.0) (16.3) (11.2) (38.8)
South Dakota 9 9 (100.0) (0.0) (11.1) (0.0) (11.1) (0.0) (66.7) (11.1)
Tennessee 127 127 (100.0) (27.6) (1.6) (0.0) (3.9) (16.5) (17.3) (33.1)
Texas 1,145 1,145 (100.0) (26.1) (3.9) (0.4) (0.9) (10.0) (22.1) (36.6)
Utah 30 30 (100.0) (26.7) (6.7) (0.0) (0.0) (13.3) (23.3) (30.0)
Vermont 4 4 (100.0) (0.0) (25.0) (0.0) (0.0) (0.0) (25.0) (50.0)
Virginia 171 171 (100.0) (10.5) (2.9) (0.0) (0.0) (13.5) (23.4) (49.7)
Washington 202 201 (99.5) (5.5) (7.5) (0.0) (4.0) (12.9) (32.8) (37.3)
West Virginia 13 13 (100.0) (0.0) (0.0) (0.0) (0.0) (15.4) (23.1) (61.5)
Wisconsin 46 46 (100.0) (4.3) (6.5) (0.0) (2.2) (0.0) (47.8) (39.1)
Wyoming 0 0 -- -- -- -- -- -- -- --
American Samoa3 2 2 (100.0) (100.0) (0.0) (0.0) (0.0) (0.0) (0.0) (0.0)
Fed. States of Micronesia3 104 98 (94.2) (55.1) (0.0) (0.0) (1.0) (1.0) (31.6) (11.2)
Guam3 37 36 (97.3) (25.0) (0.0) (0.0) (0.0) (13.9) (25.0) (36.1)
Marshall Islands3 124 124 (100.0) (54.8) (2.4) (0.8) (0.8) (0.0) (20.2) (21.0)
N. Mariana Islands3 15 15 (100.0) (0.0) (0.0) (0.0) (33.3) (6.7) (60.0) (0.0)
Puerto Rico3 50 50 (100.0) (42.0) (4.0) (0.0) (0.0) (14.0) (14.0) (26.0)
Republic of Palau3 6 6 (100.0) (33.3) (0.0) (0.0) (33.3) (16.7) (0.0) (16.7)
U.S. Virgin Islands3 1 1 (100.0) (0.0) (0.0) (0.0) (0.0) (0.0) (0.0) (100.0)
Table 48. Tuberculosis Cases and Percentages by Primary Occupation, Age >15: 
Reporting Areas, 2013
1 Occupation within past 12 months of TB diagnosis. Overall U.S. percentage based on 52 reporting areas (50 states, New York City, and 
the District of Columbia). Percentages shown only for reporting areas with information reported for >75% of cases.
2 Excludes New York City.
3 Not included in U.S. totals. 



















United States 9,582 9,357 9,271 (99.1) (0.5) (2.4) (84.6)
Alabama 108 103 103 (100.0) (0.0) (3.9) (77.7)
Alaska 71 71 69 (97.2) (1.4) (0.0) (94.2)
Arizona 184 179 176 (98.3) (0.6) (1.1) (94.3)
Arkansas 72 71 70 (98.6) (1.4) (18.6) (78.6)
California 2,171 2,125 2,105 (99.1) (0.2) (1.1) (90.8)
Colorado 74 73 72 (98.6) (2.8) (2.8) (72.2)
Connecticut 62 59 59 (100.0) (0.0) (0.0) (15.3)
Delaware 19 19 19 (100.0) (0.0) (15.8) (78.9)
District of Columbia 38 38 36 (94.7) (0.0) (0.0) (100.0)
Florida 652 633 632 (99.8) (0.3) (2.2) (87.7)
Georgia 340 327 325 (99.4) (0.9) (3.1) (37.2)
Hawaii 115 114 113 (99.1) (0.0) (2.7) (89.4)
Idaho 11 11 11 (100.0) (0.0) (9.1) (45.5)
Illinois 327 321 314 (97.8) (0.6) (6.1) (84.4)
Indiana 94 90 90 (100.0) (0.0) (3.3) (95.6)
Iowa 47 47 47 (100.0) (0.0) (4.3) (89.4)
Kansas 36 36 36 (100.0) (0.0) (8.3) (88.9)
Kentucky 59 58 58 (100.0) (0.0) (0.0) (79.3)
Louisiana 139 135 135 (100.0) (1.5) (5.2) (89.6)
Maine 15 14 14 (100.0) (0.0) (14.3) (85.7)
Maryland 176 175 175 (100.0) (1.1) (4.6) (86.9)
Massachusetts 201 198 189 (95.5) (2.1) (1.1) (78.3)
Michigan 141 138 135 (97.8) (0.7) (2.2) (52.6)
Minnesota 151 150 150 (100.0) (0.0) (2.0) (88.7)
Mississippi 65 60 60 (100.0) (0.0) (3.3) (86.7)
Missouri 104 102 102 (100.0) (0.0) (3.9) (81.4)
Montana 6 6 6 (100.0) (0.0) (0.0) (100.0)
Nebraska 21 21 21 (100.0) (0.0) (4.8) (61.9)
Nevada 92 89 89 (100.0) (0.0) (2.2) (91.0)
New Hampshire 15 15 15 (100.0) (0.0) (6.7) (73.3)
New Jersey 319 314 314 (100.0) (0.3) (2.2) (89.2)
New  Mexico 50 46 45 (97.8) (6.7) (2.2) (86.7)
New York State4 216 216 215 (99.5) (0.0) (3.7) (83.7)
New York City 656 650 646 (99.4) (0.2) (0.8) (89.9)
North Carolina 216 206 205 (99.5) (0.0) (1.5) (82.0)
North Dakota 12 9 9 (100.0) (0.0) (0.0) (66.7)
Ohio 148 145 145 (100.0) (0.0) (0.0) (95.2)
Oklahoma 69 67 66 (98.5) (6.1) (6.1) (80.3)
Oregon 73 73 72 (98.6) (0.0) (6.9) (81.9)
Pennsylvania 214 212 209 (98.6) (0.0) (0.0) (64.1)
Rhode Island 27 26 26 (100.0) (3.8) (0.0) (92.3)
South Carolina 112 107 106 (99.1) (0.9) (10.4) (82.1)
South Dakota 9 9 9 (100.0) (0.0) (0.0) (55.6)
Tennessee 142 136 136 (100.0) (0.0) (3.7) (80.9)
Texas 1,222 1,183 1,167 (98.6) (0.6) (2.5) (90.2)
Utah 33 33 32 (97.0) (0.0) (0.0) (93.8)
Vermont 5 5 5 (100.0) (0.0) (20.0) (60.0)
Virginia 180 173 173 (100.0) (0.0) (0.0) (94.8)
Washington 210 206 204 (99.0) (1.0) (2.9) (83.3)
West Virginia 13 13 13 (100.0) (0.0) (0.0) (69.2)
Wisconsin 50 50 48 (96.0) (2.1) (2.1) (60.4)
Wyoming 0 0 0 -- -- -- --
American Samoa5 2 2 2 (100.0) (0.0) (0.0) (100.0)
Fed. States of Micronesia5 130 127 127 (100.0) (0.0) (0.0) (99.2)
Guam5 48 47 47 (100.0) (0.0) (12.8) (10.6)
Marshall Islands5 153 153 153 (100.0) (0.0) (0.0) (97.4)
N. Mariana Islands5 16 16 0 (0.0) -- -- --
Puerto Rico5 50 47 47 (100.0) (0.0) (0.0) (100.0)
Republic of Palau5 6 6 6 (100.0) (0.0) (0.0) (100.0)
U.S. Virgin Islands5 2 2 2 (100.0) (0.0) (0.0) (100.0)
Table 49. Tuberculosis Cases and Percentages by Initial Drug Regimen: 
Reporting Areas, 2013
1 Includes persons who were alive at diagnosis and started on one or more drug.
2 Overall U.S. percentage based on 52 reporting areas (50 states, New York City, and the District of Columbia). Counts and percentages 
shown only for reporting areas with information reported for >75% of cases.
3 I=isoniazid; R=rifampin; Z=pyrazinamide; E=ethambutol. Cases with other drugs prescribed in addition to these regimens are excluded.
4 Excludes New York City.
5 Not included in U.S. totals.
Note: Excluding cases with no information on drug regimen, 53 (0.57%) persons were not started on any drugs, 2 (0.02%) were started 




Cases with Information on
Initial Drug Regimen1








United States 7,358 7,108 (96.6) 653 (9.2) 95 (1.3)
Alabama 83 83 (100.0) 4 (4.8) 1 (1.2)
Alaska 55 54 (98.2) 5 (9.3) 0 (0.0)
Arizona 154 154 (100.0) 17 (11.0) 1 (0.6)
Arkansas 52 51 (98.1) 1 (2.0) 0 (0.0)
California 1,759 1,705 (96.9) 182 (10.7) 27 (1.6)
Colorado 48 48 (100.0) 2 (4.2) 0 (0.0)
Connecticut 51 47 (92.2) 7 (14.9) 1 (2.1)
Delaware 13 8 (61.5) -- -- -- --
District of Columbia 26 24 (92.3) 4 (16.7) 1 (4.2)
Florida 514 484 (94.2) 37 (7.6) 9 (1.9)
Georgia 235 229 (97.4) 23 (10.0) 2 (0.9)
Hawaii 92 90 (97.8) 11 (12.2) 0 (0.0)
Idaho 9 9 (100.0) 0 (0.0) 0 (0.0)
Illinois 240 232 (96.7) 24 (10.3) 3 (1.3)
Indiana 73 72 (98.6) 8 (11.1) 0 (0.0)
Iowa 36 32 (88.9) 3 (9.4) 0 (0.0)
Kansas 32 31 (96.9) 2 (6.5) 1 (3.2)
Kentucky 47 47 (100.0) 2 (4.3) 0 (0.0)
Louisiana 117 92 (78.6) 5 (5.4) 1 (1.1)
Maine 8 8 (100.0) 0 (0.0) 0 (0.0)
Maryland 123 123 (100.0) 13 (10.6) 2 (1.6)
Massachusetts 153 149 (97.4) 18 (12.1) 7 (4.7)
Michigan 98 94 (95.9) 3 (3.2) 0 (0.0)
Minnesota 116 113 (97.4) 13 (11.5) 0 (0.0)
Mississippi 49 47 (95.9) 1 (2.1) 0 (0.0)
Missouri 72 72 (100.0) 6 (8.3) 0 (0.0)
Montana 6 6 (100.0) 1 (16.7) 0 (0.0)
Nebraska 14 14 (100.0) 0 (0.0) 0 (0.0)
Nevada 63 59 (93.7) 5 (8.5) 0 (0.0)
New Hampshire 15 14 (93.3) 2 (14.3) 0 (0.0)
New Jersey 256 253 (98.8) 29 (11.5) 5 (2.0)
New Mexico 39 39 (100.0) 5 (12.8) 1 (2.6)
New York State3 157 155 (98.7) 7 (4.5) 1 (0.6)
New York City 472 455 (96.4) 47 (10.3) 7 (1.5)
North Carolina 164 161 (98.2) 13 (8.1) 5 (3.1)
North Dakota 6 0 (0.0) -- -- -- --
Ohio 119 119 (100.0) 6 (5.0) 3 (2.5)
Oklahoma 49 44 (89.8) 2 (4.5) 0 (0.0)
Oregon 55 55 (100.0) 2 (3.6) 1 (1.8)
Pennsylvania 168 157 (93.5) 13 (8.3) 3 (1.9)
Rhode Island 13 13 (100.0) 0 (0.0) 0 (0.0)
South Carolina 79 76 (96.2) 5 (6.6) 0 (0.0)
South Dakota 6 5 (83.3) 0 (0.0) 0 (0.0)
Tennessee 102 99 (97.1) 6 (6.1) 1 (1.0)
Texas 921 894 (97.1) 61 (6.8) 5 (0.6)
Utah 24 24 (100.0) 0 (0.0) 0 (0.0)
Vermont 3 3 (100.0) 1 (33.3) 1 (33.3)
Virginia 139 135 (97.1) 16 (11.9) 1 (0.7)
Washington 177 174 (98.3) 22 (12.6) 2 (1.1)
West Virginia 12 12 (100.0) 3 (25.0) 0 (0.0)
Wisconsin 44 44 (100.0) 15 (34.1) 3 (6.8)
Wyoming 0 0 -- 0 -- 0 --
American Samoa4 2 1 (50.0) -- -- -- --
Fed. States of Micronesia4 57 40 (70.2) -- -- -- --
Guam4 25 25 (100.0) 3 (12.0) 0 (0.0)
Marshall Islands4 64 58 (90.6) 2 (3.4) 1 (1.7)
N. Mariana Islands4 15 10 (66.7) -- -- -- --
Puerto Rico4 45 43 (95.6) 4 (9.3) 1 (2.3)
Republic of Palau4 6 0 (0.0) -- -- -- --
U.S. Virgin Islands4 2 1 (50.0) -- -- -- --
1 Patients tested to at least isoniazid and rifampin
2 Isolates may be resistant to other drugs. Overall U.S. percentage based on 52 reporting areas (50 states, New York City, and the District 
of Columbia). Counts and percentages shown only for reporting areas with information reported for >75% of cases.
3 Excludes New York City.
4 Not included in U.S. totals. 
Note: Ellipses indicate data not available.
Table 50. Culture-Positive Tuberculosis Cases and Percentages with Drug-Susceptibility 











Isoniazid1 Isoniazid and Rifampin1
No. No.(%) (%)
90
United States 9,364 8,283 (88.5) 543 (6.6)
Alabama 103 98 (95.1) 2 (2.0)
Alaska 71 57 (80.3) 0 (0.0)
Arizona 179 171 (95.5) 10 (5.8)
Arkansas 71 60 (84.5) 3 (5.0)
California 2,125 1,904 (89.6) 75 (3.9)
Colorado 73 72 (98.6) 7 (9.7)
Connecticut 59 52 (88.1) 9 (17.3)
Delaware 19 13 (68.4) 0 (0.0)
District of Columbia 38 37 (97.4) 8 (21.6)
Florida 633 562 (88.8) 80 (14.2)
Georgia 328 307 (93.6) 39 (12.7)
Hawaii 114 111 (97.4) 0 (0.0)
Idaho 11 9 (81.8) 0 (0.0)
Illinois 321 276 (86.0) 16 (5.8)
Indiana 90 70 (77.8) 2 (2.9)
Iowa 47 35 (74.5) 1 (2.9)
Kansas 36 33 (91.7) 0 (0.0)
Kentucky 58 55 (94.8) 2 (3.6)
Louisiana 135 117 (86.7) 3 (2.6)
Maine 14 11 (78.6) 0 (0.0)
Maryland 175 168 (96.0) 15 (8.9)
Massachusetts 198 121 (61.1) 12 (9.9)
Michigan 139 120 (86.3) 7 (5.8)
Minnesota 150 144 (96.0) 4 (2.8)
Mississippi 60 58 (96.7) 7 (12.1)
Missouri 102 86 (84.3) 2 (2.3)
Montana 6 6 (100.0) 1 (16.7)
Nebraska 21 19 (90.5) 0 (0.0)
Nevada 89 86 (96.6) 2 (2.3)
New Hampshire 15 15 (100.0) 1 (6.7)
New Jersey 314 265 (84.4) 24 (9.1)
New Mexico 46 39 (84.8) 1 (2.6)
New York State3 216 179 (82.9) 14 (7.8)
New York City 650 540 (83.1) 39 (7.2)
North Carolina 206 206 (100.0) 13 (6.3)
North Dakota 12 12 (100.0) 0 (0.0)
Ohio 145 124 (85.5) 10 (8.1)
Oklahoma 67 62 (92.5) 0 (0.0)
Oregon 73 63 (86.3) 1 (1.6)
Pennsylvania 212 164 (77.4) 15 (9.1)
Rhode Island 26 20 (76.9) 2 (10.0)
South Carolina 107 93 (86.9) 12 (12.9)
South Dakota 9 7 (77.8) 0 (0.0)
Tennessee 136 127 (93.4) 10 (7.9)
Texas 1,183 1,060 (89.6) 78 (7.4)
Utah 33 31 (93.9) 1 (3.2)
Vermont 5 0 (0.0) 0 .
Virginia 173 170 (98.3) 10 (5.9)
Washington 208 190 (91.3) 5 (2.6)
West Virginia 13 12 (92.3) 0 (0.0)
Wisconsin 50 46 (92.0) 0 (0.0)
Wyoming 0 0 -- 0 --
American Samoa4 2 2 (100.0) 0 (0.0)
Fed. States of Micronesia4 127 108 (85.0) 0 (0.0)
Guam4 47 34 (72.3) -- --
Marshall Islands4 153 117 (76.5) 1 (0.9)
N. Mariana Islands4 16 12 (75.0) 0 (0.0)
Puerto Rico4 47 44 (93.6) 7 (15.9)
Republic of Palau4 6 6 (100.0) 0 (0.0)
U.S. Virgin Islands4 2 2 (100.0) 0 (0.0)
Table 51. Tuberculosis Cases and Percentages by HIV Status: Reporting Areas, 2013
1 Includes only those cases in persons with negative, positive, or indeterminate HIV test results and those persons not dead at diagnosis.
2 Counts and percentages shown only for reporting areas with information reported for >75% of cases. 
3 Excludes New York City.
4 Not included in U.S. totals. 





Cases with Information on HIV Status1 Cases in Persons with HIV-Positive Results2
No. (%) No. (%)
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United States 9,582 7,358 6,957 94.6
Alabama 108 83 82 98.8 
Alaska 71 55 52 94.5 
Arizona 184 154 152 98.7 
Arkansas 72 52 51 98.1 
California 2171 1,759 1,664 94.6 
Colorado 74 48 48 100.0 
Connecticut 62 51 50 98.0 
District of Columbia 38 26 19 73.1 
Delaware 19 13 9 69.2 
Florida 652 514 512 99.6 
Georgia 340 235 227 96.6 
Hawaii 115 92 88 95.7 
Idaho 11 9 9 100.0 
Illinois 327 240 193 80.4 
Indiana 94 73 73 100.0 
Iowa 47 36 33 91.7 
Kansas 36 32 29 90.6 
Kentucky 59 47 47 100.0 
Louisiana 139 117 65 55.6 
Maine 15 8 7 87.5 
Maryland 176 123 119 96.7 
Massachusetts 201 153 143 93.5 
Michigan 141 98 95 96.9 
Minnesota 151 116 116 100.0 
Mississippi 65 49 46 93.9 
Missouri 104 72 69 95.8 
Montana 6 6 5 83.3 
Nebraska 21 14 13 92.9 
Nevada 92 63 62 98.4 
New Hampshire 15 15 15 100.0 
New Jersey 319 256 255 99.6 
New Mexico 50 39 39 100.0 
New York 872 629 574 91.2 
North Carolina 216 164 158 96.3 
North Dakota 12 6 6 100.0 
Ohio 148 119 116 97.5 
Oklahoma 69 49 47 95.9 
Oregon 73 55 55 100.0 
Pennsylvania 214 168 159 94.6 
Rhode Island 27 13 13 100.0 
South Carolina 112 79 75 94.9 
South Dakota 9 6 6 100.0 
Tennessee 142 102 97 95.1 
Texas 1222 921 884 96.0 
Utah 33 24 24 100.0 
Vermont 5 3 3 100.0 
Virginia 180 139 133 95.7 
Washington 210 177 167 94.4 
West Virginia 13 12 11 91.7 
Wisconsin 50 44 42 95.5 
Wyoming 0 0 0 0.0 
American Samoa3 2 2 1 100.0 
Fed State of Micronesia3 130 57 54 94.7 
Guam3 48 25 4 16.0 
Marshall Islands3 153 64 59 92.2 
N. Mariana Islands3 16 15 13 86.7 
Puerto Rico3 50 45 41 91.1 
Republic of Palau3 6 6 4 66.7 
U.S. Virgin Islands3 2 2 0 0.0 
Table 53. Tuberculosis Genotyping Surveillance Coverage1: Reporting Areas, 2013
1 Genotype surveillance coverage is defined as the percentage of all culture positive tuberculosis (TB) cases for which there was a 
genotyped isolate.
2 National TB Performance Indicator goal for national TB genotyping surveillance coverage is 94%.



















United States 21,777 94.4 1,532 4,625 2 (2-70)
Alabama 306 98.7 34 99 2 (2-8)
Alaska 162 97.0 16 104 5 (2-16)
Arizona 507 98.8 36 94 2 (2-6)
Arkansas 146 98.6 6 22 4 (2-5)
California 5,012 93.5 423 1292 2 (2-49)
Colorado 147 100.0 6 12 2 (2-2)
Connecticut 174 99.4 6 16 2 (2-4)
District of Columbia 79 79.0 5 13 3 (2-3)
Delaware 41 82.0 1 2 2 (2-2)
Florida 1643 99.0 136 407 2 (2-70)
Georgia 713 98.5 64 181 2 (2-10)
Hawaii 248 96.5 19 56 2 (2-8)
Idaho 29 100.0 2 4 2 (2-2)
Illinois 637 83.8 45 128 2 (2-19)
Indiana 221 98.2 8 32 2 (2-11)
Iowa 92 92.0 2 4 2 (2-2)
Kansas 97 89.8 2 4 2 (2-2)
Kentucky 156 98.1 9 20 2 (2-3)
Louisiana 228 60.5 29 74 2 (2-4)
Maine 29 96.7 1 2 2 (2-2)
Maryland 443 98.4 15 36 2 (2-7)
Massachusetts 417 92.7 15 34 2 (2-4)
Michigan 317 97.8 14 52 2 (2-14)
Minnesota 338 99.1 16 44 2 (2-6)
Mississippi 177 97.8 10 33 3 (2-10)
Missouri 204 95.8 15 42 2 (2-5)
Montana 13 86.7 … … … …
Nebraska 44 95.7 2 4 2 (2-2)
Nevada 182 96.3 11 26 2 (2-5)
New Hampshire 29 87.9 1 3 3 (3-3)
New Jersey 739 98.5 30 74 2 (2-8)
New Mexico 117 97.5 3 6 2 (2-2)
New York 1832 94.0 110 282 2 (2-8)
North Carolina 498 96.3 41 117 2 (2-14)
North Dakota 23 95.8 1 9 9 (9-9)
Ohio 332 98.5 13 42 3 (2-6)
Oklahoma 177 95.2 20 48 2 (2-4)
Oregon 163 100.0 8 21 2 (2-5)
Pennsylvania 477 85.8 18 47 2 (2-5)
Rhode Island 52 100.0 3 7 2 (2-3)
South Carolina 237 87.8 20 63 2 (2-10)
South Dakota 26 100.0 1 2 2 (2-2)
Tennessee 309 95.4 18 70 2 (2-14)
Texas 2,731 95.2 231 828 2 (2-47)
Utah 76 100.0 4 8 2 (2-2)
Vermont 12 100.0 … … … …
Virginia 471 96.5 21 52 2 (2-5)
Washington 480 95.8 27 70 2 (2-7)
West Virginia 30 93.8 1 2 2 (2-2)
Wisconsin 158 98.1 13 37 2 (2-8)
Wyoming 6 85.7 … … … …
Table 54. County-based Tuberculosis Genotype Clusters1 Based on GENType: 
Reporting Areas, 2011–2013
1 Clusters are two or more cases with matching spoligotype and 24-locus mycobacterial interspersed repetitive unit-variable number tan-
dem repeat type (GENType) within a county during the specified 3-year time period (Total number of clusters from 2011–2013=1,532)
2 Genotype surveillance coverage is defined as the percentage of all culture positive tuberculosis (TB) cases for which there was a geno-
typed isolate.
Note: Ellipses indicate data not available.
See Technical Notes.








United States 10,509 10,264 10,063 (98.0) (67.1) (25.2) (7.7)
Alabama 161 156 155 (99.4) (85.8) (9.7) (4.5)
Alaska 67 65 65 (100.0) (50.8) (27.7) (21.5)
Arizona 255 246 242 (98.4) (60.3) (29.8) (9.9)
Arkansas 85 82 82 (100.0) (81.7) (17.1) (1.2)
California 2,323 2,274 2,253 (99.1) (54.5) (37.2) (8.3)
Colorado 70 68 67 (98.5) (98.5) (1.5) (0.0)
Connecticut 83 81 81 (100.0) (25.9) (49.4) (24.7)
Delaware 21 21 20 (95.2) (85.0) (15.0) (0.0)
District of Columbia 55 55 47 (85.5) (83.0) (17.0) (0.0)
Florida 754 737 731 (99.2) (66.2) (31.3) (2.5)
Georgia 347 332 315 (94.9) (79.7) (17.1) (3.2)
Hawaii 123 122 122 (100.0) (69.7) (28.7) (1.6)
Idaho 12 12 12 (100.0) (58.3) (33.3) (8.3)
Illinois 358 350 346 (98.9) (38.7) (16.2) (45.1)
Indiana 100 98 98 (100.0) (88.8) (5.1) (6.1)
Iowa 40 40 39 (97.5) (5.1) (94.9) (0.0)
Kansas 36 34 30 (88.2) (96.7) (0.0) (3.3)
Kentucky 70 69 66 (95.7) (75.8) (22.7) (1.5)
Louisiana 167 164 155 (94.5) (81.3) (12.9) (5.8)
Maine 9 8 8 (100.0) (12.5) (87.5) (0.0)
Maryland 232 227 226 (99.6) (89.8) (9.7) (0.4)
Massachusetts 195 190 170 (89.5) (77.6) (15.9) (6.5)
Michigan 170 168 155 (92.3) (78.1) (21.9) (0.0)
Minnesota 137 133 133 (100.0) (59.4) (38.3) (2.3)
Mississippi 91 89 89 (100.0) (94.4) (3.4) (2.2)
Missouri 97 94 88 (93.6) (83.0) (17.0) (0.0)
Montana 8 8 6 (75.0) (33.3) (66.7) (0.0)
Nebraska 23 23 22 (95.7) (50.0) (50.0) (0.0)
Nevada 96 94 75 (79.8) (90.7) (9.3) (0.0)
New Hampshire 11 11 10 (90.9) (30.0) (70.0) (0.0)
New Jersey 331 322 322 (100.0) (77.3) (21.4) (1.2)
New Mexico 49 46 44 (95.7) (68.2) (31.8) (0.0)
New York State3 221 218 218 (100.0) (66.5) (29.4) (4.1)
New York City 684 669 668 (99.9) (29.6) (49.9) (20.5)
North Carolina 244 235 235 (100.0) (75.7) (5.1) (19.1)
North Dakota 7 7 4 (57.1) -- -- --
Ohio 145 143 130 (90.9) (81.5) (16.2) (2.3)
Oklahoma 94 89 89 (100.0) (77.5) (7.9) (14.6)
Oregon 74 74 74 (100.0) (47.3) (27.0) (25.7)
Pennsylvania 260 252 250 (99.2) (84.4) (14.0) (1.6)
Rhode Island 27 27 26 (96.3) (96.2) (3.8) (0.0)
South Carolina 140 134 133 (99.3) (88.0) (12.0) (0.0)
South Dakota 15 15 15 (100.0) (26.7) (73.3) (0.0)
Tennessee 156 149 137 (91.9) (87.6) (11.7) (0.7)
Texas 1,317 1,292 1,283 (99.3) (83.4) (12.5) (4.1)
Utah 34 34 34 (100.0) (88.2) (11.8) (0.0)
Vermont 8 8 8 (100.0) (87.5) (12.5) (0.0)
Virginia 221 219 219 (100.0) (79.0) (20.1) (0.9)
Washington 199 195 189 (96.9) (68.8) (28.0) (3.2)
West Virginia 13 12 11 (91.7) (90.9) (9.1) (0.0)
Wisconsin 70 69 64 (92.8) (90.6) (3.1) (6.3)
Wyoming 4 4 2 (50.0) -- -- --
American Samoa4 3 3 1 (33.3) -- -- --
Fed. States of Micronesia4 142 142 136 (95.8) (100.0) (0.0) (0.0)
Guam4 80 80 79 (98.8) (98.7) (0.0) (1.3)
Marshall Islands4 148 148 39 (26.4) -- -- --
N. Mariana Islands4 31 31 31 (100.0) (100.0) (0.0) (0.0)
Puerto Rico4 50 47 47 (100.0) (76.6) (21.3) (2.1)
Republic of Palau4 8 8 2 (25.0) -- -- --
U.S. Virgin Islands4 ... ... 0 ... ... ... ...
1 Most recent year for which data are available.
2 Health Department: All outpatient care provided by the state or local health department; Private/Other: All care (except contact inves-
tigation and dispensing of medication) provided by non–health department providers; Both Health Department and Private/Other: Both 
sectors involved in the care of the patient. Percentage for U.S. based on 52 reporting areas (50 states, New York City, and the District of 
Columbia). Percentages shown only for reporting areas with information reported for >75% of cases.
3 Excludes New York City.
4 Not included in U.S. totals. 
Note: Ellipses indicate data not available.
Table 55. Tuberculosis Cases and Percentages by Type of Health Care Provider: 
Reporting Areas, 20111
Reporting Area Total  Cases
Percentage of Cases by











Cases with Information on
Type of Health Care Provider
100
United States 10,509 10,203 9,855 (96.6) (62.0) (29.3)
Alabama 161 156 155 (99.4) (45.2) (54.2)
Alaska 67 64 56 (87.5) (100.0) (0.0)
Arizona 255 240 237 (98.8) (74.7) (20.7)
Arkansas 85 82 82 (100.0) (29.3) (29.3)
California 2,323 2,260 2,238 (99.0) (49.6) (38.5)
Colorado 70 68 68 (100.0) (86.8) (8.8)
Connecticut 83 81 81 (100.0) (24.7) (55.6)
Delaware 21 21 21 (100.0) (28.6) (61.9)
District of Columbia 55 54 42 (77.8) (73.8) (21.4)
Florida 754 736 734 (99.7) (34.1) (61.7)
Georgia 347 331 324 (97.9) (85.2) (11.4)
Hawaii 123 122 122 (100.0) (53.3) (38.5)
Idaho 12 12 12 (100.0) (41.7) (41.7)
Illinois 358 346 343 (99.1) (40.8) (44.9)
Indiana 100 98 98 (100.0) (88.8) (10.2)
Iowa 40 40 39 (97.5) (66.7) (25.6)
Kansas 36 34 34 (100.0) (85.3) (14.7)
Kentucky 70 69 69 (100.0) (82.6) (13.0)
Louisiana 167 161 157 (97.5) (49.0) (31.8)
Maine 9 8 8 (100.0) (0.0) (100.0)
Maryland 232 226 225 (99.6) (80.4) (17.3)
Massachusetts 195 190 189 (99.5) (43.4) (38.6)
Michigan 170 167 158 (94.6) (63.9) (36.1)
Minnesota 137 133 133 (100.0) (85.7) (14.3)
Mississippi 91 89 89 (100.0) (82.0) (18.0)
Missouri 97 92 91 (98.9) (47.3) (49.5)
Montana 8 8 8 (100.0) (37.5) (12.5)
Nebraska 23 23 22 (95.7) (50.0) (45.5)
Nevada 96 93 78 (83.9) (92.3) (6.4)
New Hampshire 11 11 11 (100.0) (54.5) (45.5)
New Jersey 331 318 318 (100.0) (45.3) (31.4)
New Mexico 49 46 45 (97.8) (100.0) (0.0)
New York State4 221 218 217 (99.5) (23.0) (73.3)
New York City 684 665 445 (66.9) -- --
North Carolina 244 235 235 (100.0) (95.3) (4.7)
North Dakota 7 7 7 (100.0) (57.1) (42.9)
Ohio 145 141 140 (99.3) (74.3) (18.6)
Oklahoma 94 89 89 (100.0) (59.6) (39.3)
Oregon 74 74 74 (100.0) (89.2) (9.5)
Pennsylvania 260 251 251 (100.0) (70.5) (20.3)
Rhode Island 27 27 27 (100.0) (18.5) (81.5)
South Carolina 140 134 134 (100.0) (94.0) (5.2)
South Dakota 15 15 15 (100.0) (46.7) (46.7)
Tennessee 156 149 147 (98.7) (94.6) (5.4)
Texas 1,317 1,280 1,272 (99.4) (84.5) (13.9)
Utah 34 34 34 (100.0) (79.4) (20.6)
Vermont 8 8 8 (100.0) (62.5) (12.5)
Virginia 221 217 207 (95.4) (90.8) (7.2)
Washington 199 195 185 (94.9) (60.0) (15.1)
West Virginia 13 12 12 (100.0) (83.3) (16.7)
Wisconsin 70 69 66 (95.7) (40.9) (57.6)
Wyoming 4 4 3 (75.0) (0.0) (66.7)
American Samoa5 3 3 3 (100.0) (66.7) (33.3)
Fed. States of Micronesia5 142 142 138 (97.2) (87.0) (10.9)
Guam5 80 78 76 (97.4) (98.7) (1.3)
Marshall Islands5 148 148 39 (26.4) -- --
N. Mariana Islands5 31 31 28 (90.3) (96.4) (3.6)
Puerto Rico5 50 47 47 (100.0) (74.5) (2.1)
Republic of Palau5 8 8 2 (25.0) -- --
U.S. Virgin Islands5 ... ... ... ... ... ...
Table 56. Tuberculosis Cases and Percentages by Directly Observed Therapy (DOT): 
Reporting Areas, 20111
1 Most recent year for which data are available.
2 Includes persons alive at diagnosis with an initial drug regimen of one or more drugs prescribed.
3 Percentage for U.S. based on 52 reporting areas (50 states, New York City, and the District of Columbia). Percentages shown only for 
reporting areas with information reported for >75% of cases.
4 Excludes New York City.
5 Not included in U.S. totals. 
Note: Ellipses indicate data not available.
Reporting Area Total Cases
Percentage of Cases by
Directly Observed Therapy3




















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































United States 10,509 8499 (89.0) (95.7) 1036 (74.9) 9535 (93.5)
Alabama 161 138 (93.5) (98.6) 8 (75.0) 146 (97.3)
Alaska 67 53 (60.4) (64.2) 5 (80.0) 58 (65.5)
Arizona 255 166 (87.3) (95.8) 59 (67.8) 225 (88.4)
Arkansas 85 67 (83.6) (88.1) 3 (66.7) 70 (87.1)
California 2,323 1876 (87.3) (95.3) 218 (72.5) 2094 (92.9)
Colorado 70 59 (96.6) (96.6) 6 (83.3) 65 (95.4)
Connecticut 83 68 (94.1) (100.0) 7 (100.0) 75 (100.0)
Delaware 21 17 (94.1) (100.0) 4 (100.0) 21 (100.0)
District of Columbia 55 47 (80.9) (97.9) 4 (25.0) 51 (92.2)
Florida 754 607 (92.9) (98.4) 74 (77.0) 681 (96.0)
Georgia 347 277 (89.5) (96.8) 39 (59.0) 316 (92.1)
Hawaii 123 110 (90.0) (99.1) 6 (83.3) 116 (98.3)
Idaho 12 11 (81.8) (90.9) 1 (100.0) 12 (91.7)
Illinois 358 280 (91.4) (96.4) 45 (91.1) 325 (95.7)
Indiana 100 87 (89.7) (96.6) 7 (71.4) 94 (94.7)
Iowa 40 33 (84.8) (87.9) 7 (100.0) 40 (90.0)
Kansas 36 27 (88.9) (100.0) 5 (100.0) 32 (100.0)
Kentucky 70 56 (82.1) (96.4) 5 (80.0) 61 (95.1)
Louisiana 167 140 (82.9) (94.3) 12 (41.7) 152 (90.1)
Maine 9 8 (62.5) (62.5) 0 ... 8 (62.5)
Maryland 232 194 (94.8) (98.5) 21 (76.2) 215 (96.3)
Massachusetts 195 155 (83.9) (96.8) 24 (62.5) 179 (92.2)
Michigan 170 140 (89.3) (91.4) 19 (84.2) 159 (90.6)
Minnesota 137 101 (95.0) (96.0) 27 (63.0) 128 (89.1)
Mississippi 91 73 (91.8) (98.6) 4 (25.0) 77 (94.8)
Missouri 97 81 (91.4) (95.1) 7 (85.7) 88 (94.3)
Montana 8 7 (100.0) (100.0) 0 ... 7 (100.0)
Nebraska 23 20 (85.0) (90.0) 2 (50.0) 22 (86.4)
Nevada 96 82 (78.0) (82.9) 5 (100.0) 87 (83.9)
New Hampshire 11 10 (100.0) (100.0) 0 ... 10 (100.0)
New Jersey 331 253 (89.7) (96.8) 42 (78.6) 295 (94.2)
New Mexico 49 38 (92.1) (97.4) 4 (25.0) 42 (90.5)
New York State6 221 188 (94.1) (97.3) 15 (93.3) 203 (97.0)
New York City 684 565 (91.9) (96.8) 60 (81.7) 625 (95.4)
North Carolina 244 200 (95.5) (100.0) 21 (85.7) 221 (98.6)
North Dakota 7 5 (60.0) (60.0) 2 (50.0) 7 (57.1)
Ohio 145 118 (88.1) (92.4) 14 (85.7) 132 (91.7)
Oklahoma 94 72 (91.7) (100.0) 12 (100.0) 84 (100.0)
Oregon 74 64 (89.1) (96.9) 6 (100.0) 70 (97.1)
Pennsylvania 260 202 (85.1) (96.5) 28 (75.0) 230 (93.9)
Rhode Island 27 25 (80.0) (92.0) 1 (100.0) 26 (92.3)
South Carolina 140 113 (95.6) (97.3) 6 (83.3) 119 (96.6)
South Dakota 15 12 (83.3) (91.7) 2 (100.0) 14 (92.9)
Tennessee 156 131 (93.9) (97.7) 9 (66.7) 140 (95.7)
Texas 1,317 1070 (87.5) (94.6) 137 (71.5) 1207 (92.0)
Utah 34 25 (100.0) (100.0) 7 (100.0) 32 (100.0)
Vermont 8 6 (83.3) (100.0) 1 (0.0) 7 (85.7)
Virginia 221 190 (88.9) (96.8) 14 (71.4) 204 (95.1)
Washington 199 155 (85.2) (94.2) 25 (72.0) 180 (91.1)
West Virginia 13 10 (90.0) (100.0) 0 ... 10 (100.0)
Wisconsin 70 63 (87.3) (93.7) 6 (83.3) 69 (92.8)
Wyoming 4 4 (50.0) (50.0) 0 ... 4 (50.0)
American Samoa7 3 3 (0.0) (0.0) 0 ... 3 (0.0)
Fed. States of Micronesia7 142 130 (90.0) (91.5) 7 (85.7) 137 (91.2)
Guam7 80 72 (94.4) (97.2) 1 (100.0) 73 (97.3)
Marshall Islands7 148 143 (21.7) (21.7) 2 (0.0) 145 (21.4)
N. Mariana Islands7 31 29 (75.9) (86.2) 1 (0.0) 30 (83.3)
Puerto Rico7 50 34 (94.1) (97.1) 3 (100.0) 37 (97.3)
Republic of Palau7 8 7 (0.0) (0.0) 1 (0.0) 8 (0.0)
U.S. Virgin Islands7 0 0 -- -- 0 ... 0 --
Table 60. Tuberculosis Cases and Percentages by Completion of Tuberculosis Therapy 
(COT): Reporting Areas, 20111
1 Most recent year for which data are available.
2 Initial isolate susceptible to rifampin (n=6,293) or susceptibility unknown (n=102); culture negative (n=1,774); culture status unknown (n=330).
3 Number of cases in persons alive at diagnosis, with an initial regimen of one or more drugs prescribed, who did not die during therapy. Percentage for U.S. based on 52 report-
ing areas (50 states, New York City, and the District of Columbia). Percentages shown only for reporting areas with information reported for >90% of cases.
4 Therapy < 1 year indicated in persons alive at diagnosis with an initial regimen of one or more drugs prescribed, who did not die within one year of initiating therapy.  Excludes 
persons with initial isolate rifampin resistant, or patient with bone and joint disease, meningeal disease or disease of the central nervous system, or pediatric patient (aged < 15) 
with miliary disease or positive blood culture, and those who moved out of the country within one year of initiating treatment. 
5 Initial isolate rifampin resistant, or patient with meningeal disease, or pediatric patient (aged <15) with miliary disease or positive blood culture.
6 Excludes New York City.
7 Not included in U.S. totals. 





No. COT(%) No. COT(%)
Therapy <1 Year Indicated2,3,4
COT <1 Year(%)
Therapy >1 Year Indicated3,5
No. COT(%)
109
United States 11413 (85.6) 11016 (86.0) 9527 (88.7) 9127 (89.6) 8499 (89.0)
Alabama 143 (91.6) 148 (90.5) 141 (94.3) 117 (91.5) 138 (93.5)
Alaska 42 (90.5) 45 (88.9) 32 (84.4) 49 (93.9) 53 ...
Arizona 235 (71.1) 187 (72.7) 173 (83.2) 217 (86.2) 166 (87.3)
Arkansas 94 (92.6) 73 (79.5) 58 (86.2) 69 (87.0) 67 (83.6)
California 2345 (80.9) 2328 (84.7) 2081 (84.3) 1899 (88.0) 1876 (87.3)
Colorado 86 (97.7) 92 (92.4) 65 (95.4) 53 (92.5) 59 (96.6)
Connecticut 96 (81.3) 86 (91.9) 79 (88.6) 67 (92.5) 68 (94.1)
Delaware 18 (94.4) 21 (85.7) 16 (81.3) 13 (100.0) 17 (94.1)
District of Columbia 48 (72.9) 49 (79.6) 32 (81.3) 31 (87.1) 47 (80.9)
Florida 879 (90.0) 803 (90.5) 689 (93.2) 705 (95.0) 607 (92.9)
Georgia 417 (85.4) 405 (88.4) 336 (85.1) 330 (89.7) 277 (89.5)
Hawaii 107 (77.6) 113 (78.8) 92 (83.7) 104 (95.2) 110 (90.0)
Idaho 8 (75.0) 11 (90.9) 16 (93.8) 14 (85.7) 11 (81.8)
Illinois 437 (85.6) 382 (88.2) 340 (90.0) 301 (87.4) 280 (91.4)
Indiana 115 (89.6) 99 (91.9) 100 (91.0) 80 (93.8) 87 (89.7)
Iowa 35 (88.6) 44 (93.2) 39 (87.2) 39 (94.9) 33 (84.8)
Kansas 50 (86.0) 54 (92.6) 56 (100.0) 36 (100.0) 27 (88.9)
Kentucky 107 (89.7) 85 (83.5) 59 (91.5) 73 (89.0) 56 (82.1)
Louisiana 192 (79.7) 209 (78.9) 162 (88.9) 171 (80.7) 140 (82.9)
Maine 17 (94.1) 8 (87.5) 7 (100.0) 6 (100.0) 8 ...
Maryland 233 (91.4) 235 (89.4) 180 (90.0) 179 (91.6) 194 (94.8)
Massachusetts 198 (81.8) 228 (82.5) 212 (83.0) 187 (84.0) 155 (83.9)
Michigan 181 (81.2) 144 (82.6) 114 (87.7) 148 (89.2) 140 (89.3)
Minnesota 208 (91.3) 190 (93.2) 133 (93.2) 116 (90.5) 101 (95.0)
Mississippi 116 (96.6) 91 (93.4) 104 (88.5) 101 (93.1) 73 (91.8)
Missouri 103 (78.6) 96 (87.5) 72 (87.5) 95 (86.3) 81 (91.4)
Montana 9 (100.0) 4 (100.0) 7 (100.0) 6 (100.0) 7 (100.0)
Nebraska 23 (91.3) 30 (80.0) 28 (85.7) 24 (91.7) 20 (85.0)
Nevada 79 (86.1) 83 (85.5) 91 (89.0) 100 (89.0) 82 ...
New Hampshire 9 (88.9) 16 (81.3) 13 (100.0) 8 (87.5) 10 (100.0)
New Jersey 385 (87.8) 353 (89.0) 337 (93.2) 325 (92.9) 253 (89.7)
New Mexico 41 (92.7) 43 (93.0) 31 (93.5) 29 (93.1) 38 (92.1)
New York State4 220 (87.7) 262 (87.8) 193 (84.5) 207 (91.3) 188 (94.1)
New York City 768 (90.9) 756 (88.8) 633 (92.6) 599 (92.7) 565 (91.9)
North Carolina 304 (92.1) 293 (91.8) 215 (94.0) 247 (96.4) 200 (95.5)
North Dakota 3 (100.0) 2 (50.0) 3 (66.7) 8 (75.0) 5 ...
Ohio 209 (88.5) 180 (86.1) 142 (91.5) 150 (89.3) 118 (88.1)
Oklahoma 130 (81.5) 84 (77.4) 85 (87.1) 69 (94.2) 72 (91.7)
Oregon 86 (90.7) 69 (97.1) 75 (97.3) 71 (98.6) 64 (89.1)
Pennsylvania 241 (85.5) 325 (84.0) 195 (83.1) 181 (86.7) 202 (85.1)
Rhode Island 37 (91.9) 32 (90.6) 21 (90.5) 22 (68.2) 25 (80.0)
South Carolina 185 (89.2) 155 (87.1) 134 (92.5) 125 (93.6) 113 (95.6)
South Dakota 10 (100.0) 15 (93.3) 16 (93.8) 13 (84.6) 12 (83.3)
Tennessee 200 (87.0) 242 (89.3) 173 (94.2) 146 (93.2) 131 (93.9)
Texas 1312 (82.5) 1297 (79.8) 1187 (89.4) 1091 (85.2) 1070 (87.5)
Utah 34 (94.1) 23 (95.7) 26 (100.0) 13 (100.0) 25 (100.0)
Vermont 3 (33.3) 4 (75.0) 5 (80.0) 5 (100.0) 6 (83.3)
Virginia 289 (88.6) 261 (84.3) 238 (87.8) 235 (88.9) 190 (88.9)
Washington 253 (89.7) 178 (94.4) 219 (94.1) 194 (88.1) 155 (85.2)
West Virginia 16 (100.0) 22 (95.5) 15 (73.3) 12 (100.0) 10 (90.0)
Wisconsin 55 (81.8) 57 (73.7) 55 (83.6) 41 (90.2) 63 (87.3)
Wyoming 2 (50.0) 4 (75.0) 2 (50.0) 6 ... 4 ...
American Samoa5 3 ... 3 (100.0) 3 (66.7) 3 (33.3) 3 ...
Fed. States of Micronesia5 123 ... 156 ... 175 (82.9) 160 (91.9) 130 (90.0)
Guam5 90 (91.1) 80 (91.3) 93 (95.7) 86 (95.3) 72 (94.4)
Marshall Islands5 123 ... 115 (79.1) 109 (87.2) 189 ... 143 ...
N. Mariana Islands5 39 (79.5) 34 (70.6) 28 (96.4) 25 (96.0) 29 (75.9)
Puerto Rico5 81 (97.5) 69 (95.7) 50 (94.0) 70 (90.0) 34 (94.1)
Republic of Palau5 11 ... 14 ... 15 ... 15 ... 7 ...
U.S. Virgin Islands5 0 ... 4 (50.0) 0 ... 0 ... 0 ...
Reporting Area
2007 2008 2009 2010 2011
Year
No.2 No.2 No.2No.2(%)3 (%)3 (%)3 (%)3 (%)3
Table 61. Tuberculosis Cases and Percentages in Persons Completing Therapy for Whom 
Therapy Was Indicated for One Year or Less: Reporting Areas, 2007–20111
1 Most recent year for which data are available.
2 Total cases for which therapy less than 1 year indicated in persons alive at diagnosis with an initial regimen of one or more drugs prescribed, who did not die 
within one year of initiating therapy.  Excludes persons with initial isolate rifampin resistant, or patient with bone and joint disease, meningeal disease or disease 
of the central nervous system, or pediatric patient (aged < 15) with miliary disease or positive blood culture, and those who moved out of the country within one 
year of initiating treatment. 
3 Percentage of total cases in persons who completed therapy within one year for whom therapy less than 1 year was indicated. Percentages shown only for report-
ing areas with information reported for >90% of cases.
4 Excludes New York City.
5 Not included in U.S. totals. 
Note: Ellipses indicate data not available.
See Technical Notes for description of Completion of Therapy calculation.
No.2
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Morbidity Tables
Cities and Metropolitan Statistical Areas, 2013
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Albuquerque, NM 19 8
Anaheim, CA 20 31
Arlington, TX 16 20
Atlanta, GA 4 13
Austin, TX 32 33
Baltimore, MD 25 33
Birmingham, AL 12 15
Boston, MA 42 42
Buffalo, NY 14 13
Charlotte, NC 38 27
Chicago, IL 140 146
Cincinnati, OH 12 11
Cleveland, OH 22 19
Colorado Springs, CO 8 4
Columbus, OH 39 37
Corpus Christi, TX 11 8
Dallas, TX 146 123
Denver, CO 22 11
Detroit, MI 39 35
El Paso, TX 41 33
Fort Worth, TX 37 39
Fresno, CA 28 26
Honolulu, HI 41 57
Houston, TX 186 195
Indianapolis, IN 36 39
Jacksonville, FL 43 81
Las Vegas, NV 61 55
Long Beach, CA 38 34
Los Angeles, CA 222 232
Louisville, KY 20 21
Memphis, TN 42 53
Mesa, AZ 9 6
Miami, FL 86 89
Milwaukee, WI 7 26
Minneapolis, MN 29 41
Nashville, TN 22 27
Newark, NJ 28 20
New Orleans, LA 18 21
New York, NY 656 651
Norfolk, VA 6 7
Oakland, CA 35 46
Omaha, NE 9 13
Philadelphia, PA 89 86
Phoenix, AZ 52 66
Pittsburgh, PA 9 2
Portland, OR 34 26
Sacramento, CA 56 34
St. Paul, MN 33 35
San Antonio, TX 72 69
San Diego, CA 94 130
San Francisco, CA 107 116
San Jose, CA 116 102
Santa Ana, CA 25 32
Seattle, WA 46 51
Tampa, FL 13 18
Toledo, OH 3 3
Tucson, AZ 21 13
Virginia Beach, VA 7 8
Washington, DC 38 36
Wichita, KS 8 7
TOTAL - 60 CITIES 3,184 3,275
San Juan, PR 15 15
Table 62. Tuberculosis Cases in Selected Cities1: 2013 and 2012
Cases2
2013 2012City
1 Historical list of cities.
2 Case counts are based on verified cases residing within city limits. Excludes cases known to not be within city limits; residence within 
city limits was determined by the health department.
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Table 63. Tuberculosis Cases and Case Rates per 100,000 Population: Metropolitan 
Statistical Areas with >500,000 Population, 2013 and 2012
Metropolitan 
Statistical Area




Akron, OH 4 7 0.6 1 705,686
Albany-Schenectady-Troy, NY 11 13 1.3 1.5 877,905
Albuquerque, NM 24 10 2.7 1.1 902,797
Allentown-Bethlehem-Easton, PA-NJ 8 6 1 0.7 827,048
Atlanta-Sandy Springs-Roswell, GA 218 210 3.9 3.9 5,522,942
Augusta-Richmond County, GA-SC 21 20 3.6 3.5 580,270
Austin-Round Rock, TX 56 58 3 3.2 1,883,051
Bakersfield, CA 28 34 3.2 4 864,124
Baltimore-Columbia-Towson, MD 70 79 2.5 2.9 2,770,738
Baton Rouge, LA 16 19 2 2.3 820,159
Birmingham-Hoover, AL 18 35 1.6 3.1 1,140,300
Boise City, ID 4 6 0.6 0.9 650,288
Boston-Cambridge-Newton, MA-NH 159 176 3.4 3.8 4,684,299
Bridgeport-Stamford-Norwalk, CT 25 32 2.7 3.4 939,904
Buffalo-Cheektowaga-Niagara Falls, NY 24 21 2.1 1.9 1,134,115
Cape Coral-Fort Myers, FL 14 26 2.1 4 661,115
Charleston-North Charleston, SC 22 29 3.1 4.2 712,220
Charlotte-Concord-Gastonia, NC-SC 58 58 2.5 2.5 2,335,358
Chattanooga, TN-GA 11 11 2 2 541,744
Chicago-Naperville-Elgin, IL-IN-WI 295 307 3.1 3.2 9,537,289
Cincinnati, OH-KY-IN 21 30 1 1.4 2,137,406
Cleveland-Elyria, OH 32 35 1.5 1.7 2,064,725
Colorado Springs, CO 8 6 1.2 0.9 678,319
Columbia, SC 13 12 1.6 1.5 793,779
Columbus, OH 55 48 2.8 2.5 1,967,066
Dallas-Fort Worth-Arlington, TX 327 300 4.8 4.5 6,810,913
Dayton, OH 15 8 1.9 1 802,489
Deltona-Daytona Beach-Ormond Beach, FL 14 ... 2.3 ... 600,756
Denver-Aurora-Lakewood, CO 47 32 1.7 1.2 2,697,476
Des Moines-West Des Moines, IA 11 13 1.8 2.2 599,789
Detroit-Warren-Dearborn, MI 106 94 2.5 2.2 4,294,983
Durham-Chapel Hill, NC 9 14 1.7 2.7 534,578
El Paso, TX 49 37 5.9 4.4 831,036
Fresno, CA 39 34 4.1 3.6 955,272
Grand Rapids-Wyoming, MI 9 19 0.9 1.9 1,016,603
Greensboro-High Point, NC 20 19 2.7 2.6 741,065
Greenville-Anderson-Maudlin, SC 7 11 0.8 1.3 850,965
Harrisburg-Carlisle, PA 11 14 2 2.5 557,711
Hartford-West Hartford-East Hartford, CT 21 22 1.7 1.8 1,215,211
Houston-The Woodlands-Sugar Land, TX 339 340 5.4 5.5 6,313,158
Indianapolis-Carmel-Anderson, IN 42 47 2.1 2.4 1,953,961
Jackson, MS 21 31 3.6 5.4 576,382
Jacksonville, FL 61 99 4.4 7.2 1,394,624
Kansas City, MO-KS 47 35 2.3 1.7 2,054,473
Knoxville, TN 10 13 1.2 1.5 852,715
Lakeland-Winter Haven, FL 14 15 2.2 2.4 623,009
Lancaster, PA 4 9 0.8 1.7 529,600
Las Vegas-Henderson-Paradise, NV 75 70 3.7 3.5 2,027,868
Little Rock-North Little Rock-Conway, AR 17 11 2.3 1.5 724,385
Los Angeles-Long Beach-Anaheim, CA 896 862 6.8 6.6 13,131,431
Louisville/Jefferson County, KY-IN 24 29 1.9 2.3 1,262,261
Madison, WI 7 11 1.1 1.8 627,431
McAllen-Edinburg-Mission, TX 64 72 7.8 8.9 815,996
Memphis, TN-MS-AR 55 66 4.1 4.9 1,341,746
Miami-Fort Lauderdale-West Palm Beach, FL 266 229 4.6 4 5,828,191
Milwaukee-Waukesha-West Allis, WI 14 32 0.9 2 1,569,659
Minneapolis-St. Paul-Bloomington, MN-WI 114 140 3.3 4.1 3,459,146
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Modesto, CA 10 7 1.9 1.3 525,491
Nashville-Davidson-Murfreesboro--Franklin, TN 47 49 2.7 2.8 1,757,912
New Haven-Milford, CT 13 16 1.5 1.9 862,287
New Orleans-Metairie, LA 56 52 4.5 4.2 1,240,977
New York-Newark-Jersey City, NY-NJ-PA 1,040 1,027 5.2 5.2 19,949,502
Northport-Sarasota-Bradenton, FL 17 14 2.3 1.9 732,535
Ogden-Clearfield, UT 6 2 1 0.3 621,580
Oklahoma City, OK 28 31 2.1 2.4 1,319,677
Omaha-Council Bluffs, NE-IA 11 13 1.2 1.5 895,151
Orlando-Kissimmee-Sanford, FL 68 94 3 4.2 2,267,846
Oxnard-Thousand Oaks-Ventura, CA 28 34 3.3 4.1 839,620
Palm Bay-Melbourne-Titusville, FL 7 12 1.3 2.2 550,823
Philadelphia-Camden-Wilmington, PA-NJ-DE-MD 158 180 2.6 3 6,034,678
Phoenix-Mesa-Scottsdale, AZ 121 150 2.8 3.5 4,398,762
Pittsburgh, PA 25 23 1.1 1 2,360,867
Portland-South Portland, ME 6 12 1.2 2.3 519,900
Portland-Vancouver-Hillsboro, OR-WA 49 49 2.1 2.1 2,314,554
Providence-Warwick, RI-MA 35 35 2.2 2.2 1,604,291
Provo-Orem, UT 1 3 0.2 0.5 562,239
Raleigh, NC 29 20 2.4 1.7 1,214,516
Richmond, VA 25 24 2 1.9 1,245,764
Riverside-San Bernardino-Ontario, CA 111 115 2.5 2.6 4,380,878
Rochester, NY 25 16 2.3 1.5 1,083,278
Sacramento--Roseville--Arden Arcade, CA 97 74 4.4 3.4 2,215,770
St. Louis, MO-IL 49 43 1.7 1.5 2,825,599
Salt Lake City, UT 23 22 2 2 1,140,483
San Antonio-New Braunfels, TX 81 79 3.6 3.5 2,277,550
San Diego-Carlsbad, CA 206 234 6.4 7.4 3,211,252
San Francisco-Oakland-Hayward, CA 354 382 7.8 8.6 4,516,276
San Jose-Sunnyvale-Santa Clara, CA 182 176 9.5 9.3 1,919,641
Scranton-Wilkes-Barre-Hazleton, PA 9 6 1.6 1.1 562,037
Seattle-Tacoma-Bellevue, WA 162 145 4.5 4.1 3,610,105
Spokane-Spokane Valley, WA 7 ... 1.3 ... 535,724
Springfield, MA 14 13 2.2 2.1 626,915
Stockton-Lodi, CA 43 44 6.1 6.3 704,379
Syracuse, NY 9 14 1.4 2.1 661,934
Tampa-St. Petersburg-Clearwater, FL 93 77 3.2 2.7 2,870,569
Toledo, OH 4 8 0.7 1.3 608,145
Tucson, AZ 24 16 2.4 1.6 996,554
Tulsa, OK 17 27 1.8 2.8 961,561
Urban Honolulu, HI 83 96 8.4 9.8 983,429
Virginia Beach-Norfolk-Newport News, VA-NC 22 31 1.3 1.8 1,707,369
Washington-Arlington-Alexandria, DC-VA-MD-WV 250 321 4.2 5.5 5,949,859
Wichita, KS 9 8 1.4 1.3 637,394
Winston-Salem, NC 11 ... 1.7 ... 650,820
Worcester, MA-CT 22 11 2.4 1.2 926,710
Youngstown-Warren-Boardman, OH-PA 0 4 0 0.7 555,506
Total - 104 Areas 7,657 7,848 3.6 3.7 212,266,239
San Juan-Caguas-Guaynabo, PR 40 58 1.8 2.5 2,284,266
Table 63. (Cont’d) Tuberculosis Cases and Case Rates per 100,000 Population: Metropolitan 
Statistical Areas with >500,000 Population, 2013 and 2012
Metropolitan 
Statistical Area




Note: 2013 and 2012 population case counts and rates updated using County Totals Datasets: Population, Population Change and 
Estimated Components of Population Change: April 1, 2010 to July 1, 2013 (http://www.census.gov/popest/data/counties/totals/2013/
files/CO-EST2013-Alldata.csv) and Vintage 2009 County Population Datasets (http://www.census.gov/popest/data/historical/2000s/vin-
tage_2009/datasets.html) (accessed July 15, 2014).
See Technical Notes for definition of MSA.
116
Table 64. Tuberculosis Cases by Age Group: Metropolitan Statistical Areas with 
>500,000 Population, 2013
Akron, OH 4 0 0 0 1 1 2 0
Albany-Schenectady-Troy, NY 11 0 0 3 5 1 2 0
Albuquerque, NM 24 0 0 0 6 5 13 0
Allentown-Bethlehem-Easton, PA-NJ 8 0 0 0 2 2 4 0
Atlanta-Sandy Springs-Roswell, GA 218 7 9 17 86 70 29 0
Augusta-Richmond County, GA-SC 21 1 1 3 10 5 1 0
Austin-Round Rock, TX 56 0 1 9 21 20 5 0
Bakersfield, CA 28 0 0 0 15 7 6 0
Baltimore-Columbia-Towson, MD 70 3 2 7 19 31 8 0
Baton Rouge, LA 16 3 0 1 2 6 4 0
Birmingham-Hoover, AL 18 0 1 4 2 6 5 0
Boise City, ID 4 0 1 1 1 1 0 0
Boston-Cambridge-Newton, MA-NH 159 1 1 24 67 30 36 0
Bridgeport-Stamford-Norwalk, CT 25 0 0 2 8 10 5 0
Buffalo-Cheektowaga-Niagara Falls, NY 24 1 0 2 9 7 5 0
Cape Coral-Fort Myers, FL 14 0 0 1 8 4 1 0
Charleston-North Charleston, SC 22 0 1 1 9 6 5 0
Charlotte-Concord-Gastonia, NC-SC 58 3 1 8 23 16 7 0
Chattanooga, TN-GA 11 2 0 1 3 0 5 0
Chicago-Naperville-Elgin, IL-IN-WI 295 9 5 33 85 94 69 0
Cincinnati, OH-KY-IN 21 0 1 8 2 6 4 0
Cleveland-Elyria, OH 32 1 0 0 10 8 13 0
Colorado Springs, CO 8 1 0 1 4 0 2 0
Columbia, SC 13 1 0 1 5 4 2 0
Columbus, OH 55 0 4 6 25 12 8 0
Dallas-Fort Worth-Arlington, TX 327 11 3 36 105 119 53 0
Dayton, OH 15 0 0 1 3 8 3 0
Deltona-Daytona Beach-Ormond Beach, FL 14 0 1 0 2 8 3 0
Denver-Aurora-Lakewood, CO 47 1 0 6 15 11 14 0
Des Moines-West Des Moines, IA 11 0 1 1 7 0 2 0
Detroit-Warren-Dearborn, MI 106 0 2 12 29 38 25 0
Durham-Chapel Hill, NC 9 0 0 1 5 2 1 0
El Paso, TX 49 4 1 5 2 16 21 0
Fresno, CA 39 2 1 2 5 15 14 0
Grand Rapids-Wyoming, MI 9 0 0 1 4 1 3 0
Greensboro-High Point, NC 20 0 1 3 8 7 1 0
Greenville-Anderson-Maudlin, SC 7 0 0 0 3 3 1 0
Harrisburg-Carlisle, PA 11 0 0 2 4 5 0 0
Hartford-West Hartford-East Hartford, CT 21 1 0 1 10 5 4 0
Houston-The Woodlands-Sugar Land, TX 339 9 6 46 100 126 52 0
Indianapolis-Carmel-Anderson, IN 42 2 0 8 7 19 6 0
Jackson, MS 21 0 1 2 1 10 7 0
Jacksonville, FL 61 2 0 6 16 30 7 0
Kansas City, MO-KS 47 4 1 6 13 12 11 0
Knoxville, TN 10 0 0 1 0 2 7 0
Lakeland-Winter Haven, FL 14 0 0 1 5 4 4 0
Lancaster, PA 4 0 1 0 2 0 1 0
Las Vegas-Henderson-Paradise, NV 75 15 1 5 23 18 13 0
Little Rock-North Little Rock-Conway, AR 17 0 0 3 3 5 6 0
Los Angeles-Long Beach-Anaheim, CA 896 20 9 78 222 295 272 0
Louisville/Jefferson County, KY-IN 24 0 0 3 11 7 3 0
Madison, WI 7 0 0 0 4 1 2 0
McAllen-Edinburg-Mission, TX 64 5 1 10 19 22 7 0
Memphis, TN-MS-AR 55 6 5 8 18 10 8 0
Miami-Fort Lauderdale-West Palm Beach, FL 266 9 7 24 91 85 50 0




Cases Under 5 15 –24
Unknown 
or 
Missing5–14 25–44 45–64 >65
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Minneapolis-St. Paul-Bloomington, MN-WI 114 2 4 15 47 30 16 0
Modesto, CA 10 3 0 1 1 4 1 0
Nashville-Davidson-Murfreesboro--Franklin, TN 47 2 0 4 21 13 7 0
New Haven-Milford, CT 13 0 0 0 7 4 2 0
New Orleans-Metairie, LA 56 2 1 7 13 25 8 0
New York-Newark-Jersey City, NY-NJ-PA 1,040 16 14 111 381 297 221 0
Northport-Sarasota-Bradenton, FL 17 2 0 1 6 3 5 0
Ogden-Clearfield, UT 6 0 0 1 3 0 2 0
Oklahoma City, OK 28 2 0 6 3 14 3 0
Omaha-Council Bluffs, NE-IA 11 0 0 1 3 5 2 0
Orlando-Kissimmee-Sanford, FL 68 2 0 10 16 28 12 0
Oxnard-Thousand Oaks-Ventura, CA 28 2 0 2 9 4 11 0
Palm Bay-Melbourne-Titusville, FL 7 0 0 1 3 1 2 0
Philadelphia-Camden-Wilmington, PA-NJ-DE-MD 158 1 3 18 59 51 26 0
Phoenix-Mesa-Scottsdale, AZ 121 2 3 26 42 27 21 0
Pittsburgh, PA 25 0 0 2 8 6 9 0
Portland-South Portland, ME 6 0 0 0 3 3 0 0
Portland-Vancouver-Hillsboro, OR-WA 49 4 1 4 12 18 10 0
Providence-Warwick, RI-MA 35 2 1 2 10 8 12 0
Provo-Orem, UT 1 0 0 0 1 0 0 0
Raleigh, NC 29 2 0 2 15 5 5 0
Richmond, VA 25 0 1 1 7 5 11 0
Riverside-San Bernardino-Ontario, CA 111 4 5 10 27 32 33 0
Rochester, NY 25 2 1 1 9 6 6 0
Sacramento--Roseville--Arden Arcade, CA 97 1 3 7 22 36 28 0
St. Louis, MO-IL 49 2 0 2 9 24 12 0
Salt Lake City, UT 23 2 1 2 9 7 2 0
San Antonio-New Braunfels, TX 81 4 2 7 22 28 18 0
San Diego-Carlsbad, CA 206 3 5 29 61 58 50 0
San Francisco-Oakland-Hayward, CA 354 7 3 20 82 111 130 1
San Jose-Sunnyvale-Santa Clara, CA 182 2 2 14 53 52 59 0
Scranton-Wilkes-Barre-Hazleton, PA 9 1 0 0 4 2 2 0
Seattle-Tacoma-Bellevue, WA 162 4 1 20 56 50 31 0
Spokane-Spokane Valley, WA 7 0 0 2 5 0 0 0
Springfield, MA 14 0 0 3 5 3 3 0
Stockton-Lodi, CA 43 4 1 5 7 6 20 0
Syracuse, NY 9 0 0 1 4 3 1 0
Tampa-St. Petersburg-Clearwater, FL 93 1 1 8 27 40 16 0
Toledo, OH 4 0 0 1 1 0 2 0
Tucson, AZ 24 0 1 1 9 7 6 0
Tulsa, OK 17 0 1 2 3 8 3 0
Urban Honolulu, HI 83 1 2 8 15 27 30 0
Virginia Beach-Norfolk-Newport News, VA-NC 22 0 2 2 9 5 4 0
Washington-Arlington-Alexandria, DC-VA-MD-WV 250 7 6 22 116 66 33 0
Wichita, KS 9 1 1 1 2 2 2 0
Winston-Salem, NC 11 0 0 0 4 3 4 0
Worcester, MA-CT 22 0 0 3 8 8 3 0
Youngstown-Warren-Boardman, OH-PA 0 0 0 0 0 0 0 0
Total - 104 Areas 7,657 214 136 791 2,408 2,378 1,729 1
San Juan-Caguas-Guaynabo, PR 40 0 0 3 8 20 9 0
Table 64. (Cont’d) Tuberculosis Cases by Age Group: Metropolitan Statistical Areas with 
>500,000 Population, 2013
Metropolitan 






Note: See Technical Notes for definition of MSA.
5–14 25–44 45–64 >65
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Akron, OH 4 0 0 4 0 0 0 0 0
Albany-Schenectady-Troy, NY 11 1 0 6 3 0 0 0 1
Albuquerque, NM 24 10 2 7 0 1 4 0 0
Allentown-Bethlehem-Easton, PA-NJ 8 1 0 3 3 0 1 0 0
Atlanta-Sandy Springs-Roswell, GA 218 40 0 55 109 0 14 0 0
Augusta-Richmond County, GA-SC 21 0 1 4 13 0 3 0 0
Austin-Round Rock, TX 56 18 0 13 14 0 11 0 0
Bakersfield, CA 28 20 0 2 1 0 4 1 0
Baltimore-Columbia-Towson, MD 70 9 0 20 26 0 15 0 0
Baton Rouge, LA 16 2 0 3 2 0 9 0 0
Birmingham-Hoover, AL 18 2 0 2 10 0 4 0 0
Boise City, ID 4 1 0 2 0 0 1 0 0
Boston-Cambridge-Newton, MA-NH 159 24 0 55 44 1 34 1 0
Bridgeport-Stamford-Norwalk, CT 25 10 0 8 4 0 3 0 0
Buffalo-Cheektowaga-Niagara Falls, NY 24 0 0 10 6 0 8 0 0
Cape Coral-Fort Myers, FL 14 5 0 2 5 0 2 0 0
Charleston-North Charleston, SC 22 4 0 1 9 0 8 0 0
Charlotte-Concord-Gastonia, NC-SC 58 7 0 17 23 0 9 2 0
Chattanooga, TN-GA 11 1 0 3 2 0 5 0 0
Chicago-Naperville-Elgin, IL-IN-WI 295 89 0 114 66 0 25 0 1
Cincinnati, OH-KY-IN 21 3 0 7 6 0 5 0 0
Cleveland-Elyria, OH 32 1 0 12 9 0 9 1 0
Colorado Springs, CO 8 3 0 1 3 0 1 0 0
Columbia, SC 13 1 0 2 8 0 2 0 0
Columbus, OH 55 3 0 14 27 0 11 0 0
Dallas-Fort Worth-Arlington, TX 327 104 0 72 107 0 44 0 0
Dayton, OH 15 1 0 2 4 0 8 0 0
Deltona-Daytona Beach-Ormond Beach, FL 14 1 0 5 2 0 6 0 0
Denver-Aurora-Lakewood, CO 47 11 0 12 16 0 6 2 0
Des Moines-West Des Moines, IA 11 2 0 5 2 0 1 1 0
Detroit-Warren-Dearborn, MI 106 6 0 38 35 2 22 1 2
Durham-Chapel Hill, NC 9 0 0 4 3 0 1 1 0
El Paso, TX 49 43 0 4 0 0 1 1 0
Fresno, CA 39 18 0 18 1 0 1 1 0
Grand Rapids-Wyoming, MI 9 1 0 5 1 0 2 0 0
Greensboro-High Point, NC 20 2 0 7 10 0 1 0 0
Greenville-Anderson-Maudlin, SC 7 1 0 1 2 0 3 0 0
Harrisburg-Carlisle, PA 11 1 0 8 1 0 1 0 0
Hartford-West Hartford-East Hartford, CT 21 3 0 10 3 0 5 0 0
Houston-The Woodlands-Sugar Land, TX 339 156 0 68 62 0 51 1 1
Indianapolis-Carmel-Anderson, IN 42 3 0 14 14 0 11 0 0
Jackson, MS 21 4 0 2 13 0 2 0 0
Jacksonville, FL 61 1 0 13 26 0 21 0 0
Kansas City, MO-KS 47 6 1 16 12 3 9 0 0
Knoxville, TN 10 0 0 3 1 0 6 0 0
Lakeland-Winter Haven, FL 14 4 0 1 4 0 5 0 0
Lancaster, PA 4 0 0 2 1 0 1 0 0
Las Vegas-Henderson-Paradise, NV 75 27 0 26 11 0 10 0 1
Little Rock-North Little Rock-Conway, AR 17 0 0 2 8 0 7 0 0
Los Angeles-Long Beach-Anaheim, CA 896 349 0 405 66 0 53 22 1
Louisville/Jefferson County, KY-IN 24 6 0 3 9 0 6 0 0
Madison, WI 7 3 0 2 1 0 1 0 0
McAllen-Edinburg-Mission, TX 64 61 0 0 1 0 2 0 0
Memphis, TN-MS-AR 55 7 0 2 42 0 4 0 0
Miami-Fort Lauderdale-West Palm Beach, FL 266 101 0 20 121 1 23 0 0
Milwaukee-Waukesha-West Allis, WI 14 0 0 8 4 0 2 0 0
Minneapolis-St. Paul-Bloomington, MN-WI 114 11 3 46 45 0 9 0 0
Table 65. Tuberculosis Cases by Hispanic Ethnicity and Non-Hispanic Race: Metropolitan 


























Modesto, CA 10 8 0 1 0 0 1 0 0
Nashville-Davidson-Murfreesboro--Franklin, TN 47 5 0 11 22 0 9 0 0
New Haven-Milford, CT 13 4 0 6 1 0 2 0 0
New Orleans-Metairie, LA 56 9 0 6 25 0 16 0 0
New York-Newark-Jersey City, NY-NJ-PA 1,040 309 1 439 198 1 84 7 1
Northport-Sarasota-Bradenton, FL 17 10 0 1 1 0 5 0 0
Ogden-Clearfield, UT 6 4 0 1 0 0 1 0 0
Oklahoma City, OK 28 9 0 3 2 0 13 1 0
Omaha-Council Bluffs, NE-IA 11 4 0 2 1 0 3 1 0
Orlando-Kissimmee-Sanford, FL 68 15 1 13 26 0 13 0 0
Oxnard-Thousand Oaks-Ventura, CA 28 14 0 8 0 0 4 1 1
Palm Bay-Melbourne-Titusville, FL 7 0 0 1 1 0 5 0 0
Philadelphia-Camden-Wilmington, PA-NJ-DE-MD 158 18 0 61 55 0 24 0 0
Phoenix-Mesa-Scottsdale, AZ 121 71 3 18 7 0 22 0 0
Pittsburgh, PA 25 2 0 9 5 0 9 0 0
Portland-South Portland, ME 6 1 0 1 1 0 3 0 0
Portland-Vancouver-Hillsboro, OR-WA 49 7 0 18 6 2 16 0 0
Providence-Warwick, RI-MA 35 8 0 10 10 0 7 0 0
Provo-Orem, UT 1 0 0 0 0 0 1 0 0
Raleigh, NC 29 9 0 10 10 0 0 0 0
Richmond, VA 25 1 0 11 9 0 4 0 0
Riverside-San Bernardino-Ontario, CA 111 57 0 31 5 0 18 0 0
Rochester, NY 25 3 0 9 5 0 7 1 0
Sacramento--Roseville--Arden Arcade, CA 97 14 0 51 12 1 8 11 0
St. Louis, MO-IL 49 0 0 19 16 0 14 0 0
Salt Lake City, UT 23 7 0 6 5 2 3 0 0
San Antonio-New Braunfels, TX 81 54 0 11 8 0 8 0 0
San Diego-Carlsbad, CA 206 115 0 60 11 1 16 3 0
San Francisco-Oakland-Hayward, CA 354 47 2 203 30 3 45 24 0
San Jose-Sunnyvale-Santa Clara, CA 182 19 0 115 6 0 9 33 0
Scranton-Wilkes-Barre-Hazleton, PA 9 4 0 1 0 0 4 0 0
Seattle-Tacoma-Bellevue, WA 162 15 1 101 24 4 17 0 0
Spokane-Spokane Valley, WA 7 2 0 1 0 2 2 0 0
Springfield, MA 14 2 0 3 5 0 4 0 0
Stockton-Lodi, CA 43 10 0 27 0 0 4 2 0
Syracuse, NY 9 0 0 5 3 0 1 0 0
Tampa-St. Petersburg-Clearwater, FL 93 19 1 21 23 0 29 0 0
Toledo, OH 4 0 0 1 1 0 2 0 0
Tucson, AZ 24 10 1 7 3 0 3 0 0
Tulsa, OK 17 2 2 3 2 0 6 2 0
Urban Honolulu, HI 83 0 0 63 2 12 1 5 0
Virginia Beach-Norfolk-Newport News, VA-NC 22 2 0 12 7 0 1 0 0
Washington-Arlington-Alexandria, DC-VA-MD-WV 250 36 0 78 113 2 21 0 0
Wichita, KS 9 3 0 2 1 0 3 0 0
Winston-Salem, NC 11 2 0 4 5 0 0 0 0
Worcester, MA-CT 22 4 0 10 7 0 1 0 0
Youngstown-Warren-Boardman, OH-PA 0 0 0 0 0 0 0 0 0
Total - 104 Areas 7,657 2,123 19 2,665 1,695 38 982 126 9
San Juan-Caguas-Guaynabo, PR 40 36 0 2 2 0 0 0 0
Table 65. (Cont’d) Tuberculosis Cases by Hispanic Ethnicity and Non-Hispanic Race: Metropolitan 
Statistical Areas with >500,000 Population, 2013
1 Persons of Hispanic or Latino origin may be of any race or multiple race.
2 Indicates two or more races reported for a person.
Note: Case counts for race categories (American Indian or Alaska Native, Asian, Black or African American, Native Hawaiian or Other Pacific Is-
lander, and White) are mutually exclusive and do not include persons of Hispanic ethnicity or multiple race. Multiple Race does not include persons 
of Hispanic ethnicity.


























Akron, OH 4 0 (0.0) 4 (100.0) 0 (0.0)
Albany-Schenectady-Troy, NY 11 1 (9.1) 10 (90.9) 0 (0.0)
Albuquerque, NM 24 8 (33.3) 16 (66.7) 0 (0.0)
Allentown-Bethlehem-Easton, PA-NJ 8 3 (37.5) 5 (62.5) 0 (0.0)
Atlanta-Sandy Springs-Roswell, GA 218 84 (38.5) 134 (61.5) 0 (0.0)
Augusta-Richmond County, GA-SC 21 17 (81.0) 4 (19.0) 0 (0.0)
Austin-Round Rock, TX 56 22 (39.3) 34 (60.7) 0 (0.0)
Bakersfield, CA 28 5 (17.9) 23 (82.1) 0 (0.0)
Baltimore-Columbia-Towson, MD 70 29 (41.4) 41 (58.6) 0 (0.0)
Baton Rouge, LA 16 11 (68.8) 5 (31.3) 0 (0.0)
Birmingham-Hoover, AL 18 16 (88.9) 2 (11.1) 0 (0.0)
Boise City, ID 4 1 (25.0) 3 (75.0) 0 (0.0)
Boston-Cambridge-Newton, MA-NH 159 26 (16.4) 133 (83.6) 0 (0.0)
Bridgeport-Stamford-Norwalk, CT 25 4 (16.0) 21 (84.0) 0 (0.0)
Buffalo-Cheektowaga-Niagara Falls, NY 24 7 (29.2) 17 (70.8) 0 (0.0)
Cape Coral-Fort Myers, FL 14 6 (42.9) 8 (57.1) 0 (0.0)
Charleston-North Charleston, SC 22 18 (81.8) 4 (18.2) 0 (0.0)
Charlotte-Concord-Gastonia, NC-SC 58 29 (50.0) 29 (50.0) 0 (0.0)
Chattanooga, TN-GA 11 9 (81.8) 2 (18.2) 0 (0.0)
Chicago-Naperville-Elgin, IL-IN-WI 295 87 (29.5) 208 (70.5) 0 (0.0)
Cincinnati, OH-KY-IN 21 8 (38.1) 13 (61.9) 0 (0.0)
Cleveland-Elyria, OH 32 14 (43.8) 18 (56.3) 0 (0.0)
Colorado Springs, CO 8 5 (62.5) 3 (37.5) 0 (0.0)
Columbia, SC 13 7 (53.8) 6 (46.2) 0 (0.0)
Columbus, OH 55 17 (30.9) 38 (69.1) 0 (0.0)
Dallas-Fort Worth-Arlington, TX 327 147 (45.0) 180 (55.0) 0 (0.0)
Dayton, OH 15 11 (73.3) 4 (26.7) 0 (0.0)
Deltona-Daytona Beach-Ormond Beach, FL 14 7 (50.0) 7 (50.0) 0 (0.0)
Denver-Aurora-Lakewood, CO 47 5 (10.6) 42 (89.4) 0 (0.0)
Des Moines-West Des Moines, IA 11 2 (18.2) 9 (81.8) 0 (0.0)
Detroit-Warren-Dearborn, MI 106 43 (40.6) 61 (57.5) 2 (1.9)
Durham-Chapel Hill, NC 9 5 (55.6) 4 (44.4) 0 (0.0)
El Paso, TX 49 15 (30.6) 34 (69.4) 0 (0.0)
Fresno, CA 39 8 (20.5) 31 (79.5) 0 (0.0)
Grand Rapids-Wyoming, MI 9 0 (0.0) 9 (100.0) 0 (0.0)
Greensboro-High Point, NC 20 8 (40.0) 12 (60.0) 0 (0.0)
Greenville-Anderson-Maudlin, SC 7 5 (71.4) 2 (28.6) 0 (0.0)
Harrisburg-Carlisle, PA 11 3 (27.3) 8 (72.7) 0 (0.0)
Hartford-West Hartford-East Hartford, CT 21 8 (38.1) 13 (61.9) 0 (0.0)
Houston-The Woodlands-Sugar Land, TX 339 144 (42.5) 195 (57.5) 0 (0.0)
Indianapolis-Carmel-Anderson, IN 42 19 (45.2) 23 (54.8) 0 (0.0)
Jackson, MS 21 16 (76.2) 5 (23.8) 0 (0.0)
Jacksonville, FL 61 45 (73.8) 16 (26.2) 0 (0.0)
Kansas City, MO-KS 47 22 (46.8) 25 (53.2) 0 (0.0)
Knoxville, TN 10 7 (70.0) 3 (30.0) 0 (0.0)
Lakeland-Winter Haven, FL 14 8 (57.1) 6 (42.9) 0 (0.0)
Lancaster, PA 4 0 (0.0) 4 (100.0) 0 (0.0)
Las Vegas-Henderson-Paradise, NV 75 27 (36.0) 48 (64.0) 0 (0.0)
Little Rock-North Little Rock-Conway, AR 17 15 (88.2) 2 (11.8) 0 (0.0)
Los Angeles-Long Beach-Anaheim, CA 896 166 (18.5) 728 (81.3) 2 (0.2)
Louisville/Jefferson County, KY-IN 24 10 (41.7) 14 (58.3) 0 (0.0)
Madison, WI 7 1 (14.3) 6 (85.7) 0 (0.0)
McAllen-Edinburg-Mission, TX 64 23 (35.9) 41 (64.1) 0 (0.0)
Memphis, TN-MS-AR 55 45 (81.8) 10 (18.2) 0 (0.0)
Miami-Fort Lauderdale-West Palm Beach, FL 266 72 (27.1) 194 (72.9) 0 (0.0)
Milwaukee-Waukesha-West Allis, WI 14 4 (28.6) 10 (71.4) 0 (0.0)
Minneapolis-St. Paul-Bloomington, MN-WI 114 20 (17.5) 94 (82.5) 0 (0.0)
Table 66. Tuberculosis Cases and Percentages, U.S.-born Persons and Foreign-born 
Persons1: Metropolitan Statistical Areas with >500,000 Population, 2013
Metropolitan 
Statistical Area







Modesto, CA 10 4 (40.0) 6 (60.0) 0 (0.0)
Nashville-Davidson-Murfreesboro--Franklin, TN 47 26 (55.3) 21 (44.7) 0 (0.0)
New Haven-Milford, CT 13 2 (15.4) 11 (84.6) 0 (0.0)
New Orleans-Metairie, LA 56 40 (71.4) 16 (28.6) 0 (0.0)
New York-Newark-Jersey City, NY-NJ-PA 1,040 177 (17.0) 862 (82.9) 1 (0.1)
Northport-Sarasota-Bradenton, FL 17 8 (47.1) 9 (52.9) 0 (0.0)
Ogden-Clearfield, UT 6 1 (16.7) 5 (83.3) 0 (0.0)
Oklahoma City, OK 28 18 (64.3) 9 (32.1) 1 (3.6)
Omaha-Council Bluffs, NE-IA 11 3 (27.3) 8 (72.7) 0 (0.0)
Orlando-Kissimmee-Sanford, FL 68 33 (48.5) 35 (51.5) 0 (0.0)
Oxnard-Thousand Oaks-Ventura, CA 28 9 (32.1) 19 (67.9) 0 (0.0)
Palm Bay-Melbourne-Titusville, FL 7 6 (85.7) 1 (14.3) 0 (0.0)
Philadelphia-Camden-Wilmington, PA-NJ-DE-MD 158 54 (34.2) 104 (65.8) 0 (0.0)
Phoenix-Mesa-Scottsdale, AZ 121 25 (20.7) 96 (79.3) 0 (0.0)
Pittsburgh, PA 25 11 (44.0) 14 (56.0) 0 (0.0)
Portland-South Portland, ME 6 3 (50.0) 3 (50.0) 0 (0.0)
Portland-Vancouver-Hillsboro, OR-WA 49 15 (30.6) 34 (69.4) 0 (0.0)
Providence-Warwick, RI-MA 35 9 (25.7) 26 (74.3) 0 (0.0)
Provo-Orem, UT 1 1 (100.0) 0 (0.0) 0 (0.0)
Raleigh, NC 29 4 (13.8) 25 (86.2) 0 (0.0)
Richmond, VA 25 12 (48.0) 13 (52.0) 0 (0.0)
Riverside-San Bernardino-Ontario, CA 111 30 (27.0) 81 (73.0) 0 (0.0)
Rochester, NY 25 9 (36.0) 16 (64.0) 0 (0.0)
Sacramento--Roseville--Arden Arcade, CA 97 23 (23.7) 74 (76.3) 0 (0.0)
St. Louis, MO-IL 49 23 (46.9) 26 (53.1) 0 (0.0)
Salt Lake City, UT 23 5 (21.7) 18 (78.3) 0 (0.0)
San Antonio-New Braunfels, TX 81 45 (55.6) 36 (44.4) 0 (0.0)
San Diego-Carlsbad, CA 206 65 (31.6) 141 (68.4) 0 (0.0)
San Francisco-Oakland-Hayward, CA 354 68 (19.2) 285 (80.5) 1 (0.3)
San Jose-Sunnyvale-Santa Clara, CA 182 15 (8.2) 165 (90.7) 2 (1.1)
Scranton-Wilkes-Barre-Hazleton, PA 9 6 (66.7) 3 (33.3) 0 (0.0)
Seattle-Tacoma-Bellevue, WA 162 33 (20.4) 129 (79.6) 0 (0.0)
Spokane-Spokane Valley, WA 7 4 (57.1) 3 (42.9) 0 (0.0)
Springfield, MA 14 8 (57.1) 6 (42.9) 0 (0.0)
Stockton-Lodi, CA 43 17 (39.5) 26 (60.5) 0 (0.0)
Syracuse, NY 9 1 (11.1) 8 (88.9) 0 (0.0)
Tampa-St. Petersburg-Clearwater, FL 93 48 (51.6) 45 (48.4) 0 (0.0)
Toledo, OH 4 3 (75.0) 1 (25.0) 0 (0.0)
Tucson, AZ 24 3 (12.5) 21 (87.5) 0 (0.0)
Tulsa, OK 17 11 (64.7) 5 (29.4) 1 (5.9)
Urban Honolulu, HI 83 25 (30.1) 58 (69.9) 0 (0.0)
Virginia Beach-Norfolk-Newport News, VA-NC 22 5 (22.7) 17 (77.3) 0 (0.0)
Washington-Arlington-Alexandria, DC-VA-MD-WV 250 36 (14.4) 214 (85.6) 0 (0.0)
Wichita, KS 9 5 (55.6) 4 (44.4) 0 (0.0)
Winston-Salem, NC 11 3 (27.3) 8 (72.7) 0 (0.0)
Worcester, MA-CT 22 2 (9.1) 20 (90.9) 0 (0.0)
Youngstown-Warren-Boardman, OH-PA 0 0 (0.0) 0 (0.0) 0 (0.0)
Total - 104 Areas 7,657 2,299 (30.0) 5,348 (69.8) 10 (0.1)
San Juan-Caguas-Guaynabo, PR 40 29 (72.5) 11 (27.5) 0 (0.0)
Table 66. (Cont’d) Tuberculosis Cases and Percentages, U.S.-born Persons and Foreign-born 
Persons1: Metropolitan Statistical Areas with >500,000 Population, 2013
1 Includes persons born outside the United States, American Samoa, the Federated States of Micronesia, Guam, the Republic of the 
Marshall Islands, Midway Island, the Commonwealth of the Northern Mariana Islands, Puerto Rico, the Republic of Palau, the U.S. Virgin 
Islands, and U.S. minor and outlying Pacific islands. 
Note: See Technical Notes for definition of MSA.
Metropolitan 
Statistical Area







Akron, OH 4 4 (100.0) 0 (0.0)
Albany-Schenectady-Troy, NY 11 11 (100.0) 0 (0.0)
Albuquerque, NM 24 24 (100.0) 1 (4.2)
Allentown-Bethlehem-Easton, PA-NJ 8 8 (100.0) 0 (0.0)
Atlanta-Sandy Springs-Roswell, GA 202 202 (100.0) 17 (8.4)
Augusta-Richmond County, GA-SC 19 19 (100.0) 2 (10.5)
Austin-Round Rock, TX 55 55 (100.0) 3 (5.5)
Bakersfield, CA 28 27 (96.4) 1 (3.6)
Baltimore-Columbia-Towson, MD 65 64 (98.5) 2 (3.1)
Baton Rouge, LA 13 13 (100.0) 1 (7.7)
Birmingham-Hoover, AL 17 17 (100.0) 1 (5.9)
Boise City, ID 3 3 (100.0) 1 (33.3)
Boston-Cambridge-Newton, MA-NH 157 157 (100.0) 3 (1.9)
Bridgeport-Stamford-Norwalk, CT 25 25 (100.0) 1 (4.0)
Buffalo-Cheektowaga-Niagara Falls, NY 23 21 (91.3) 0 (0.0)
Cape Coral-Fort Myers, FL 14 14 (100.0) 0 (0.0)
Charleston-North Charleston, SC 21 21 (100.0) 4 (19.0)
Charlotte-Concord-Gastonia, NC-SC 54 53 (98.1) 3 (5.6)
Chattanooga, TN-GA 9 9 (100.0) 0 (0.0)
Chicago-Naperville-Elgin, IL-IN-WI 281 281 (100.0) 13 (4.6)
Cincinnati, OH-KY-IN 20 20 (100.0) 1 (5.0)
Cleveland-Elyria, OH 31 31 (100.0) 0 (0.0)
Colorado Springs, CO 7 7 (100.0) 1 (14.3)
Columbia, SC 12 12 (100.0) 0 (0.0)
Columbus, OH 51 51 (100.0) 4 (7.8)
Dallas-Fort Worth-Arlington, TX 313 313 (100.0) 33 (10.5)
Dayton, OH 15 15 (100.0) 0 (0.0)
Deltona-Daytona Beach-Ormond Beach, FL 13 11 (84.6) 1 (7.7)
Denver-Aurora-Lakewood, CO 46 45 (97.8) 3 (6.5)
Des Moines-West Des Moines, IA 10 10 (100.0) 0 (0.0)
Detroit-Warren-Dearborn, MI 104 102 (98.1) 6 (5.8)
Durham-Chapel Hill, NC 9 9 (100.0) 1 (11.1)
El Paso, TX 44 44 (100.0) 2 (4.5)
Fresno, CA 36 36 (100.0) 0 (0.0)
Grand Rapids-Wyoming, MI 9 8 (88.9) 0 (0.0)
Greensboro-High Point, NC 19 19 (100.0) 0 (0.0)
Greenville-Anderson-Maudlin, SC 7 7 (100.0) 1 (14.3)
Harrisburg-Carlisle, PA 11 11 (100.0) 0 (0.0)
Hartford-West Hartford-East Hartford, CT 20 20 (100.0) 2 (10.0)
Houston-The Woodlands-Sugar Land, TX 324 324 (100.0) 17 (5.2)
Indianapolis-Carmel-Anderson, IN 40 40 (100.0) 8 (20.0)
Jackson, MS 20 20 (100.0) 1 (5.0)
Jacksonville, FL 59 59 (100.0) 13 (22.0)
Kansas City, MO-KS 42 42 (100.0) 0 (0.0)
Knoxville, TN 10 10 (100.0) 1 (10.0)
Lakeland-Winter Haven, FL 14 14 (100.0) 1 (7.1)
Lancaster, PA 3 3 (100.0) 0 (0.0)
Las Vegas-Henderson-Paradise, NV 59 58 (98.3) 5 (8.5)
Little Rock-North Little Rock-Conway, AR 17 17 (100.0) 3 (17.6)
Los Angeles-Long Beach-Anaheim, CA 867 866 (99.9) 70 (8.1)
Louisville/Jefferson County, KY-IN 24 24 (100.0) 0 (0.0)
Madison, WI 7 7 (100.0) 0 (0.0)
McAllen-Edinburg-Mission, TX 58 58 (100.0) 1 (1.7)
Memphis, TN-MS-AR 44 44 (100.0) 3 (6.8)
Miami-Fort Lauderdale-West Palm Beach, FL 250 248 (99.2) 12 (4.8)
Milwaukee-Waukesha-West Allis, WI 14 14 (100.0) 1 (7.1)
Minneapolis-St. Paul-Bloomington, MN-WI 108 108 (100.0) 4 (3.7)
Table 67. Tuberculosis Cases and Percentages by Homeless Status,1 Age >15: 
Metropolitan Statistical Areas with >500,000 Population, 2013
Metropolitan 
Statistical Area





Cases Reported as Being 
Homeless2
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Modesto, CA 7 7 (100.0) 1 (14.3)
Nashville-Davidson-Murfreesboro--Franklin, TN 45 45 (100.0) 4 (8.9)
New Haven-Milford, CT 13 13 (100.0) 0 (0.0)
New Orleans-Metairie, LA 53 53 (100.0) 5 (9.4)
New York-Newark-Jersey City, NY-NJ-PA 1,010 997 (98.7) 22 (2.2)
Northport-Sarasota-Bradenton, FL 15 15 (100.0) 0 (0.0)
Ogden-Clearfield, UT 6 6 (100.0) 0 (0.0)
Oklahoma City, OK 26 23 (88.5) 0 (0.0)
Omaha-Council Bluffs, NE-IA 11 11 (100.0) 0 (0.0)
Orlando-Kissimmee-Sanford, FL 66 66 (100.0) 10 (15.2)
Oxnard-Thousand Oaks-Ventura, CA 26 26 (100.0) 1 (3.8)
Palm Bay-Melbourne-Titusville, FL 7 7 (100.0) 0 (0.0)
Philadelphia-Camden-Wilmington, PA-NJ-DE-MD 154 154 (100.0) 4 (2.6)
Phoenix-Mesa-Scottsdale, AZ 116 104 (89.7) 14 (12.1)
Pittsburgh, PA 25 25 (100.0) 0 (0.0)
Portland-South Portland, ME 6 6 (100.0) 1 (16.7)
Portland-Vancouver-Hillsboro, OR-WA 44 43 (97.7) 3 (6.8)
Providence-Warwick, RI-MA 32 32 (100.0) 0 (0.0)
Provo-Orem, UT 1 1 (100.0) 0 (0.0)
Raleigh, NC 27 27 (100.0) 1 (3.7)
Richmond, VA 24 24 (100.0) 2 (8.3)
Riverside-San Bernardino-Ontario, CA 102 102 (100.0) 4 (3.9)
Rochester, NY 22 22 (100.0) 1 (4.5)
Sacramento--Roseville--Arden Arcade, CA 93 92 (98.9) 1 (1.1)
St. Louis, MO-IL 47 47 (100.0) 0 (0.0)
Salt Lake City, UT 20 20 (100.0) 1 (5.0)
San Antonio-New Braunfels, TX 75 75 (100.0) 9 (12.0)
San Diego-Carlsbad, CA 198 198 (100.0) 13 (6.6)
San Francisco-Oakland-Hayward, CA 343 342 (99.7) 18 (5.2)
San Jose-Sunnyvale-Santa Clara, CA 178 176 (98.9) 6 (3.4)
Scranton-Wilkes-Barre-Hazleton, PA 8 8 (100.0) 0 (0.0)
Seattle-Tacoma-Bellevue, WA 157 156 (99.4) 8 (5.1)
Spokane-Spokane Valley, WA 7 7 (100.0) 0 (0.0)
Springfield, MA 14 14 (100.0) 1 (7.1)
Stockton-Lodi, CA 38 38 (100.0) 2 (5.3)
Syracuse, NY 9 9 (100.0) 0 (0.0)
Tampa-St. Petersburg-Clearwater, FL 91 91 (100.0) 12 (13.2)
Toledo, OH 4 4 (100.0) 0 (0.0)
Tucson, AZ 23 23 (100.0) 0 (0.0)
Tulsa, OK 16 9 (56.3) 1 (6.3)
Urban Honolulu, HI 80 79 (98.8) 5 (6.3)
Virginia Beach-Norfolk-Newport News, VA-NC 20 20 (100.0) 0 (0.0)
Washington-Arlington-Alexandria, DC-VA-MD-WV 237 237 (100.0) 7 (3.0)
Wichita, KS 7 7 (100.0) 1 (14.3)
Winston-Salem, NC 11 11 (100.0) 1 (9.1)
Worcester, MA-CT 22 22 (100.0) 0 (0.0)
Youngstown-Warren-Boardman, OH-PA 0 0 . 0 .
Total - 104 Areas 7,306 7,249 (99.2) 407 (5.6)
San Juan-Caguas-Guaynabo, PR 40 40 (100.0) 2 (5.0)
Table 67. (Cont’d) Tuberculosis Cases and Percentages by Homeless Status,1 Age >15: 
Metropolitan Statistical Areas with >500,000 Population, 2013
1 Homeless within past 12 months of TB diagnosis. 
2 Percent of those with known status. 
Note: See Technical Notes for definition of MSA.
Metropolitan 
Statistical Area No. No.(%) (%)
Total
Cases
Cases with Information on 
Homeless Status
Cases Reported as Being 
Homeless2
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Tuberculosis in the United States
National Tuberculosis Surveillance System Highlights from 2013
Slide 1 (title slide). Tuberculosis in the United States—National Tuberculosis Surveillance System, Highlights 
from 2013.  This slide set was prepared by the Division of Tuberculosis Elimination, Centers for Disease Control 
and Prevention (CDC), Department of Health and Human Services (DHHS).  It provides trends for the recent past 
and highlights data collected through the National Tuberculosis Surveillance System for 2013.  Since 1953, through 
the cooperation of state and local health departments, CDC has collected information on newly reported cases of 
tuberculosis (TB) disease in the United States.  The data presented here were collected via the revised TB case 
report introduced in 2009.  Currently, each individual TB case report (Report of Verified Case of Tuberculosis or 
RVCT) is submitted electronically to CDC.  The data for this slide set are based on updates received by CDC as of 
June 11, 2014.  All case counts and rates for years 1993–2013 have been updated.
Slide 2. Reported TB Cases, United States, 1982–2013.  The resurgence of TB in the mid-1980s was marked by 
several years of increasing case counts until its peak in 1992.  Case counts began decreasing again in 1993, and 
2013 marked the twenty-first year of decline in the total number of TB cases reported in the United States since the 
peak of the resurgence.  From 1992 until 2002, the total number of TB cases decreased 5%–7% annually.  From 
2002 to 2003, however, the total number of TB cases decreased by only 1.4%.  An unprecedented decrease oc-
curred in 2009, when the total number of TB cases decreased by more than 10% from 2008 to 2009. In 2013, a 
total of 9,582 cases were reported from the 50 states and the District of Columbia (DC).  This represents a decline 
of 3.6% from 2012 and 64.1% from 1992.  
Slide 3. TB Morbidity, United States, 2008-2013.   This slide provides the total number of reported U.S. TB cases 
and the associated rates for each of the past 6 years.  Rate is defined as cases per 100,000 population.  The number 
of TB cases decreased from 12,893 in 2008 to 9,582 in 2013, and the TB rate decreased from 4.2 in 2008 to 3.0 in 
2013. 
Slide 4. TB Case Rates, United States, 2013.  This map shows TB rates for 2013.  Thirty-seven states reported a 
rate less than 3.0 TB cases per 100,000, the 2013 national average. Fourteen states and DC reported a rate above 
3.0 TB cases per 100,000; these accounted for 69% of the national total in 2013 and have experienced substantial 
overall decreases in cases and rates from 1992 through 2013.
Slide 5. Map of U.S.-Affiliated Pacific Islands by TB Case Rates, 2013. This map of the Pacific region shows 
the case rates by jurisdiction.
Slide 6. TB Case Rates, U.S.-Affiliated Pacific Islands, 2013. This bar chart shows TB rates for the U.S. Pacific 
Islands for reported cases in 2013. These case rates range from 3.7 per 100,000 in American Samoa to 219.4 per 
100,000 in the Republic of the Marshall Islands. The overall case rate for the United States (3.0 per 100,000) and 
for Hawaii (8.2 per 100,000) are also shown.
Slide 7. TB Case Rates by Age Group, United States, 1993–2013.  This slide shows the last 21 years’ declining 
trend in TB rates by age group.  In 2013, case rates in all age groups declined by more than 50% from 1993 values: 
persons 65 years and older (from 17.7 per 100,000 in 1993 to 4.9 in 2013); adults aged 45 to 64 years (from 12.4 
to 3.6); adults aged 25 to 44 years (from 11.5 to 3.6); those 15 to 24 years of age (from 5.0 to 2.2); and in children 
under 15 years of age (from 2.9 to 0.8)
Slide 8. Reported TB Cases by Age Group, United States, 2013.  This pie chart shows the age distribution of 
persons reported with TB in 2013.  Five percent were children under 15 years of age, 10% were age 15 to 24, 31% 
were age 25 to 44, 31% were age 45 to 64, and 23% were at least 65 years old.
Slide 9. TB Case Rates by Age Group and Sex, United States, 2013.  This slide graphs the TB rates in 2013 by 
age group and sex.  It shows that rates tended to increase with age, ranging from a low of less than 1 per 100,000 
in children aged 5 - 14 to a high of 6.9 per 100,000 in men 65 years and older. As age increased, the case rate in 
men increased faster than women; the rates in men 45 years and older were approximately more than twice those in 
same-age women.
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Slide 10. TB Case Rates by Race/Ethnicity, United States, 2003–2013.  This slide shows the declining trend in 
TB rates by race/ethnicity during the last 12 years.  Asians had the highest TB rates, which declined from 29.9 per 
100,000 in 2003 to 18.7 in 2013, and had a percent decline over the time period of 37%.  Rates also declined in the 
following racial/ethnic groups: among non-Hispanic blacks or African-Americans, from 11.7 in 2003 to 5.4 in 2013 
(-54%); among Hispanics, from 10.3 to 5.0 (-51%); among American Indians and Alaska Natives, from 8.2 to 5.4 
(-34%); among non-Hispanic whites, from 1.4 to 0.7 (-50%); and among Native Hawaiian or Other Pacific Island-
ers, from 16.2 to 11.3 (-30%).
Several important factors likely contribute to the disproportionate burden of TB in minorities.  In persons who were 
born in countries where TB is common, TB disease may result from infection acquired in the country of origin.  
Unequal distribution of TB risk factors, such as HIV infection, may also contribute to increased exposure to TB or 
to an increased risk of developing TB once infected with M. tuberculosis. 
Slide 11. TB Case Rates by Age Group and Race/Ethnicity, United States, 2013.  This slide presents TB rates 
in 2013 by age group and race/ethnicity.  After infancy (age under 5), risk typically increased with age across all 
racial and ethnic groups. Rates were consistently higher in minority racial and ethnic groups than in non-Hispanic 
whites.  Rates were the highest in Asians and Native Hawaiians and Other Pacific Islanders, particularly in adult 
age groups.  
Slide 12. Reported TB Cases by Race/Ethnicity, United States, 2013.  In 2013, 83% of all reported TB cases oc-
curred in racial and ethnic minorities (32% in Asians , 29% in Hispanics,  22% in non-Hispanic blacks or African-
Americans, 1% in American Indians or Alaska Natives, and  1% in Native Hawaiians or Other Pacific Islanders), 
whereas 15% of cases occurred in non-Hispanic whites.  Persons reporting two or more races accounted for 2% of 
all cases.  
Slide 13. Number of TB Cases in U.S.-born vs. Foreign-born Persons, United States, 1993–2013.  This graph 
plots the number of U.S.-born vs. foreign-born persons reported with TB each year, from 1993 through 2013.  It 
illustrates the increase in the percentage of cases occurring in foreign-born persons during this period, from 29% 
in 1993 to 65% in 2013.  Overall, the number of cases in foreign-born persons remained virtually level, with ap-
proximately 7,600–8,000 cases each year before 2009, until 2009 when the number dropped to 6,956. That decreas-
ing trend continued in 2013 with the number of foreign-born cases dropping to 6,193. The number in U.S.-born 
persons decreased from more than 17,000 in 1993 to 3,375 in 2013.
Slide 14. Trends in TB Cases in Foreign-born Persons, United States, 1993–2013.  This slide shows trends in 
the past 21 years of TB cases in foreign-born persons in the United States from 1993 through 2013. The percentage 
of TB cases accounted for by foreign-born persons increased from 29% in 1992 to 65% in 2013.
Slide 15. Reported TB Cases by Origin and Race/Ethnicity, United States, 2013.  Among U.S.-born persons 
with TB in 2013, 37% were non-Hispanic black or African-American, 33% were non-Hispanic white, 20% were 
Hispanic or Latino, 5% were Asian, 4% were American Indian or Alaska Native, and 1% were Native Hawaiian or 
Other Pacific Islander.  Among the foreign-born, 46% were Asian, 33% were Hispanic or Latino, 14% were non-
Hispanic black or African-American, and 5% were non-Hispanic white.  Cases among American Indians or Alaska 
Natives and among Native Hawaiians or Other Pacific Islanders constituted less than 1%, respectively, of the cases 
among the foreign-born and are not shown.  Persons reporting two or more races totaled less than 1% of all cases. 
Slide 16. Percentage of TB Cases Among Foreign-born Persons, United States, 2003 and 2013.  The percent-
age range of the total number of TB cases that occurred in foreign-born persons in each state is highlighted for 
2003 and 2013 in these side-by-side maps.  The number of states with less than 25% of their TB cases among the 
foreign-born decreased from 10 states in 2003 to 7 states in 2013. The number of states with at least 25-49% of 
cases among the foreign-born decreased from 16 states in 2003 to 9 states in 2013. However, the number of states 
that had 50% or more of their cases among the foreign-born increased from 27 states in 2003 to 36 states in 2013.
Slide 17. TB Case Rates in U.S.-born vs. Foreign-born Persons, United States, 1993–2013.  TB rates in 
foreign-born persons remain higher than those in the U.S.-born population.  From 1993 through 2013, the rates in 
U.S.-born persons decreased from 7.4 per 100,000 to 1.2, whereas the rates in foreign-born persons decreased from 
34.0 per 100,000 to 15.6.
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Slide 18. TB Case Rates in U.S.-born vs. Foreign-born Persons, United States, 1993–2013.  This is the same as 
Slide 15, but the rates are presented on a logarithmic scale to better illustrate the trend in TB rates among the U.S.-
born and foreign-born. The lines show a greater rate of decline among the U.S.-born compared with the foreign-
born during this period.
Slide 19. Countries of Birth of Foreign-born Persons Reported with TB, United States, 2013.  This slide 
shows the overall distribution of the countries of birth of foreign-born persons reported with TB in 2013, with the 
top seven highlighted.  The list of countries has remained relatively constant since 1986, when information on 
country of birth was first reported by all areas submitting reports to CDC. In 2013 the seven top countries account-
ed for 60% of all foreign-born cases, with Mexico accounting for 20%; the Philippines, 13%; India, 8%; Vietnam, 
7%; China, 6%; Guatemala, 3%; and Haiti, 3%. Persons from more than 135 other countries each accounted for 2% 
or less of the total, but altogether accounted for 40% of foreign-born persons reported with TB.
Slide 20. Percent of Foreign-born with TB by Time of Residence in U.S. Prior to Diagnosis, 2013.  The length 
of U.S. residence among foreign-born persons prior to their TB diagnosis in 2013 is shown in these stacked bars.  
Overall, 15% had been in the United States for less than 1 year, 16% between 1 and 4 years, and 60% for at least 
5 years.  The distribution is also shown for the top three countries of birth: Mexico, the Philippines, and India.  
Among persons born in Mexico, 8% had been in the United States for less than 1 year, 8% between 1 and 4 years, 
and 74% for at least 5 years. Among persons born in the Philippines, 11% had been in the United States for less 
than 1 year, 13% between 1 and 4 years, and 68% for at least 5 years.  Among persons born in India, 20% had 
been in the United States for less than 1 year, 21% between 1 and 4 years, and 49% for at least 5 years. Values for 
unknown length of residence in U.S. for these top three countries ranged between 9 – 10% for 2013.
Slide 21. Primary Anti-TB Drug Resistance, United States, 1993–2013.  Primary drug resistance is shown for 
the past 21 years.  The graph starts in 1993, the year in which the individual TB case reports submitted to the na-
tional surveillance system began collecting information on initial susceptibility test results for patients with culture-
positive TB.  Data were available for more than 85% of culture-positive cases for each year.  Primary resistance 
was calculated by using data from persons with no reported prior TB episode. Resistance to at least isoniazid was 
8.2% in 1993; however by 2013, this had increased to 8.8%.  Resistance to at least isoniazid and rifampin, known 
as multidrug-resistant TB (MDR TB), was 2.5% in 1993. The percent of primary MDR TB has remained approxi-
mately stable since it decreased to 1.0% in 1998. In 2013 the percent of primary MDR TB was 1.2%.
Slide 22. Primary MDR TB, United States, 1993–2013.  This graph focuses on trends in primary MDR TB 
(based on initial isolates from persons with no prior history of TB) in the United States from 1993 through 2013.  
The number of primary MDR TB cases, represented by bars, steadily declined from 407 in 1993 to 132 in 2002.  
Since then, the total number of primary MDR TB cases has fluctuated between 87 to 103 cases, with 82 cases 
reported for 2013.  Primary MDR TB, shown by the line, decreased from 2.5% in 1993 to approximately 1.0% in 
1998, and has fluctuated around 1.0% since then. In 2013, the percentage was 1.2%. 
Slide 23. Primary Isoniazid Resistance in U.S.-born vs. Foreign-born Persons, United States, 1993–2013.  
This graph shows primary isoniazid resistance in U.S.-born vs. foreign-born persons.  Based on initial isolates 
from persons with no prior history of TB, the percentage of isoniazid resistance is more than twice as high among 
foreign-born persons than among U.S.-born persons.  In foreign-born persons, the percentage declined from 12.1% 
in 1993 to 10.5% in 2013.  In U.S.-born persons, the percentage decreased from 6.7% in 1993 to 4.2% in 2007, but 
has increased since then to 5.6% in 2013. 
Slide 24. Primary MDR TB in U.S.-born vs. Foreign-born Persons, United States, 1993–2013.  This graph 
highlights primary MDR TB in U.S.-born versus foreign-born persons.  The percentage with primary MDR TB 
has declined among both groups since 1993, although the decline in the U.S.-born has been greater.  As a result, 
the proportion of primary MDR TB cases in the US that are attributed to foreign-born persons increased from ap-
proximately 25% in 1993 to 92% in 2013 (not shown on slide).  Among the U.S.-born, the percentage with primary 
MDR TB has been less than 1% since 1997 and was 0.3% in 2013.  The percentage among foreign-born persons 
has fluctuated year by year, although it has remained between 1.2 and 1.8% since 1995. In 2013, the percentage of 
primary MDR TB among foreign-born persons was 1.7%
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Slide 25. Extensively Drug Resistant (XDR) TB, as Defined on Initial Drug Susceptibility Testing (DST), 
United States, 1993–2013.  This graph shows the annual number of counted XDR TB cases as defined on initial 
DST from 1993-2013. XDR TB is defined as resistance to isoniazid and rifampin, plus resistance to any fluoroqui-
nolone and at least one of three injectable second-line anti-TB drugs. Four cases of XDR TB were reported in 2013. 
The most reported in a single year was 10 in 1993, while there were no cases reported in 2003 and 2009. There is 
no apparent trend in the number of cases over time. 
Slide 26. Reporting of HIV Test Results in Persons with TB by Age Group, United States, 1993–2013.  This 
slide shows the completeness of reporting of HIV test results in persons with TB by age group from 1993 through 
2013.  The percentage of TB patients for whom test results were reported increased from 30% among all ages in 
1993 to 88% in 2013.  Among adults aged 25–44 years, the percentage increased from 45% in 1993 to 94% in 
2013.   California began reporting HIV test results to CDC in 2011; this accounts for the substantial percentage 
increase for that year.
Slide 27. Estimated HIV Coinfection in Persons Reported with TB, United States, 1993–2013.  This slide pro-
vides minimum estimates of HIV coinfection among persons reported with TB from 1993 through 2013.  Since the 
addition of the request for HIV status to the individual TB case report in 1993, incomplete reporting has provided a 
challenge to calculating reliable estimates, although reporting improved substantially beginning in 2011 (see previ-
ous Slide 26).  Results from the cross-matching of TB and AIDS registries have been used to supplement reported 
HIV test results.  For all ages, the estimated percentage of HIV coinfection in persons who reported HIV testing 
(positive, negative, or indeterminate test results) with TB decreased from 48% to 7% overall from 1993 – 2013, and 
from 63% to 9% among persons aged 25 to 44 years during this period. 
Slide 28. TB Cases by Residence in Correctional Facilities, Age ≥15, United States, 1993-2013. This graph 
highlights the number of cases that were a resident of any type of correctional facility at the time of TB diagnosis. 
Cases must have been 15 years of age or greater. The number of cases residing in a correctional facility has de-
creased from a high of 1,117 cases in 1994 to 359 cases in 2013. Between the years 2000 and 2010, the number of 
cases residing in a correctional facility ranged between the high-400s and high-500s; 2011 was the first year to drop 
below this range to 422 cases. Of total cases, the percentage of cases residing in a correctional facility has ranged 
from 5.0% in 1994 to 3.3% in 2002. The 1990s saw a decreasing trend in percentage until 2002. Since 2002, there 
has been an increasing trend in percentage; in 2013 the percentage of total cases was 4.0%.
Slide 29. TB Cases by Homeless Status, Age ≥15, United States, 1993-2013. This graph highlights the status of 
cases that were homeless within twelve months prior of TB diagnosis from 1993 through 2013. Cases must have 
been 15 years of age or greater. The number of homeless cases has decreased from a high of 1,379 cases in 1994 to 
514 in 2013. This category has seen an overall decrease in cases since 1994; increases were observed in the years 
2003 (6.7%), 2006 (6.3%), and 2010 (5.6%); these have been exceptions with a small increase in cases. Of total 
cases, 6.1% were homeless in 1994 and percentages have ranged between 6.8% in 1997 and a low of 5.3% in 2009. 
It has since increased to 5.7% in 2013. 
Slide 30. Mode of Treatment Administration in Persons Reported with TB, United States, 1993–2011.  In 
1993, the reporting areas began providing information about mode of treatment administration on the individual TB 
case report form.  Treatment administered as only directly observed therapy (DOT) increased from 21.7% in 1993 
to 62% in 2011, the latest year with available data.  The proportion of patients who received at least some portion 
of their treatment as DOT (based on combining the percentage of patients who received only DOT and the percent-
age for whom some portion was self-administered) was 29% in 2011.
Slide 31. Completion of TB Therapy, United States, 1993–2011.  The reporting areas began providing infor-
mation on completion of therapy in 1993 through the individual TB case report form.  The calculations exclude 
persons with initial isolate rifampin resistant, or patient with meningeal disease, or pediatric patient (aged <15) with 
miliary disease or positive blood culture.  Overall completion of therapy had remained at approximately 92-93% 
from 1998 through 2008, but increased to 96% in 2011, the latest year with available data. Completion in 1 year or 
less increased from 63% in 1993 to 89% in 2011. The current DHHS Healthy People 2020 objective is completion 
of therapy in 1 year or less in 93% of patients.  CDC is working with state and local health departments to deter-
mine and evaluate reasons for apparently delayed completion of therapy, which may vary by jurisdiction.
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Slide 32. Definition for Tuberculosis Genotyping in the United States.  This slide shows the schematic for 
sequential assignment of unique spoligotypes and initial 12-locus MIRU-VNTR combination or 24-locus MIRU-
VNTR combination.
Slide 33. National Tuberculosis Genotyping Surveillance Coverage by Year, United States, 2004–2013.  This 
slide shows the increase in genotyping surveillance coverage from 2004 to 2013. In 2004 the proportion of positive 
cultures with at least one genotyped isolate was 52.6%; in 2013 it was 94.6%. The national indicator for genotyp-
ing surveillance coverage is 94%.
Slide 34. Number and Percent of Unique and County-GENType Clustered Cases, United States, 2011–2013.  
This slide shows a chart with the percentage of unique and clustered cases. Unique cases are those with a spoligo-
type and 24-locus MIRU-VNTR (GENType) that does not match any other case in that county during the speci-
fied three year time period. Clustered cases are two or more cases with matching spoligotype and 24-locus locus 
MIRU-VNTR (GENType) within a county during the specified three year time period. In the 2011 – 2013 three 
year time period, there were 79% unique cases, and 21% clustered cases.
Slide 35. Number of County-based Tuberculosis Genotype Clusters by Cluster Size, United States, 2011–
2013.  This slide shows the number of county-based TB genotype clusters by the size of the clusters; genotype 
cluster is defined as two or more cases with matching spoligotype and 24-locus MIRU-VNTR (GENType) within 
a county  during the specified three year time period. In the 2011 – 2013 three year time period, there were 1,015 
two-case clusters, 250 three-case clusters, 111 four-case clusters, 59 five-case clusters, 23 six-case clusters, 17 
seven-case clusters, 12 eight-case clusters, 7 nine-case clusters, and 38 case clusters that were greater or equal to 10 
in size.
Slide 36. Tuberculosis Genotype Clusters by TB GIMS Alert Levels, United States, 2011-2013.  This slide 
shows a chart with percentage of genotype clusters by alert level. Alert level is determined by the log likelihood ra-
tio statistic (LLR) for a given cluster, identifying higher than expected geospatial concentrations for a TB genotype 
cluster in a specific county, compared to the national distribution of that genotype; TB GIMS generates alert level 
notifications based on this statistic: “No alert” is indicated if LLR is between 0–5, “medium” is for LLR of 5.1–10 
and “high” alert is for clusters with LLR >10. In the 2011-2013 three year time period, high alerts made up 7% of 






Tuberculosis Case Definition for Public Health Surveillance
(Revised May 13, 2009) 
Clinical description
A chronic bacterial infection caused by Mycobacterium tuberculosis, usually characterized patho-
logically by the formation of granulomas. The most common site of infection is the lung, but other 
organs may be involved. 
Clinical case definition
A case that meets all of the following criteria: 
•	 A positive tuberculin skin test result or positive interferon gamma release assay for M. tuber-
culosis
•	 Other signs and symptoms compatible with tuberculosis (TB) (e.g., abnormal chest radio-
graph, abnormal chest computerized tomography scan or other chest imaging study, or clini-
cal evidence of current disease)
•	 Treatment with two or more anti-TB medications
•	 A completed diagnostic evaluation
Laboratory criteria for diagnosis 
•	 Isolation of M. tuberculosis complex from a clinical specimen,* 
or
•	 Demonstration of M. tuberculosis complex from a clinical specimen by nucleic acid amplifi-
cation test,† 
or
•	 Demonstration of acid-fast bacilli in a clinical specimen when a culture has not been or can-
not be obtained or is falsely negative or contaminated.
Case classification
Confirmed: a case that meets the clinical case definition or is laboratory confirmed
Comment
A case should not be counted twice within any consecutive 12-month period. However, a case oc-
curring in a patient who had previously had verified TB disease should be reported and counted 
again if more than 12 months have elapsed since the patient completed therapy. A case should also 
be reported and counted again if the patient was lost to supervision for greater than 12 months and 
TB disease can be verified again. Mycobacterial diseases other than those caused by M. tuberculosis 
complex should not be counted in tuberculosis morbidity statistics unless there is concurrent tuber-
culosis.
                                                                                                                  
*Use of rapid identification techniques for M. tuberculosis (e.g., DNA probes and mycolic acid high-pressure liquid 
chromatography performed on a culture from a clinical specimen) are acceptable under this criterion.
†Nucleic acid amplification (NAA) tests must be accompanied by culture for mycobacteria species for clinical purposes. 
A culture isolate of M. tuberculosis complex is required for complete drug susceptibility testing and also genotyping. 
However, for surveillance purposes, CDC will accept results obtained from NAA tests approved by the Food and Drug 
Administration (FDA) and used according to the approved product labeling on the package insert, or a test produced 
and validated in accordance with applicable FDA and Clinical Laboratory Improvement Amendments (CLIA) regula-




Recommendations for Reporting and Counting Tuberculosis Cases
(Revised May 13, 2009)
Since publication of the “Recommendations for Counting Reported Tuberculosis Cases”1 in July 
1997, numerous changes have occurred, and many issues have been raised within the field of tu-
berculosis (TB) surveillance.  This current version updates and supersedes the previous version.
A distinction should be made between reporting TB cases to a health department and counting 
TB cases for determining incidence of disease.  Throughout each year, TB cases and suspected 
cases are reported to public health authorities by sources such as clinics, hospitals, laboratories, 
and health care providers.  From these reports, the state or local TB control officer must deter-
mine which cases meet the current surveillance definition for TB disease and whether the case 
is countable.  These countable TB cases are then reported to the Centers for Disease Control and 
Prevention (CDC).  
Beginning in 2009, state and local TB control officers may also report to CDC those TB cases 
that are verified but not countable for morbidity statistics, as a measure of programmatic and case 
management burden. The noncountable report can include persons with TB disease recurring 
within a consecutive 12-month period after the patient completed TB therapy. 
I. Reporting TB Cases. CDC recommends that health care providers and laboratories be 
required to report all TB cases or suspected cases to state and local health departments 
based on the current “Tuberculosis Case Definition for Public Health Surveillance” (Ap-
pendix A). This notification is essential in order for TB programs to:
•	 Ensure case supervision
•	 Ensure completion of appropriate therapy
•	 Ensure completion of contact investigations
•	 Evaluate program effectiveness
•	 Assess trends and characteristics of TB morbidity
II. TB Surveillance. For purposes of surveillance, a case of TB is defined on the basis of 
laboratory or clinical evidence of active disease due to M. tuberculosis complex.*
________________________________
* Because most laboratories use tests that do not routinely distinguish Mycobacterium tuberculosis from very closely related species, 
these laboratories report culture results as being positive or negative for “Mycobacterium tuberculosis complex.” Although in almost 
all cases of human disease, isolates in the M. tuberculosis complex are, in fact, M. tuberculosis, other species are possible. Other spe-
cies in the Mycobacterium tuberculosis complex include M. bovis, M. africanum, M. microti, M. canetii, M. caprae, M. pinnipedii, and 
M. mungi; the inclusion of these species in M. tuberculosis complex should not impact public health laboratories or programs, because 
only a few laboratories identify to the species level.  These seven species are almost identical in DNA homology studies. In terms of 
their ability to cause clinical disease or be transmissible from person to person, M. bovis, M. africanum, M. microti, M. canetii, M. pin-
nipedii, and M. mungi behave like M. tuberculosis; therefore, disease caused by any of the organisms should be reported as TB, using 
the Report of Verified Case of Tuberculosis (RVCT). The only exception is the BCG strain of M. bovis, which may be isolated from 
persons who have received the vaccine for protection against TB or as cancer immunotherapy; disease caused by the BCG strain of M. 
bovis should not be reported as TB.
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a. Laboratory Case Definition
•	 Isolation of M. tuberculosis complex from a clinical specimen.  The use of rapid identi-
fication techniques for M. tuberculosis performed on a culture from a clinical specimen, 
such as DNA probes and high-pressure liquid chromatography (HPLC), is acceptable 
under this criterion.
OR
•	 Demonstration of M. tuberculosis from a clinical specimen by nucleic acid amplifica-
tion (NAA) test. NAA tests must be accompanied by cultures of mycobacterial species. 
However, for surveillance purposes, CDC will accept results obtained from NAA tests 
approved by the Food and Drug Administration (FDA) and used according to the ap-
proved product labeling on the package insert, or a test produced and validated in accor-
dance with applicable FDA and Clinical Laboratory Improvement Amendments (CLIA) 
regulations.     
OR   
•	 Demonstration of acid-fast bacilli (AFB) in a clinical specimen when a culture has not 
been or cannot be obtained or is falsely negative or contaminated; historically, this crite-
rion has been most commonly used to diagnose TB in the postmortem setting.  
b.   Clinical Case Definition. In the absence of laboratory confirmation of M. tuberculosis com-
plex after a diagnostic process has been completed, persons must have all of the following 
criteria for clinical TB:
•	 Evidence of TB infection based on a positive tuberculin skin test result or positive inter-
feron gamma release assay for M. tuberculosis 
•	 Current treatment with two or more anti-TB medications
AND
•	 One of the following:
(1) Signs and symptoms compatible with current TB disease, such as an abnormal chest 
radiograph or abnormal chest computerized tomography scan or other chest imag-
ing study, 
OR
(2) Clinical evidence of current disease (e.g., fever, night sweats, cough, weight loss, 
hemoptysis)
NOTE: The software for TB surveillance developed by CDC includes a calculated variable called “Vercrit,” 
for which one of the values is “Provider Diagnosis.”  “Provider Diagnosis” is selected when the user chooses 
to override a “Suspect” default value in the case verification screen as “Verified by Provider Diagnosis.”  Thus, 
“Provider Diagnosis” is not a component of the case definition for TB in the current “Tuberculosis Case Defini-
tion for Public Health Surveillance” (Appendix A).  CDC’s national morbidity reports have traditionally included 
all TB cases that are considered verified by the reporting areas, without a requirement that cases meet the pub-
lished case definition.
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III. Counting TB Cases. Cases that meet the current CDC surveillance case definition for 
verified TB are counted by 52 reporting areas with count authority (50 states, District of 
Columbia, and New York City) to determine annual incidence for the United States.  The 
remaining 8 reporting areas (American Samoa, Federated States of Micronesia, Guam, 
Marshall Islands, Northern Mariana Islands, Puerto Rico, Republic of Palau, and U.S. 
Virgin Islands) report cases to CDC but are not included in the annual incidence for the 
United States. The laboratory and clinical case definitions are the two diagnostic catego-
ries used in the CDC “Tuberculosis Case Definition for Public Health Surveillance.”
Most verified TB cases are accepted for counting based on laboratory confirmation 
of M. tuberculosis complex from a clinical specimen.
A person may have more than one discrete (separate and distinct) episode of TB.  If 
disease recurs in a person within any 12-consecutive-month period after the patient 
completed therapy, count only one episode as a case. However, if TB disease recurs 
in a person, and if more than 12 months have elapsed since the person completed 
TB therapy or was lost to supervision, the TB case is considered a separate episode 
and should be counted as a new case.  
Mycobacterial diseases other than those caused by M. tuberculosis complex should 
not be counted in TB morbidity statistics unless there is concurrent TB. 
a. Verified TB Cases
COUNT
Count only verified TB cases that meet the laboratory or clinical case definitions 
(see Section II).  The diagnosis of TB must be verified by the TB control officer 
or designee.  The current CDC surveillance case definition for TB describes and 
defines the criteria to be used in the case definition for TB disease. 
DO NOT COUNT
If diagnostic procedures have not been completed, do not count; wait for confirma-
tion of disease.  Do not count as a case the patient for which two or more anti-TB 
medications have been prescribed for preventive therapy for exposure to multidrug- 
resistant (MDR) TB, or while the diagnosis is still pending
b. Nontuberculous Mycobacterial Diseases (NTM)
COUNT
An episode of TB disease diagnosed concurrently with another nontuberculous my-
cobacterial disease should be counted as a TB case.
DO NOT COUNT
Disease attributed to or caused by nontuberculous mycobacteria alone should not be 
counted as a TB case.
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c. TB Cases Reported at Death
COUNT
TB cases first reported to the health department at the time of a person’s death are 
counted as incident cases, provided the person had current disease at the time of 
death. The TB control officer should verify the diagnosis of TB.
DO NOT COUNT
Do not count as a case of TB if there is no evidence of current disease at the time of 
death or at autopsy.
d. Immigrants, Refugees, Permanent Resident Aliens, Border Crossers,* and Foreign Visi-
tors3
COUNT
Immigrants and refugees who are examined after arriving in the United States and 
diagnosed with clinically active TB requiring anti-TB medications should be re-
ported and counted by the locality of their current residence at the time of diagnosis 
regardless of citizenship status.
Border crossers* who are diagnosed with TB and plan to receive anti-TB therapy 
from a locality in the United States for 90 days or more should be reported and 
counted by the locality where they receive anti-TB therapy.
Foreign visitors (e.g., students, commercial representatives, and diplomatic person-
nel) who are diagnosed with TB, are receiving anti-TB therapy, and have been, 
or plan to remain in, the United States for 90 days or more should be reported and 
counted by the locality of current residence.
DO NOT COUNT
Any person who was diagnosed and started on anti-TB drugs in another country 
should not be counted as a new case but should be reported as a verified noncount-
able TB case.  
Border crossers* and foreign visitors who are diagnosed with TB and receive anti-
TB therapy from a locality in the United States for less than 90 days but plan to 
return to their native country to continue therapy should not be reported or counted 
by the locality where they receive anti-TB therapy.
*Border crosser — defined, by the U.S. Citizenship and Immigration Services (US-
CIS)2 as “an alien resident of the United States reentering the country after an ab-
sence of less than six months in Canada or Mexico, or a nonresident alien entering 
the United States across the Canadian border for stays of no more than six months, 
or across the Mexican border for stays of no more than 72 hours.” Border crossers 
may go back and forth across the border many times in a short period
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e. Out-of-State or Out-of-Area Residents 
COUNT 
A person’s TB case should be counted by the locality in which he or she resides at 
the time of diagnosis.  TB in a person who has no address should be counted by the 
locality that diagnosed and is treating the TB.  The TB control officer should notify 
the appropriate out-of-state or out-of-area TB control officer of the person’s home 
locality to (1) determine whether the case has already been counted to avoid “dou-
ble counting,” and (2) agree on which TB control office should count the case if it 
has not yet been counted. 
DO NOT COUNT 
Do not count a case in a newly diagnosed TB patient who is an out-of-area resident 
and whose TB has already been counted by the out-of-area TB control office.
f. Migrants and Other Transients 
COUNT
Persons without any fixed U.S. residence are considered to be the public health 
responsibility of their present locality and their TB case should be reported and 
counted where diagnosed.
DO NOT COUNT
Cases in transient TB patients should not be counted when there is evidence that 
they have already been counted by another locality.  
g. Federal Facilities (e.g., Military and Veterans Administration Facilities)  
COUNT
Cases in military personnel, dependents, or veterans should be reported and counted 
by the locality where the persons are residing in the United States at the time of 
diagnosis and initiation of treatment.
However, if military personnel or dependents are discovered to have TB at a mili-
tary base outside the United States but are referred elsewhere for treatment (e.g., a 
military base located within the United States), the TB case should be reported and 
counted where treated and not where the diagnosis was made.
DO NOT COUNT
Do not count if the case was already counted by another locality in the United 
States.
h. Indian Health Service
COUNT
TB should be reported to the local health authority (e.g., state or county) and count-
ed where diagnosed and treatment initiated.  However, for a specific group such as 
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the Navajo Nation, which is geographically located in multiple states, health depart-
ments should discuss each case and determine which locality should count the case.
DO NOT COUNT
Do not count if the case was already counted by another locality. 
i. Correctional Facilities (e.g., Local, State, Federal, and Military)
COUNT
Persons who reside in local, state, federal, or military correctional facilities may 
frequently be transferred or relocated within and/or between various correctional 
facilities. TB in these persons should be reported to the local health authority and 
counted by the locality where the diagnosis was made and treatment plans were 
initiated.
DO NOT COUNT
Do not count correctional facility residents’ TB cases that were counted elsewhere 
by another locality or correctional facility, even if treatment continues at another 
locale or correctional facility. 
j. Peace Corps, Missionaries, and Other Citizens Residing Outside the United States
DO NOT COUNT
TB in persons diagnosed outside the United States should not be counted.  TB in 
these persons should be counted by the country in which they are residing, regard-
less of their plans to return to the United States for further work-up or treatment.
IV. Suggested Administrative Practices
To promote uniformity in TB case counting, the following administrative procedures 
are recommended:
(a) All TB cases verified by the 52 reporting areas with count authority (50 states, District 
of Columbia, and New York City) during the calendar year (by December 31) will be 
included in the annual U.S. incidence count for that year. All tuberculosis cases verified 
during the calendar year by a reporting area with count authority from one of the remain-
ing 8 reporting areas (American Samoa, Federated States of Micronesia, Guam, Marshall 
Islands, Northern Mariana Islands, Puerto Rico, Republic of Palau, and U.S. Virgin Is-
lands) are also counted but are not included in the annual incidence for the United States. 
Cases for which bacteriologic results are pending or for which confirmation of disease is 
questionable for any other reason should not be counted until their status is clearly deter-
mined; they should be counted at the time they meet the criteria for counting. This means 
that a case reported in one calendar year could be included in the morbidity count for the 
following year. All reporting areas should ensure that there is agreement between final 
local and state TB figures reported to CDC. Currently, some reporting areas may not use 
this suggested protocol. Some of these areas may wait until the beginning of the follow-
ing year when they have received and processed all of the TB cases for inclusion in the 
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annual case count for the previous year.  If reporting areas decide to revise their proto-
cols, they should be aware that their TB trends may change.
(b) TB is occasionally reported to health departments over the telephone, by letter or fax, or 
on forms other than the Report of Verified Case of Tuberculosis (RVCT). Such informa-
tion should be accepted as an official morbidity report if sufficient details are provided; 
otherwise, the notification should be used as an indicator of a possible TB case (suspect) 
which should be investigated promptly for confirmation.
V. TB Surveillance Definitions
Case - an episode of TB disease in a person meeting the laboratory or clinical 
criteria for TB as defined in the document “Tuberculosis Case Definition for Public 
Health Surveillance” (see Section II for criteria).
Suspect - a person for whom there is a high index of suspicion for active TB (e.g., 
a known contact to an active TB case or a person with signs or symptoms consistent 
with TB) who is currently under evaluation for TB disease.
Verification of a TB case - the process whereby a TB case, after the diagnostic 
evaluation is complete, is reviewed at the local level (e.g., state or county) by a TB 
control official who is familiar with TB surveillance definitions; if all the criteria for 
a TB case are met, the TB case is then verified and eligible for counting. 
Counting of a TB case - the process whereby a reporting area with count author-
ity evaluates verified TB cases against count criteria (e.g., assesses for case dupli-
cation). These cases are then counted for morbidity in that locality (e.g., state or 
county) and reported to CDC for national morbidity counting. Noncountable, veri-
fied cases may also be sent to CDC.
Mycobacterium tuberculosis complex (M. tuberculosis complex) - Because most 
laboratories use tests that do not routinely distinguish Mycobacterium tuberculosis 
from very closely related species, these laboratories report culture results as being 
positive or negative for “Mycobacterium tuberculosis complex.” Although in almost 
all cases of human disease, isolates in the M. tuberculosis complex are, in fact, M. 
tuberculosis, other species are possible. For example, one study in San Diego found 
that 6% of human tuberculosis was caused by Mycobacterium bovis; cultures from 
these cases would be reported by most laboratories as being positive for M. tuber-
culosis complex. Other species in the Mycobacterium tuberculosis complex include 
M. africanum, M. microti, M. canetii, M. caprae, and M. pinnipedii. Although M. 
microti, M. canetii, M. caprae, and M. pinnipedii are newly described species, their 
inclusion in M. tuberculosis complex should not impact public health laboratories or 
programs because only a few laboratories identify to the species level. These seven 
species are almost identical in DNA homology studies. In terms of their ability to 
cause clinical disease or be transmissible from person to person, M. bovis, M. afri-
canum, M. microti, M. canetti, M. caprae, and M. pinnipedii behave like M. tuber-
culosis; therefore, disease caused by any of the organisms should be reported as TB, 
179
using the Report of Verified Case of Tuberculosis (RVCT). The only exception is 
the BCG strain of M. bovis, which may be isolated from persons who have received 
the vaccine for protection against TB or as cancer immunotherapy; disease caused 
by the BCG strain of M. bovis should not be reported as TB.
 
Nontuberculous mycobacteria (NTM) - mycobacteria other than Mycobacterium 
tuberculosis complex that can cause human infection or disease.  Common nontu-
berculous mycobacteria include M. avium complex or MAC (M. avium, M. intracel-
lulare), M. kansasii, M. marinum, M. scrofulaceum, M. chelonae, M. fortuitum, and 
M. simiae.  Other terms have been used to represent NTM, including MOTT (myco-
bacteria other than TB) and “atypical” mycobacteria.
Reporting area - areas responsible for counting and reporting verified TB cases to 
CDC.  Currently there are 60 reporting areas: the 50 states, District of Columbia, 
New York City, American Samoa, Federated States of Micronesia, Guam, Marshall 
Islands, Northern Mariana Islands, Puerto Rico, Republic of Palau, and U.S. Virgin 
Islands.  The annual incidence of tuberculosis for the United States is based on 52 
of these reporting areas (the 50 states, District of Columbia, and New York City).
Alien - defined by the U.S. Citizenship and Immigration Services (USCIS)2 as “any 
person not a citizen or national of the United States.”
Border crosser - defined, by the U.S. Citizenship and Immigration Services 
(USCIS)2 as “an alien resident of the United States reentering the country after an 
absence of less than six months in Canada or Mexico, or a nonresident alien en-
tering the United States across the Canadian border for stays of no more than six 
months, or across the Mexican border for stays of no more than 72 hours.”  Border 
crossers may go back and forth across the border many times in a short period.
Class A TB with waiver3 
All applicants who have tuberculosis disease and have been granted a waiver. 
Class B1 TB, Pulmonary3 
 
 No treatment 
•	 Applicants who have medical history, physical exam, HIV, or CXR findings 
suggestive of pulmonary TB but have negative AFB sputum smears and 
cultures and are not diagnosed with TB or can wait to have TB treatment 
started after immigration. 
Completed treatment 
•	 Applicants who were diagnosed with pulmonary TB and successfully 
completed directly observed therapy prior to immigration. The cover sheet 
should indicate if the initial sputum smears and cultures were positive and if 
drug susceptibility testing results are available. 
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Class B1 TB, Extrapulmonary3 
Applicants with evidence of extrapulmonary TB. Document the anatomic site of 
infection. 
Class B2 TB, Latent TB Infection (LTBI) Evaluation3 
 
Applicants who have a tuberculin skin test ≥10 mm but otherwise have a negative 
evaluation for TB. The size of the TST reaction, the applicant’s status with respect 
to LTBI treatment, and the medication(s) used should be documented. For appli-
cants who had more than one TST, whether the applicant converted the TST should 
be documented (i.e., initial TST <10 mm but subsequent TST ≥10 mm). 
Class B3 TB, Contact Evaluation3 
 
Applicants who are a recent contact of a known tuberculosis case. The size of the 
applicant’s TST reaction should be documented. Information about the source case, 
name, alien number, relationship to contact, and type of tuberculosis should also be 
documented.
Immigrant - defined by the USCIS2  as “an alien admitted to the United States as 
a lawful permanent resident.  Immigrants are those persons lawfully accorded the 
privilege of residing permanently in the United States.  They may be issued immi-
grant visas by the Department of State overseas or adjusted to permanent resident 
status by the USCIS of the United States.”
Permanent Resident Alien - see Immigrant. 
Waivers3 - A provision allows applicants undergoing pulmonary or laryngeal 
tuber culosis treatment to petition for a Class A TB with waiver. Waivers should be 
pursued for any immigrant or refugee who has a complicated clinical course and 
would benefit from receiving treatment of their tuberculosis in the United States. 
Applicants diag nosed with tuberculosis disease who are both smear- and culture-
negative and will be traveling to the United States prior to start of treatment do not 
need to complete the waiver process.
References
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2. U.S. Department of Homeland Security, U.S. Citizenship and Immigration Services; 
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Appendix C
National Surveillance for Severe Adverse Events Associated with Treatment for 
Latent Tuberculosis Infection - Reporting Information
This information is included to alert our public health partners of the importance of reporting se-
vere (i.e., hospitalization or death) adverse events associated with treatment for latent TB infec-
tion (LTBI). Data on severe adverse events (SAEs) among persons receiving treatment for LTBI 
are needed to serve as a basis for periodic evaluation of guidelines for treatment of LTBI. 
 In April 2000, after the publication of updated Guidelines for Targeted Tuberculin Testing and 
Treatment of Latent Tuberculosis Infection1, DTBE began receiving reports of SAEs related to the 
use of a 2-month course of rifampin and pyrazinamide (RZ) for treatment of LTBI.  In response, 
DTBE requested and received reports and conducted on-site investigations of liver injury in persons 
on treatment for LTBI, and treatment guidelines were revised to recommend against the general use 
of rifampin and pyrazinamide to treat LTBI.2, 3 In January 2004, DTBE implemented the National 
Surveillance System for Severe Adverse Events Associated with Treatment for LTBI, which collects 
reports about SAEs associated with any treatment regimen for LTBI, to quantify the frequency of 
SAEs and to characterize the clinical features of affected patients.4 
Local medical providers should report possible LTBI-treatment associated SAEs to their respective 
local/state health departments. State health departments should report SAEs that occurred on or after 
January 1, 2004 to DTBE (e-mail: LTBIdrugevents@cdc.gov).
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Appendix D
Genotyping Background Information and Glossary
Tuberculosis (TB) genotyping is a laboratory-based analysis of the genetic material of the bac-
teria that cause TB disease, Mycobacterium tuberculosis complex. The total genetic content 
is referred to as the genome. Specific sections of the genome contain distinct genetic patterns 
that help distinguish different strains of M. tuberculosis. TB genotyping examines the location, 
number, and presence of different types of spacer or repetitive DNA patterns. The areas of the 
genome examined in TB genotyping are different from those related to drug resistance. 
Applications of Genotyping
Persons with TB disease who are related by transmission should have matching genotype results. 
Conversely, persons with matching TB genotyping results are probably related by transmission in 
some way, although the connection might not be recent or direct. 
Genotyping results, when combined with epidemiologic data, can help identify persons with TB 
disease involved in the same chain of transmission. This information adds value to conventional 
TB control activities in a variety of ways. These applications are summarized as follows:
Patient-level Applications of Genotyping
• Complete contact investigations
• Confirm or refute patient connections (epidemiologic linkages) identified that 
may or may not be found through routine contact investigations
• Cluster investigations
• Find patient connections that were not identified through routine contact inves-
tigations
• Detect, refute, or confirm potential false-positive culture results
• Distinguish relapse TB disease from new TB infection among TB cases with recurrent 
TB disease
Population-level Applications of Genotyping
• Detect potential outbreaks using geospatial or other analyses of genotype clusters
• Refute outbreaks when cases thought to be part of the same outbreak have non-match-
ing genotype results
• Define the scope of potential outbreaks by identifying all cases in an area with a 
matching genotype
• Monitor known outbreaks over time by watching for new cases with the outbreak 
genotype that get added to existing clusters (outbreak surveillance)
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History of TB Genotyping Surveillance in the United States
In 1996, CDC started the National Tuberculosis Genotyping Surveillance Network (NTG-
SN), a 5-year initiative which established the utility of genotyping in TB control efforts.1   
In 2004, based on the knowledge gained from NTGSN  and associated studies,2  CDC es-
tablished the National TB Genotyping Service (NTGS) and funded a national genotyping 
laboratories, located in Michigan, to genotype at least one M. tuberculosis isolate from 
each culture-positive TB case reported in the United States.3   All TB control programs 
may use NTGS at no cost to the patients, healthcare providers, or health departments.   
NTGS participation is voluntary, with individual programs determining how genotyping 
data will be used for their TB control activities. Since 2004, over 85,000 M. tuberculosis 
isolates have been successfully genotyped through NTGS and its partnerships between 
CDC, national genotyping laboratories, and 58 states and jurisdictions. 
In 2010, CDC launched the TB Genotyping Information Management System (TB 
GIMS), a secure web-based database available to all 50 states, the District of Columbia, 
Puerto Rico, the U.S. Virgin Islands, and the U.S.-affiliated Pacific Islands. TB GIMS 
makes genotyping data easily available to users and links genotyping data to patient 
surveillance records. Key features include tools to link genotype results of isolate records 
from NTGS to patient surveillance records from the National TB Surveillance System 
(NTSS). Additional features include database queries on genotypes and clusters, data 
quality checks, aggregate reports, maps, and outbreak detection tools. TB GIMS currently 
has over 400 users among local, state, federal, and territorial partners. 
Genotyping-based Outbreak Detection
CDC identifies genotype clusters that are most likely to represent TB outbreaks. Geno-
typing-based outbreak detection involves the use of geospatial analysis to identify un-
usual groupings of TB cases with matching genotypes that may represent outbreaks.  TB 
control programs can use outbreak detection information to help allocate and prioritize 
resources for investigation and intervention on specific TB genotype clusters. 
Currently, CDC’s primary outbreak detection method is based on identifying higher than 
expected geospatial concentrations of a TB genotype in a specific county, compared to 
the national distribution of that genotype. This method calculates a log-likelihood ratio 
(LLR) statistic; clusters with higher LLRs are more likely to represent greater geospa-
tial concentrations than clusters with lower LLRs; higher LLRs might indicate recent 
transmission of TB. LLR is then classified into alert levels within TB GIMS based on 
established cut points. Clusters are classified as no alert (LLR < 5.0), medium alert (LLR 
≥ 5.0 and < 10.0), or high alert (≥ 10.0). The alert level and changes in alert levels (e.g., 
from none to medium or high) can help TB programs identify outbreaks and prioritize TB 
genotype clusters for further investigation or intervention. 
1 Cowan LS, Crawford JT.  Genotype analysis of Mycobacterium tuberculosis isolates from a sentinel surveillance popu-
lation.  Emerg Infect Dis 2002; 8(11): 1294–302.
2 Haddad MB, Diem MA, Cowan LS, et al.  Tuberculosis genotyping in six low-incidence states, 2000–2003.  Am J Prev 
Med 2007; 32(3):239-43.
3 Ghosh S, Moonan PK, Cowan L, Grant J, Kammerer S, Navin TR.  Tuberculosis Genotyping Information Management 
System: Enhancing Tuberculosis Surveillance in the United States. Infect Genet Evol 2012;12:782–8.
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Genotyping Terminology
In NTGS, a genotype is currently defined as a unique combination of spacer oligonucle-
otide typing results (spoligotype) and 24-locus mycobacterial interspersed repetitive unit–
variable number tandem repeat typing (MIRU–VNTR) results.  Each unique combination 
of results is assigned a ‘‘GENType’’ designated as ‘‘G” followed by five digits, which 
are assigned sequentially to every genotype identified in the U.S. (e.g., G00162).  This 
nomenclature is designed for convenience and ease of communication, but the specific 
numbers assigned have no additional significance outside of NTGS. Genotyping data 
from NTGS should not be used for clinical decision making.
National TB Genotyping Surveillance Coverage in the United States
National TB genotyping surveillance coverage refers to the proportion of culture-positive 
TB cases with a genotyped M. tuberculosis isolate.  High levels of coverage in the United 
States can provide a better understanding of the epidemiology of TB transmission within 
a specific geographic area, as well as the entire country. Additionally, since outbreak 
detection algorithms are based on identifying unusual geospatial concentrations of geno-
types, high coverage levels help decrease the likelihood of false- negative alerts. The 
National Tuberculosis Indicator Project (NTIP) national genotyping surveillance cover-
age objective is 94%. 
GLOSSARY
Alert level 
A mechanism used by TB GIMS to notify users of genotype clusters, possibly representing TB out-breaks, 
in a specific county. The alert level is determined by the log likelihood ratio statistic (LLR) for a given 
cluster. This is calculated by TB GIMS and is updated whenever a new case is added to a genotype cluster. 
Email notifications are generated whenever an alert level changes from a “none” LLR (0–5) to “medium” 
LLR (5.1–10) or “high” LLR (>10), or from a “medium” LLR to a “high” LLR. 
Cluster investigation 
A cluster investigation identifies epidemiologic links between TB patients whose isolates have matching 
genotypes. It may consist of reviewing information from public health and medical re-cords and interview-
ing case managers and outreach workers. It can also involve re-interviewing TB patients. 
Epidemiologic link (epi link)
An epidemiologic link is a relationship that two TB patients share that explains where, when, and how M. 
tuberculosis could have been transmitted between them. Patients that named each other as contacts have an 
epidemiologic link. However, an epidemiologic link could be a location where the two persons spent time 
together or an activity that brought them together. 
Geospatial concentration 
Geospatial concentration is a measure of how concentrated a genotype is in time and space. It suggests that 
recent transmission has occurred since cases with the same genotype in the same location are more likely to 
have come in contact with each other.  TB GIMS uses the log likelihood ratio (LLR) to generate a numeric 
measure of geospatial concentration of a given TB genotype. 
Genotype
The designation that represents one or more of the three genotyping techniques used for M. tuberculosis: 
spoligotyping, MIRU-VNTR analysis, and IS6110-based RFLP. These designations were developed to 
facilitate communication of genotyping information within and between TB programs. In the U.S., we use 
GENType or PCRType to define a genotype.
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Genotyping cluster
A genotyping cluster consists of two or more cases in a jurisdiction during a specified time period with 
M. tuberculosis isolates that share matching genotypes. In the U.S., all cases with matching GENType or 
PCRType are considered to be in a genotype cluster. The jurisdiction and time period used vary based on 
the specific application of the term cluster. Within TB GIMS, a single county and a 3-year time period are 
used to define a cluster.
Genotype Surveillance Coverage
Genotyping surveillance coverage is defined as the proportion of culture-positive TB cases with a genotype 
result.
GENType
A designation for each unique combination of spoligotype and 24-locus MIRU–VNTR results. GENType is 
designated as ‘‘G’’ followed by five digits, which are assigned sequentially to every genotype identified in 
the U.S. (e.g., G00017).
LLR (log likelihood ratio) 
A measure of the geographic concentration of a specific genotype in a county, compared to the national 
distribution of that same genotype, over a 3-year period. The higher the LLR, the greater the evidence that 
the local genotype cluster within the county represents a greater geospatial concentration than the national 
average, which might indicate recent transmission of M. tuberculosis.
Linking
In TB GIMS, linking refers to the process of connecting genotyping results with a reported TB case from 
the National TB Surveillance System (NTSS). This step is essential to ensure that demographic, risk factor 
and geographic data can be viewed in TB GIMS for genotype clusters.
MDR
Multidrug-resistant (MDR) tuberculosis strains are resistant to at least isoniazid (INH) and rifampin (RIF).
MIRU-VNTR 
Mycobacterial interspersed repetitive unit–variable number tandem repeat typing analysis. MIRU-VTNR is 
a PCR-based genotyping assay. The CDC genotyping program currently performs 24-locus MIRU-VNTR 
analysis on every isolate submitted for genotyping. Before 2009, only 12-locus MIRU-VNTR was per-
formed. 
Mycobacterium bovis
A member of the M. tuberculosis complex that is commonly associated with cattle, particularly in the de-
veloping world. In the United States, human cases of M. bovis TB generally have a foodborne origin, such 
as through consumption of unpasteurized dairy products. M. bovis is typically resistant to pyrazinamide 
(PZA).  Identification of TB isolates that are M. bovis can be done through genotyping; however, this infor-
mation should not be relied on for clinical decision making. 
Mycobacterium tuberculosis complex
Often abbreviated MTC, a group of closely related mycobacterial species that can cause latent TB infection 
(LTBI) and TB disease (i.e., M. tuberculosis, M. bovis, M. bovis BCG, M. africanum, M. canetti, M. microti, 
M. pinnipedii, and M. mungi). In humans, most TB is caused by M. tuberculosis.
NTGS
The National TB Genotyping Service has provided TB genotyping services to local and state TB control 
programs since 2004. Two national genotyping laboratories are contracted by CDC to provide genotyping 
services at no cost to the patients, healthcare providers, or health departments.
NTSS 
National TB Surveillance System administered by CDC. NTSS collects surveillance data through an elec-
tronic reporting registry. Data collected include socio-demographic, clinical, and risk factor variables that 
are reported to CDC by states and local health departments.
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PCR
Polymerase chain reaction (PCR) is a laboratory method that can rapidly amplify small quantities of DNA, 
thereby enabling certain types of laboratory testing. The national genotyping laboratories routinely use two 
PCR-based techniques, spoligotyping and MIRU-VNTR analysis.
PCRType
A designation for each a unique combination of spoligotype and 12-locus MIRU–VNTR results. PCRType 
is designated as ‘‘PCR’’ followed by five digits, which are assigned sequentially to every genotype identi-
fied in the U.S. (e.g., PCR01974).
Recent Transmission
Although the precise time interval is not well defined, “recent” transmission for TB is often considered to 
be TB disease that is due to exposure 2-3 years prior to disease onset. That is, the chain of transmission 
spanning from exposure to source case through onset of symptoms for secondary cases would be <3 years.  
Immunocompromised patients (e.g., patients with HIV or diabetes) may be at a higher risk for acquiring TB 
disease.
Relapse vs. reinfection
A case of relapsed TB represents a worsening of signs and symptoms of disease after a period of improve-
ment, caused by the same strain of M. tuberculosis. TB that represents a new infection (or reinfection) is 
disease caused by a second infection (often with a strain that is different from the strain that caused the 
initial infection). Genotyping the initial and the subsequent M. tuberculosis isolate might distinguish these 
two possibilities.
RFLP
Restriction fragment length polymorphism. Also called IS6110-based restriction fragment length poly-
morphism (RFLP) analysis was the first widely used method for genotyping M. tuberculosis isolates. A 
genotyping technique based on measuring the num¬ber and length of specific DNA fragments that are cut 
using specific restriction enzymes.
RVCT
Report of a Verified Case of TB. National surveillance data on patients with tuberculosis is recorded on this 
form, and subsequently reported to CDC’s National TB Surveillance System (NTSS).
Spoligotyping
Spacer oligonucleotide genotyping. A genotyping technique based on spacer sequences found in the direct 
repeat region in the chromosomes (genetic makeup) of the M. tuberculosis complex.  The “spoligotype” is 
reported as a 15-digit number.
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